Neonatal pharmacology: towards improved predictability by Smits, Anne
 
KU Leuven 
Biomedical Sciences Group 
Faculty of Medicine 
Department of Development and Regeneration                                                                                            
 
 
 
 
 
 
 
 
 
 
CLINICAL PHARMACOLOGY IN NEONATES: 
TOWARDS IMPROVED PREDICTABILITY 
 
 
Anne SMITS 
Jury: 
 
Promotor:          Prof. Dr. Karel Allegaert 
 
Co-promotor:     Prof. Dr. Jan de Hoon 
 
Chair: NN 
 
Secretary: NN 
 
Jury members:  Prof. Pieter Annaert 
      Prof. Dr. Elena Levtchenko 
          Prof. Dr. Johannes N. van den Anker 
      Dr. Thomas E. Young 
      Prof. Dr. Bart Van Overmeire 
 
 
Dissertation presented in partial fulfilment of the requirements for the degree of 
Doctor in Biomedical Sciences. 
 
Leuven, 28.08.2014 
 
 
Chapter 2 
  
1 
 
Table of Contents 
 
Introduction: Clinical pharmacology in neonates: Towards improved predictability 
 
Chapter 1. Introduction and research aims 
 
 
Part 1: Problem identification and covariate exploration: Variability in drug exposure 
in neonates 
 
Chapter 2. Disposition of intravenous vancomycin in neonates 
 
        Prospective validation of neonatal vancomycin dosing regimens is urgently needed 
 
Chapter 3. Disposition of intravenous amikacin in neonates 
 
                   Amikacin quantification in bronchial epithelial lining fluid in neonates 
 
Chapter 4. Disposition of intravenous propofol bolus in neonates 
 
                   4.1. Urinary metabolites and its covariates after intravenous propofol bolus in neonates 
                   4.2. Is indirect hyperbilirubinaemia a useful biomarker of neonatal propofol clearance? 
                   4.3. Dose-finding and pharmacodynamics of intravenous propofol bolus in neonates 
 
 
Part 2: Drug exposure prediction: Population PK as a tool for covariate exploration and 
internal PK/PD model validation 
 
Chapter 5.  Disposition of intravenous cefazolin in neonates  
 
               5.1.  Cefazolin plasma protein binding and its covariates in neonates  
                5.2.  Cefazolin plasma protein binding in different human populations 
                5.3.  Population pharmacokinetic analysis of total and unbound cefazolin in neonates 
  
 
Part 3: Prospective dosing validation: Development of individualized dosing regimens in 
neonates 
 
Chapter 6. Prospective validation of a model-based amikacin dosing regimen in neonates 
 
                    
Part 4: General discussion  
 
Chapter 7: General discussion and future perspectives 
 
Summary 
 
Nederlandse samenvatting 
Chapter 1 
 
2 
 
Appendices 
 
Curriculum vitae 
List of publications 
 
 
  
 3 
 
Introduction and research aims 
 
 
 
 
Introduction 
Clinical pharmacology in neonates: Towards improved predictability  
 
 
 
 
  
Chapter 1 
 
4 
 
  
 5 
 
Introduction and research aims 
 
 
CHAPTER 1  
Introduction and research aims 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter is in part based on 
 
Perinatal pharmacology: Applications for neonatal neurology. Eur J Paediatr Neurol 2011; 15: 478-86 
 
Drug disposition and clinical practice in neonates: Cross talk between developmental physiology and 
pharmacology. Int J Pharm 2013; 452: 8-13 
  
Chapter 1 
 
6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 7 
 
Introduction and research aims 
Introduction 
 
General concepts of clinical pharmacology 
In clinical care, drugs are administered to patients with the intention to achieve a therapeutic 
effect, preferably without disproportional adverse effects. Clinical pharmacology aims to 
predict these drug-specific (side)effects based on pharmacokinetics (PK, concentration/time 
relationship) and pharmacodynamics (PD, concentration/effect relationship). One hereby 
takes into account characteristics of both the drug and the patient. The pharmacokinetic 
processes generally considered are drug absorption, distribution, metabolism and excretion. 
Although not exclusive, drug metabolism is mainly hepatic and excretion primarily renal 
(glomerular filtration and/or tubular secretion). Pharmacodynamics in part depends on the 
number, affinity and type of drug receptors/targets as well as post-receptor effects, but also 
outcome definitions and reference values used to interpret pharmacodynamic parameters 
1,2
. 
These general principles of clinical pharmacology also apply to neonates, but their specific 
characteristics require not only a more integrated, but rather challenging approach. This is 
because safe and effective pharmacotherapy in neonates likely cannot be based on simple 
linear extrapolation of adult concepts or adult drug doses based on weight but needs 
integration of the impact of maturational aspects on PK and PD (i.e. developmental 
pharmacology). Interestingly, maturational (often non-linear) changes in humans are most 
prominent during the first year of life, more specifically during the neonatal period. To further 
illustrate this, body weight doubles in the first 3-4 months of life and increases 3 times in the 
first year of life. This is accompanied by an extensive increase in growth velocity, most 
pronounced in the last trimester of pregnancy and the first trimester of postnatal life 
3
. Besides 
clinical characteristics (age, weight) reflecting the rapid and dynamic character of growth and 
development in early life, also co-medication and comorbidity contribute to the extensive 
inter-individual variability observed in neonatal PK and PD.  
 
Developmental pharmacokinetics: Intriguing variability in early life  
Pharmacokinetics (ADME) describes the processes involved when a drug is administered to 
the body, often cited as ‘what the body does to the drug’. In the next paragraphs, we further 
focus on the different PK aspects and provide examples of relevance for the clinician taking 
care of newborns.  
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Absorption 
In (pre)term neonates admitted to a neonatal intensive care unit (NICU), many compounds are 
administered by intravenous route. However, in case of extravascular administration, the 
process of absorption (from the site of administration to the blood compartment) reflects and 
quantifies the ability of a specific drug formulation to overcome or cross barriers (e.g. 
physical, chemical, biologic) to subsequently appear in the systemic circulation. 
Developmental changes in intestinal motility, gastric emptying, gastric pH, biliary function 
and absorptive surfaces of organ(systems) involved in drug absorption (e.g. gastro-intestinal 
tract, lung, skin) can influence the absorption, and consequently the bioavailability of a drug 
1
. 
Maturational differences in the activity of intestinal drug metabolizing enzymes or 
transporters further contribute to variability in bioavailability. Albani and Wernicke described 
that oral phenytoin therapy in infants required unexpectedly high doses (18 mg/kg body 
weight) to achieve and maintain therapeutic serum concentrations, due to impaired 
bioavailability, and that the absorption rate and extent is age-dependent 
4
.  
 
In neonates, the absorption rate following oral administration is generally slower because of 
delayed gastric emptying. This has consequences for the time needed to achieve peak plasma 
concentrations. Compared to infants or children this peak will therefore often be delayed 
1,5
. 
The clinical relevance subsequently depends on the compound evaluated, and the effect aimed 
for. Following oral administration of an analgesic drug, the peak concentration and the 
maximal analgesic effect may be obtained later in a neonate compared to the adult. In 
contrast, in a setting of treatment for neonatal opioid withdrawal syndrome, delayed and 
prolonged absorption may contribute to the effectiveness of opioid weaning.  
 
A specific issue in neonates is the unanticipated higher absorption following (unintended) 
cutaneous application due to a proportionally higher body surface area (m²/kg) and a more 
permeable skin 
6
. Application of iodide containing disinfectant potentially results in acquired 
hypothyroidism during a time interval where the subsequent effects (e.g. neurocognitive) of 
transient hypothyroidism are more pronounced (maturational PD). Topical use of local 
anesthetics as (lipophilic) ointments to alleviate pain will potentially result in 
methemoglobinaemia in neonates because of the higher systemic absorption and the reduced 
capacity to metabolize these compounds (i.e. deficiency in the methemoglobin reductase 
enzyme). These observations reinforce the relevance to consider systemic exposure following 
cutaneous application in neonates 
6
.  
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Distribution 
Distribution refers to the shift of compounds from the systemic circulation to various (deep) 
body compartments, tissues or cells. Together with clearance (Cl), the distribution volume 
(Vd) predicts the concentration/time profile while both are reflected in the terminal 
elimination half life (t1/2, h) of a compound. Since both Cl and Vd values will appear 
throughout different chapters in this thesis, we feel it appropriate to define both concepts in 
this general introduction section. Clearance of a drug, expressed in L/h or a weight-corrected 
derivative (e.g. mL/kg/h) refers to the rate of net removal of a compound and is either based 
on metabolism or excretion (cfr. infra). Volume of distribution, usually expressed in L or 
L/kg, is a mathematical or ‘apparent’ volume into which an administered amount of drug 
would be dispersed if the concentrations throughout this volume were equal to that in the 
serum. As mentioned earlier, the terminal elimination half-life reflects both Cl and Vd. By 
definition, terminal elimination half-life is the time needed to have a decrease of 50% 
compared to the initial concentration 
7
. In case of first-order elimination, t1/2 = 0.693 x Vd/Cl. 
This explains why t1/2 of aminoglycosides in neonates, known to be patients with a decreased 
clearance, will further prolong in conditions resulting in an increase of Vd, like during sepsis 
8
. 
 
The pattern of drug distribution will in part depend on patient-specific (e.g. body composition, 
systemic and regional blood flow, membrane permeability) and compound-specific (e.g. 
lipophilic or hydrophilic drug, molecular size, ionization, extend of protein binding) 
characteristics. Variability in organ perfusion and permeability of membranes (e.g. increase in 
capillary leak) are often associated with disease states and will further influence drug 
distribution 
1
. We hereby would like to highlight two important covariates of distribution that 
need to be taken into account in neonates, i.e. body composition and drug binding capacity 
related to circulating plasma proteins 
9
. Changes in body composition are most prominent in 
neonates: the total body water content (/kg) (80-85%) is markedly higher compared to values 
at the end of infancy (60-65%). Subsequently, the total body water content stabilizes 
throughout childhood. For the extracellular water, a similar trend is seen, starting at 40% and 
decreasing to about 25-30% at the end of infancy. The body fat content (/kg) at birth is low 
(10-15%) and increases to 20-25% at the end of infancy, with a subsequent decrease back to 
10-15% until adolescence 
5
. Consequently, water soluble and lipophilic drugs will result – 
when administered in a mg/kg approach – in lower and higher plasma concentrations during 
distribution, respectively. These findings might also be of clinical relevance. The peak plasma 
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concentrations of aminoglycosides, water soluble antibiotics frequently administered to 
neonates, will not only be delayed, but also blunted compared to older children or adults, 
when a similar mg/kg dose is applied. Therefore, this maturational aspect needs to be taken 
into account in neonatal aminoglycoside dosing regimens. A similar (/kg) dose of propofol 
will result in a higher peak concentration in a newborn compared to older children or adults, 
because of the lower body fat content 
10
. Together with a reduced clearance, this can 
contribute to faster and more pronounced accumulation.  
 
Plasma protein binding of drugs is typically reversible, with drug-protein binding associations 
generally due to hydrophobic forces or ionic interactions 
11
. The amount and type of 
circulating plasma proteins (e.g. albumin, alfa 1-acid glycoprotein) influences drug 
disposition (PK) as well as drug action (PD), since only the unbound drug can be distributed 
throughout the body and only the unbound drug can have a pharmacological effect 
12
. 
Neonates often display hypoalbuminemia in the first days of life, resulting in a reduction of 
total albumin binding capacity available 
11
. Furthermore, competitive binding at the albumin 
sites between endogenous (e.g. bilirubin, free fatty acids) and exogenous compounds (e.g. 
ibuprofen, diazepam, phenytoin, propofol) can result in an increase in the free fraction of an 
exogenous compound or an increase in free bilirubin, potentially resulting in kernicterus 
despite perceived ‘safe’ bilirubin plasma concentrations. Additionally the presence of fetal 
albumin, characterized by a reduced binding affinity for weak acids has been suggested 
1
. 
Alfa-1 acid glycoprotein, an acute phase protein, is lower in neonates and will increase 
following surgical trauma. Alfa-1 acid glycoprotein binds local anesthetics like bupivacaine. 
An increased free fraction may result in seizures during continuous epidural infusion in 
infants, resulting in the recommendation not to continue bupivacaine beyond 24h in infants 
9
. 
 
Clinical implications of alterations in drug protein binding are most relevant for drugs which 
are highly protein bound, have a narrow therapeutic index and of which dose is not titrated 
based on effect 
13
. In literature, drug protein binding can be expressed as unbound drug 
fraction or bound drug fraction. The unbound drug fraction equals the unbound plasma 
concentration of the drug divided by the total plasma concentration of the drug. The bound 
drug fraction equals the bound concentration divided by the total concentration and is also 
calculated by 1- the unbound fraction 
11
.  
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Metabolism 
Metabolism or biotransformation, are enzymatic reactions frequently resulting in the 
formation of a more hydrophilic derivative of a given endogenous substance (e.g. bilirubin) or 
exogenous compound (e.g. paracetamol, propofol), which can subsequently be excreted 
easier. Besides elimination of the parent compound, drug metabolism can also result in active 
metabolites with specific pharmacodynamic (side)effects (e.g. codeine or tramadol 
metabolites and analgesia). The most important site for drug metabolism, although not 
exclusive, is the liver. Drug metabolism mechanisms are classified into phase I and phase II 
reactions. The former primarily involves non-synthetic modification (e.g. oxidation, 
reduction, hydrolysis) of the drug while the latter consists of conjugation with another usually 
more water-soluble moiety (e.g. glucuronidation, sulphation, acetylation) 
14
. The most 
important group of enzymes involved in phase I processes are the cytochrome P450 (CYP) 
iso-enzymes with CYP3A4 representing 30-40% of the total CYP content. CYP3A4 activity 
is very low before birth but increases rapidly thereafter. Between the age of 6-12 months, 50% 
of adult levels are reached. During infancy, CYP3A4 activity appears to be even slightly 
higher than that of adults 
1,15
. The largest group of enzymes involved in phase II reactions are 
uridin diphosphate glucuronosyltransferase (UGT) iso-enzymes responsible for 
glucuronidation. Data on ontogeny of UGT activity are scant and mainly based on studies 
with morphine or paracetamol as probes 
16,17
.  
 
In general, drug metabolism is low in neonates and phenotypic activity of drug metabolising 
enzymes is even considered as a major contributor to the overall pharmacokinetic differences 
between neonates, children and adults. However, this does not exclude extensive 
interindividual variability within the neonatal population. The majority of drug metabolism is 
performed by the 23 iso-enzymes belonging to 1 of 3 groups distinguished by Hines et al 
18
, 
based on extensive in vitro research. Although somewhat simplified, ontogeny of drug 
metabolizing enzymes can be classified as: (1) group 1 [enzymes expressed at their highest 
levels early in fetal life (first trimester) and subsequently remaining at high concentrations, or 
decreasing during gestation, but silenced or only low expression up to 2 years after birth (e.g. 
CYP 3A7)], (2) group 2 [enzymes expressed at constant levels throughout gestation with only 
minimal postnatal changes (e.g. CYP3A5 or CYP2C19)] and finally, (3) group 3 [enzymes 
not (or only at low levels) expressed during fetal life (second or third trimester), but display a 
perinatal onset or significant increase in expression within the first 1-2 years after birth (e.g. 
CYP3A4, CYP2D6)] 
18
. In vivo research not only allows to mirror these maturational patterns 
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described in in vitro experiments, but also allows to further investigate the impact of disease 
characteristics: besides age-related maturation (both postmenstrual and postnatal age), it is 
documented that phenotypic enzyme activity also depends on comorbidity (e.g. asphyxia, 
cardiopathy), genetic polymorphisms and environmental factors (e.g. maternal smoking, co-
medication, repeated drug administration) 
19
.  
 
Excretion  
Besides metabolic elimination (mainly hepatic), drugs can be eliminated by direct excretion 
(mainly renal) of the parent compound and/or its metabolites. A thorough understanding of 
the developmental changes in renal elimination function is needed to estimate renal clearance 
capacity. The rate of renal clearance is expressed as the sum of the glomerular filtration rate 
(GFR) (unidirectional diffusion) and the rate of tubular secretion (bidirectional active 
transport) minus the rate of tubular reabsorption (bidirectional active and passive processes) 
20
. At birth, anatomic and functional immaturity of the kidney limits the glomerular and 
tubular functional capacities, which results in inefficient drug elimination and delayed 
clearance for many compounds eliminated by renal route. During this stage of human life, 
renal drug clearance almost entirely depends on GFR which increases during the postnatal 
period. At birth, GFR is low (2-4 ml/min/1.73 m² in term neonates, and even 0.6-0.8 
ml/min/1.73 m² in preterm neonates) compared to adults. During the first 2 weeks of life GFR 
augments and reaches adult values (6L/h/70 kg) by the first year of life 
21
.  
Similar to drug metabolism, overall renal clearance (i.e. the combined result of GFR and 
tubular functions) in neonates is low, but more predictable and its assessment (diuresis, 
creatinaemia) is more readily available. The most important factors that influence the renal 
elimination capacity are gestational age (GA), postnatal age (PNA), prenatal drug exposure 
(e.g. betamethasone), perinatal asphyxia or postnatal exposure to drugs such as ibuprofen, 
caffeine, dopamine or furosemide. The maturation of renal elimination capacity itself is 
driven by gestational age (nephrons are being formed from the 4
th
 up to the 34-36
th
 gestational 
week in an uneventful pregnancy) 
20
 and hemodynamic changes, i.e. a decrease in vascular 
resistance and increase in cardiac output and renal blood flow after birth (related to postnatal 
age) 
14
. At present, the age-dependent functional development of renal tubular processes is 
less well explored compared to the age-dependent morphological development of the 
nephrons themselves 
20
. It is generally accepted that renal tubular functions are not yet fully 
developed at birth, in part due to both the immaturity of the active transport processes as well 
as the smaller renal tubular mass and size compared to later life 
22,23
. However, robust data on 
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e.g. ontogeny of renal drug transporters and relation between regional blood flow and 
metabolic activity of renal tubular transporters are still very limited. 
 
Developmental pharmacodynamics: Questioning the endpoint when evaluating the effect 
Pharmacodynamics refers to the exposure – effect relation of a drug, also described as ‘what 
the drug does to the body’. While knowledge about the impact of developmental changes on 
drug disposition, metabolism and excretion (PK) is increasing, information regarding 
ontogeny (age-related maturation) on drug effects (PD) is still more limited and mostly related 
to the number, affinity and type of receptors or the availability of natural ligands 
9
. However, 
examples from clinical and animal data on ontogeny of receptors e.g. opioid receptors and 
expression of adrenergic receptors, resulted in strong evidence for changes in drug response 
during development, in addition to but independent from pharmacokinetic alterations 
24
. 
Another example is dopamine, a catecholamine with peripheral as well as central nervous 
system effects, acting through a family of dopamine receptors with different subtypes (e.g. 
D1-D5). Via dopamine receptors in the kidney, dopamine increases renal blood flow, diuresis 
and sodium excretion. Data of several animal species documented a different PD response to 
low doses of dopamine between mature (renal vasodilatation) and newborn (vasoconstriction 
due to α-adrenergic receptor stimulation) animals 
24-26
. The natriuretic response to D1 agonists 
in the newborn seemed hereby blunted. Whether this is based on differences in receptor 
affinity, receptor density, coupling to second messengers or intracellular mechanisms is at 
present unknown. Interestingly, human studies indicating increased urine output in very low 
birth weight neonates receiving dopamine were published 
26
. More research on the mechanism 
of action, (side)effects and indications to use dopamine in neonates are needed. 
 
Besides maturational changes in opioid, adrenergic and dopamine receptors also gamma-
aminobutyric acid (GABA) mediated effects during the first weeks of life are different 
compared to older age. Although GABA is the principal inhibitory neurotransmitter in the 
adult mammalian brain 
27
, it is the main neurotransmitter of excitation in the first postnatal 
weeks of life. Changes in the GABAA receptor subunit composition, resulting in a decrease in 
intracellular chloride concentration, occur at 1-2 weeks after birth in rats. It is not yet fully 
known when this occurs in humans 
9,28
.  
 
Immaturity can also result in an altered risk of drug toxicity, even a decreased risk. To 
illustrate this, infants appear to be less susceptible to renal toxicity induced by 
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aminoglycosides compared to older patients. A reduced intracellular accumulation of these 
compounds in the tubular epithelial cells of the renal cortex due to reduced endocytosis 
capacity via the multi-ligand receptor megalin after glomerular filtration, is considered to be 
the underlying mechanism of this PD characteristic 
24,29
.  
 
Surrogate markers, clinical scores and long term outcome 
In addition to developmental changes influencing final PD effects in neonates, correct 
measurement, evaluation and interpretation of exposure – effect relationships in this specific 
patient population is also of relevance. For many drugs commonly administered to neonates, 
this aspect remains poorly investigated. Following administration of a sedative or an anti-
arrhythmic drug, the short-term effect will likely be obvious based on clinical examination of 
the patient and/or inspection of cardiac monitoring, respectively. For other drugs e.g. 
antibiotics, direct short-term effects are less obvious, which makes evaluation of the 
exposure-effect relationship more complex. In such cases, surrogate markers are used e.g. 
peak/MIC (minimal inhibitory concentration for a given pathogen) for aminoglycosides, 
T>MIC for cephalosporins and AUC/MIC>400 for glycopeptides. Unfortunately, target 
values aimed for when applying these criteria are derived from adult studies and not 
systematically investigated in neonates. Because of specific diseases, pathogens involved and 
the maturation of the immune system in neonates, it is urgently needed to validate the above 
mentioned PD targets in this population 
30
.  
 
Even validated population specific assessment tools may have their limitations when used in 
the clinical setting. In order to evaluate and interpret drug effects in the absence of verbal 
communication, scoring systems e.g. pain score (analgesics), Finnegan score (opioid 
withdrawal), sedation and relaxation scores (sedatives) are tools to guide the clinician taking 
care of neonates. However, these instruments also have their limitations. First, scoring 
systems reflecting short-term phenotypic effects, will not inform us on the long-term effects 
of drugs administered. Nevertheless, long-term outcome measures are often even more 
important. Second, scores based on clinical assessments remain to a certain extent indirect and 
(inter)subjective. Furthermore, these observations might differ from the direct physiologic or 
neurobiologic effects occurring after administration of a compound. To illustrate this, small 
volumes of sucrose reduce behavioral responses and composite pain scores (pain expression) 
in neonates receiving painful procedures 
31
, while the nociceptive brain activity in these 
children (nociception) is not significantly different from those receiving placebo (sterile 
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water) 
32
. Therefore, the impact of oral sucrose on clinical scores after painful events in 
neonates should not be interpreted as pain relief 
32
. The same even holds true for vital signs 
without robust data on safe blood pressure.  
 
Strategies to improve predictability of drug exposure: the search for covariates 
One important general message emerges from the topics discussed above: variability is the 
core finding of neonatal pharmacology. Due to the highly dynamic period of neonatal life, 
many covariates influence PK/PD in neonates, resulting in a large inter- and intra-individual 
variability in drug exposure and effects. Consequently, in addition to median values of PK 
estimates or outcome parameters, the range and its contributing covariates are of utmost 
importance 
33
.  
The main objective throughout this doctoral thesis is to further explore the covariates 
explaining PK/PD variability of frequently used drugs in neonates. Such an effort may reduce 
the observed variability, and in the meanwhile, can improve drug exposure predictability in an 
individual patient. One of the methodological approaches frequently applied to explore 
covariates of neonatal PK, (but also PD and PK/PD) is population pharmacokinetic modeling. 
 
Population pharmacokinetic modeling  
Two different methods can be used to describe concentration-time and concentration-effect 
data collected in a population: the classical, standard two-stage approach and the population 
approach using non-linear mixed effect modelling 
34
.  
 
In the classical approach, pharmacokinetic parameters (e.g. Cl, Vd) are estimated for each 
individual, based on individual concentration-time profiles. This necessitates a large number 
of samples collected at pre-defined fixed time points in each individual, hereby avoiding as 
much as possible variability 
24,34
. Subsequently, the individual structural parameters are 
treated as variables and combined to calculated summary (mean, median) measures. If the 
number of observations for each study patient is not equal or if the responses are highly 
variable, weighting is needed to a certain extent 
35
. Variability can theoretically be estimated, 
but is often overestimated 
35
. Additionally, no firm discrimination of between-patient and 
within-patient variability or residual variability can be determined using the classical 
approach 
34
. In addition to the large number of samples needed, this is considered as a 
disadvantage of the classical approach. In contrast, the population pharmacokinetic approach 
using non-linear mixed effect modelling allows a sparse (i.e. limited number of samples) and 
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random (i.e. unbalanced, allowing chaos in the time frame to collect samples) sampling 
design, which is preferable and feasible in an intensive care setting.  
 
     
Figure 1: Presentation of concentration-time profiles (theoretically) achieved using a classical 
pharmacokinetic (PK) approach (different samples at fixed time points to create individual trend lines) 
versus the population PK approach (sparse and unbalanced sampling to create a one population trend 
line with subsequent identification of covariates explaining between- and within-patient variability).  
 
 
As a result of this sparse sampling strategy, population PK allows inclusion of a broader 
spectrum of a heterogeneous cohort of participants who receive the drug in clinical settings 
24
. 
In essence, the primary goal of a population PK analysis is to describe the overall 
pharmacokinetic parameters of the study group. As a second goal, it aims to quantify both 
between- and within-patient variability as well as to define covariates (e.g. clinical 
characteristics) explaining this variability 
36
. This means that population PK is a perfect tool 
to characterize the impact of development and age on drug PK. In addition to the logistic 
advantages mentioned above, this methodological approach fits in the care for vulnerable and 
highly variable populations such as neonates and children 
24,34
. Therefore, population PK 
became a standard method in neonatal PK/PD studies.  
 
Non-linear mixed effects models describe data by integration of both fixed and random 
effects. Fixed effects predict the impact of a covariate (e.g. weight) on the between-subject 
variability of a parameter (e.g. Cl, Vd), while the random effects describe the remaining 
between-subject variability, not predictable from the fixed effect average 
35
.  
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During the model building process using non-linear mixed effect modelling, 3 different steps 
can be distinguished. In a first step, the most appropriate structural model (e.g. a one or two 
compartment model) is determined depending on the available data (and using fixed effect 
parameters such as Cl and Vd for PK). This structural model describes the overall trend in the 
data 
34,35
. In a second step, a statistical submodel is defined (random effects), hereby aiming to 
reduce the remaining variability not explained by the structural model 
34
. In a third step, a 
covariate analysis is performed, resulting in a covariate submodel. Relationships between 
covariates (e.g. age, weight) and parameters of the structural model (Cl, Vd) are explored and 
the nature of these relationships (i.e. linear, exponential) is defined 
34
. Covariates which 
significantly improve the explained variability are added to the model. Discrimination 
between different models is based on the objective function (i.e. a number that evaluates the 
probability of achieving the observed data taking into account the model and its parameters) 
35
. This final model needs an evaluation or internal model validation. Both the stability and 
the accuracy of the model are tested to verify if the final model adequately describes the data 
which are used to build the model. The former can be done by a bootstrap analysis, the latter 
by e.g. visually comparing observed versus predicted concentrations 
34
.  
 
Population PK models can be used to simulate which concentrations (and/or effects) would be 
achieved in case different drug doses are given to patients. It is considered as a tool to 
evaluate and to optimize drug dosing regimens since covariates explaining inter-individual PK 
variability may be integrated in new drug dosing regimens. As such, drug exposure 
predictability can improve for an individual patient. However, each dosing regimen adaptation 
needs further validation, either external (is the model able to adequately describe external 
datasets) and/or prospective (is the model able to adequately describe prospectively collected 
datasets using a model-based dosing regimen). Based on this research strategy, PK knowledge 
in neonates has improved last decades, as nicely illustrated in the overview of population PK 
studies performed up to the age of 2 years, by Marsot et al, 
37
 and additionally offers 
opportunities to facilitate future drug evaluation 
36
. Nevertheless, unexplained neonatal PK 
variability remains extensive for many drugs. For newly developed drugs, companies are 
encouraged to conduct PK/PD studies in neonates and children. Although this initiative, 
driven by law, will further improve PK/PD knowledge of new compounds, neonates remain a 
therapeutic ‘orphaned’ population 
38
. This is reflected by the limited contribution of studies 
conducted in neonates found in public registers, but also by the fact that many neonates do not 
benefit from the drugs studied since a relevant percentage is even not used in NICUs, or 
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remains off label 
38
. For old, but often frequently used drugs in neonates (e.g. antibiotics, 
propofol) covariates explaining PK/PD variability as well as optimal dosing regimens, also 
remain unknown. This resulted in the origin of the general research objective of this doctoral 
thesis. 
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Research aims 
 
General objective 
The aim of this doctoral thesis is to further improve drug exposure predictability in neonates 
based on PK and/or PD studies of frequently used drugs in this population. The compounds 
studied are vancomycin, amikacin, propofol and cefazolin. We hereby aim to integrate 
different aspects of clinical pharmacological research in neonates using the research sequence 
presented in Figure 2, which reflects the 3 main parts of this thesis: 
 
PART 1: Identification of clinical pharmacology-related problems and exploration of 
               covariates contributing to inter-individual variability in drug exposure in neonates. 
PART 2: Integration of these covariates to improve drug dosing and drug exposure prediction 
PART 3: Prospective validation of model-based dosing regimens in neonates 
 
 
 
   PART 1            PART 2         PART 3 
 
 
           Vancomycin 
 
 Propofol 
 
 Cefazolin 
 
 Amikacin 
 
 
 
Figure 2: Schematic overview of the 3-step general objective of this thesis. Arrows along the 
compounds indicate the part in which the compound-specific objectives are investigated.  
 
 
Problem 
Identification,   
Covariate 
Exploration 
Drug  
Exposure 
Prediction 
Prospective  
Dosing  
Validation 
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Compound-specific objectives  
Part 1: Problem identification and covariate exploration 
 
Vancomycin 
Vancomycin, a glycopeptide antibiotic, is used for more than 50 years to treat late onset sepsis in 
neonates. However, PK variability in this population is extensive and there is no clear consensus on 
the optimal vancomycin dosing regimen. Specific objective investigated in chapter 2: 
 
§ To evaluate neonatal vancomycin exposure achieved using 2 published dosing regimens and to 
explore covariates of (sub)optimal exposure. 
 
 
Amikacin 
Amikacin, an aminoglycoside, is used to treat (suspected) neonatal sepsis. Its efficacy relies on peak 
concentrations and the possibility to reach therapeutic levels at the infection site. However, reports of 
amikacin quantification in deep neonatal body compartments are limited and amikacin quantification 
in bronchial epithelial lining fluid is absent. Specific objective investigated in chapter 3: 
 
§ To describe amikacin concentrations in bronchial epithelial lining fluid in neonates. 
 
 
Propofol 
Propofol is a short acting anaesthetic. Compared to adults, propofol clearance in neonates is lower, 
with postmenstrual age (PMA) and postnatal age (PNA) as major covariates. There is preliminary 
evidence that propofol mainly undergoes hydroxylation with only limited glucuronidation in neonates. 
Covariates explaining the inter-individual variability in neonatal propofol metabolism need further 
exploration. Specific objectives investigated in chapter 4: 
 
§ To explore urinary metabolites and its covariates after intravenous propofol bolus in neonates. 
§ To explore if hyperbilirubinaemia can improve predictability of neonatal propofol clearance. 
§ To document the ED50 propofol bolus dose (i.e. the dose effective for 50% of the patients) for 
(semi)elective endotracheal intubation in neonates, to explore propofol PD as a safety analysis and 
to define PD covariates.  
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Part 2: Drug exposure prediction  
 
Cefazolin 
Cefazolin, a first-generation cephalosporin, is mainly used as prophylactic agent for surgical 
procedures. In plasma, cefazolin is bound to albumin. As explained in the introduction, protein binding 
influences drug disposition drug action since only the unbound drug is pharmacologically active. 
However, neonatal cefazolin PK data are limited and mainly based on total plasma concentrations 
collected in a limited number of neonates. Specific objectives investigated in chapter 5: 
 
§ To determine cefazolin plasma protein binding and its covariates in neonates. 
§ To explore cefazolin protein binding and its covariates across different human populations. 
§ To perform a population PK analysis of total and unbound cefazolin concentrations as a guide to 
improve cefazolin dosing in neonates.  
 
 
Part 3: Prospective dosing validation 
 
Amikacin 
Over the last 14 years, our research group improved predictability of amikacin disposition in neonates 
based on extensive pharmacokinetic analysis and dosing optimalisation. Subsequently, routine 
measurement of amikacin peak levels was stopped. However, the current dosing regimen (based on 
drug exposure prediction), introduced in 2011 still needs prospective validation. Specific objective 
investigated in chapter 6:  
 
§ To prospectively validate the currently used amikacin dosing regimen in our neonatal department, 
including its feasibility in clinical practice.  
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Variability in drug exposure in neonates 
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Abstract  
 
Introduction Although vancomycin is frequently used to treat neonatal late-onset sepsis, 
there is no consensus on the optimal dosing regimen. Because many neonates needed dosing 
adaptation due to suboptimal trough values, the vancomycin dosing regimen in our neonatal 
department was changed in 2012. We aimed to document the need for validation of neonatal 
vancomycin dosing by exploring serum trough levels achieved using 2 published dosing 
regimens [previous regimen (2011): based on postmenstrual age and serum creatinine, new 
regimen (2012): based on postmenstrual age and postnatal age] and to identify covariates 
associated with suboptimal vancomycin trough levels (<10 mg/L).  
 
Methods Routine therapeutic drug monitoring serum trough levels quantified after initiation 
of intravenous vancomycin therapy and clinical covariates were retrospectively collected. 
Median vancomycin trough levels of both dosing regimens were compared using the Mann-
Whitney U test. The impact of continuous and dichotomous covariates on achieving a 
suboptimal trough level was explored using the Van Elteren test (stratified Mann-Whitney U 
test) and Mantel-Haenszel test (stratified χ² test) respectively. Covariates significant in 
monovariate analysis were subsequently included in a logistic regression analysis. 
 
Results In total, 294 observations [median current weight 1870 g (range 420 – 4863 g) and 
postmenstrual age 35.07 weeks (range 25.14 – 56.00 weeks)] were included. Using the 
previous and new dosing regimens, 66.3% and 76.2% of trough levels, respectively, were 
below 10 mg/L. Overall, suboptimal vancomycin trough values were significantly associated 
with lower weight (birth weight, current weight) and age (gestational age, postmenstrual age).  
 
Conclusions The majority of vancomycin trough levels in neonates achieved using 2 
published dosing regimens did not reach the target of 10 mg/L. This illustrates the urgent need 
for prospective validation of neonatal vancomycin dosing regimens. We anticipate that dosing 
regimens integrating covariates reflecting general physiological maturation, renal maturation 
as well as disease characteristics could improve vancomycin exposure in neonates.  
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What is already known on this topic 
 
 
§ Targets to evaluate vancomycin exposure in neonates are derived from studies in adults. 
 
§ Extensive variability in vancomycin pharmacokinetics is documented in neonates. 
 
§ Many neonatal vancomcyin dosing suggestions are available, but they all lack prospective 
validation. 
 
§ Due to these multifaceted problems of vancomycin therapy in neonates (and children), the 
drug is on the revised priority list for studies into off-patent paediatric medicinal products 
of the European Medicines Agency'. 
 
 
What this study adds 
 
 
§ 66.3 to 76.2% of early vancomycin trough levels, obtained using 2 published neonatal 
dosing regimens, do not reach 10 mg/L. 
 
§ Weight and age, both reflecting ontogeny, were major covariates associated with 
vancomycin serum trough levels in neonates. 
 
§ We demonstrated that prospective validation of vancomycin dosing approaches in 
neonates is of major priority to achieve safe and effective therapy.  
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Introduction 
 
According to the Neonatal Research Network of the National Institute of Child Health and 
Human Development, 21% of very low birth weight infants experience at least one episode of 
late-onset sepsis (LOS), a major cause of morbidity and mortality in this specific population. 
Gram-positive bacteria are the most common isolated pathogens (70%) causing LOS, with 
coagulase-negative staphylococci (CONS) accounting for 48% of the isolates 
1
. Vancomycin, 
a glycopeptide antibiotic, is frequently used to treat these pathogens. However, an optimal 
vancomycin dosing regimen for neonates is not available and prospective validation of 
published dosing guidelines is lacking. 
 
In adults, a 24 hour area under the concentration-time curve divided by the minimum 
inhibitory concentration for a given pathogen (AUC0-24/MIC) ≥400 is considered to be the 
best predictor of vancomycin efficacy 
2,3
. During routine clinical care, vancomycin serum 
trough concentrations are used as a surrogate marker for AUC, aiming to achieve trough 
levels above 10 mg/L during intermittent intravenous administration 
3
. In neonates, there is no 
strong correlation between serum trough levels and vancomycin efficacy. Consequently, 
serum vancomycin target levels for this special population are derived from adults. However, 
neonates differ from adults based on their specific physiology and diseases, resulting in 
population-specific pharmacokinetics (PK). Furthermore, neonates require population-specific 
pharmacodynamic (PD) targets because they have an immature innate immune system but  
otherwise are at risk for (maturational) toxicity.  
 
The fact that we have been using vancomycin in neonatal care for more than half a century, 
but are still searching for the optimal dosing regimen and efficacy targets confirms the 
complexity of neonatal vancomycin pharmacology. These deficits can also be noticed in daily 
clinical care. First of all, clinicians are confronted with a diversity of dosing regimens 
presented in commonly used handbooks (Table 1) 
4-12
. Secondly, subtherapeutic vancomycin 
trough levels are still frequently observed in neonates.  
 
Since many neonates displayed vancomycin trough levels below the target value (needing 
subsequent dosing adaptation) when using a previously published postmenstrual age (PMA) 
and serum creatinine-based dosing regimen 
13
, we decided to introduce the PMA and 
postnatal age (PNA)-based Neofax
®
 dosing approach in the UZ Leuven NICU in 2012 as new 
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vancomycin dosing regimen 
4
. To illustrate the need for prospective validation of neonatal 
vancomycin dosing regimens, we explored serum trough levels achieved using both dosing 
approaches and, by pooling all observations, we aimed to identify covariates associated with 
vancomycin serum trough levels below 10 mg/L in neonates and young infants.  
 
Table 1: Intermittent vancomycin dosing regimens for neonates as retrieved in reference handbooks 
4-
12
. Data are adapted to mg/kg/dose. PMA: postmenstrual age, PNA: postnatal age, GA: Gestational 
age, bacteremia 
a
, meningitis 
b
. 
 
 
Reference 
 
PMA 
(weeks) 
PNA 
(days) 
Current 
weight (g) 
Creatinine 
(mg/dL) 
Dose  
(mg/kg) 
Interval 
(h) 
Neofax 2011
4
 and 
 
The Harriet Lane Handbook 
2012 
5 
 and 
 
The Sanford guide    
2012-2013 
6
 
≤ 29 
0 - 14   
10 
a
, 15 
b
 
18 
> 14   12 
30 - 36 
0 - 14   
10 
a
, 15 
b
 
12 
> 14   8 
37 - 44 
0 - 7   
10 
a
, 15 
b
 
12 
> 7   8 
≥ 45 any PNA   10 
a
, 15 
b
 6 
BNF for children 2011 
7
 
< 29          15 24 
29 - 35    15 12 
> 35    15 8 
Neonatal Formulary 2011 
8
 
 
< 29  GA 
0 - 7   15 24 
> 7   15 12 
29 - 35    15 12 
36 - 44    15 8 
> 44    15 6 
Dutch Children’s Formulary 
9
 
 < 7   10 12 
 7 - 28   10 8 
Nelsons's texbook of 
Pediatrics 2007 
10
 
 
 
≤ 7 
< 1200  15 24 
 1200 - 2000  7.5 - 11.3 12 - 18 
 > 2000  15 12 
 any weight  15 12 
b
 
 
> 7 
< 1200  15 24 
 1200 - 2000  5 - 7.5 8 - 12 
 > 2000  15 8 
 7 - 28 any weight  10 - 15 8  
b
 
Red book 2012 
11
 
   < 0.7 15 12 
   0.7 - 0.9 20 24 
   1 - 1.2 15 24 
   1.3 - 1.6 10 24 
   > 1.6 15 48 
Neonatal and pediatric 
pharmacology 2011  
(Drug formulary for the 
newborn) 
12
 
 
< 7 
< 1200  15 24 
 1200 - 2000  10 - 15 12 - 18 
 > 2000  10 - 15  8 - 12 
 
> 7 
< 2000  10 - 15  8 - 12 
 > 2000  15 - 20 8 
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Methods 
 
Study population, data collection and ethics 
Vancomycin Therapeutic Drug Monitoring (TDM) observations of neonates and young 
infants treated with intravenous vancomycin, mainly for (suspected) late-onset sepsis (i.e. 
>72h after birth), in the NICU of the University Hospitals Leuven Belgium, between June 
2011 and December 2012, were considered for inclusion in this retrospective study. This 
patient population consists of (pre)term neonates, inborn or transferred, in need of  specialized 
care related to prematurity, infections, perinatal asphyxia, congenital diseases (e.g. surgery for 
cardiopathy, congenital diaphragmatic hernia, esophageal atresia) or other diseases. Clinical 
characteristics at birth [gestational age (GA) (weeks), birth weight (BW) (g)], as well as 
characteristics at the moment of TDM [PMA (weeks), PNA (days), current weight (CW) (g), 
concurrent treatment with ibuprofen (yes/no) or dopamine (yes/no), respiratory support 
(continuous positive airway pressure or mechanical ventilation) (yes/no), mechanical 
ventilation (conventional or high frequency) (yes/no), patent ductus arteriosus (PDA) 
(yes/no), positive blood culture (yes/no), serum creatinine concentration (mg/dL), serum 
albumin concentration (g/L) and serum vancomycin concentration (mg/L)] were extracted 
from the patient files. The daily nursing progress reports were used to collect data regarding 
vancomycin prescription (dose and interval). Results were excluded if data regarding 
vancomycin prescription could not be obtained or in case of an administration or sampling 
time error. We aimed to document early vancomycin exposure (i.e. after 24h of treatment 
initiation), therefore only first trough levels were included.  The ethical board of our hospital 
approved the study protocol. 
 
Vancomycin indication, administration and TDM assay 
Vancomycin (Vancocin®, Elly Lilly, Brussels, Belgium), combined with amikacin, is used as 
standard therapy for (suspected) late-onset sepsis in the UZ Leuven NICU and administration 
occurs as an intravenous infusion over 60 minutes. Add-on therapy of vancomycin for other 
indications (e.g. severe early-onset sepsis, prophylaxis) is limited. The previous vancomycin 
dosing regimen (based on PMA and creatinine, Table 2a) was used between June 2011 and 
June 2012 
13
. The new dosing regimen (based on PMA and PNA, Table 2b) was introduced in 
June 2012 
4
. Since we noticed no improvement in trough levels during clinical practice, we 
felt it to be inappropriate to continue with this new regimen. Therefore, only data up to 
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December 2012 were available for inclusion. As part of routine clinical care, blood samples 
for TDM were collected at the end of the dosing interval, in most cases 24 h after treatment 
onset. Serum vancomycin assay was performed either with a particle enhanced turbidimetric 
inhibition immunoassay method (Siemens Dimension, Dade Behring) (June 2011 – October 
2012) or with an enzyme multiplied immunoassay technique (Cobas c702 , Roche 
Diagnostics) (November 2012 – December 2012). In November 2012, the assay was changed 
throughout the entire hospital for unrelated (i.e. no clinical) reasons. The hospital laboratory 
has a quality system conform ISO15189. This implies clinical interchangeability of results is 
verified when changing from one assay to another. To avoid censoring of values below the 
lower limit of quantification (LLOQ, 2 mg/L), these concentrations were replaced by LLOQ/2 
(i.e. 1 mg/L) as suggested in literature 
14
. An enzymatic technique (Cobas c702 module, 
Roche Diagnostics) was used to quantify serum creatinine levels 
15
. A colorimetric method 
(bromcresol green) was used to quantify serum albumin concentrations. 
 
Table 2: The 2 vancomycin dosing regimens evaluated in this study. a) Previous dosing regimen 
(2011) based on postmenstrual age (PMA) and serum creatinine, published by Anderson et al 
13
. b) 
New dosing regimen (2012, Neofax
®
), based on PMA and postnatal age (PNA) and limited to sepsis 
indication 
4
. 
 
a) 
PMA (weeks) Creatinine (mg/dL) Dose (mg/kg) Interval (h) 
< 29  15 24 
29-35 
< 0.6 
> 0.6 
15 
12 
24 
>35 
< 0.6 
> 0.6 
15 
8 
12 
 
b) 
PMA (weeks) PNA (days) Dose (mg/kg) Interval (h) 
≤ 29 
0-14 
> 14 
10 
18 
12 
30-36 
0-14 
> 14 
10 
12 
8 
37-44 
0-7 
> 7 
10 
12 
8 
            > 45           All         10       6 
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Statistical analysis 
Comparison of continuous clinical characteristics as well as median vancomycin serum trough 
level between observations of both dosing regimens was determined using the Mann-Whitney 
U (MWU) test. Comparison of dichotomous covariates was done by χ² test.  
On the total dataset, the impact of continuous and dichotomous covariates on achieving 
suboptimal trough levels (< 10 mg/L) was explored using the Van Elteren test (stratified 
MWU test) and Mantel-Haenszel test (stratified χ² test), respectively. Stratification was done 
for dosing regimen. Covariates significantly associated with suboptimal vancomycin trough 
levels in monovariate analysis were entered in a logistic regression analysis. Spearman 
correlation was used to evaluate relations between continuous variables before inclusion in 
the logistic regression analysis. A p-value <0.05 was considered statistically significant. 
Vancomycin serum trough levels and clinical characteristics were presented as median and 
range or incidence. Statistical analyses were performed using MedCalc12 (MedCalc Software, 
Mariakerke, Belgium) and the coin package in R version 3.0.2 (R Foundation for Statistical 
Computing,Vienna, Austria).  
 
 
Results 
 
Dataset 
In total, 593 TDM observations were obtained in 223 patients. Sixty-one observations were 
excluded based on criteria summarized in Figure 1. Another 238 observations, collected after 
dosing adjustments were also excluded. The final dataset comprised 294 vancomycin TDM 
observations: 193 observations of the previous (2011) dosing regimen, 101 of the new (2012) 
dosing regimen. Both cohorts had comparable clinical characteristics, but differences for 
serum albumin and creatinine were documented (Table 3a). Taking into account the 294 
vancomycin treatment episodes, indications to start vancomycin were (suspected) sepsis 
[87.7%, of which 8.8% were early-onset cases (≤72 hours after birth) and 78.9% were late-
onset cases], presence of foreign body material e.g. thoracic drain, pacemaker (2.4%), 
prophylaxis (e.g. perforation umbilical catheter, disconnection ventricular-external drain) 
(2.7%), (sub)cutaneous wound infection (3.4%), pneumonia (3.1%) or unknown (0.7%). 
Incidences of indications stratified by dosing regimen and by age at initiation of therapy are 
presented in Table 3b.  
Chapter 2 
36 
 
Sixteen vancomycin trough values were below the lower limit of quantification. Median 
vancomycin concentration of samples achieved using the same dosing regimen (Neofax
®
), but 
with different vancomycin quantification assays used during the study period, were compared 
and did not differ significantly (5.9 mg/L Behring versus 5.5 mg/L Roche, MWU test, 
p=0.773).  
 
 
Figure 1: Flowchart of included vancomycin therapeutic drug monitoring (TDM) observations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All vancomcyin 
TDM results 
N= 593 
61 results excluded: 
- missing data regarding prescription (22) 
- administration error (12) 
- sampling time error (18) 
- follow up after toxic concentration (9) 
 
TDM results 
initially retained  
N= 532 
238 results excluded: 
- TDM after dosing adjustment 
 
First TDM results 
N=294    
Previous dosing regimen (2011) 
13
 
N=193 
New dosing regimen (2012) 
4
 
N=101 
yc
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Previous versus new dosing regimen  
The previous dosing regimen (Table 2) resulted in a significantly higher median (range) 
vancomycin trough concentration compared with the new regimen [7.8 (1–37.8) mg/L versus 
5.8 (1–20.1) mg/L] (Figure 2). In the previous regimen, 128/193 (66.32%) of the observations 
were <10 mg/L and 65/193 (33.68%) were ≥10 mg/L. In the new regimen, 77/101 (76.24 %) 
of the observations were <10 mg/L and 24/101 (23.76%) reached levels ≥10 mg/L.   
 
 
Figure 2: Vancomycin serum trough concentrations (mg/L) achieved by the 2 vancomycin 
dosing regimens used in our neonatal department are presented as boxplots (Mann Whitney U 
test, p<0.05) 
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Table 3a: Clinical characteristics of included vancomycin trough concentrations achieved by the 
previous versus the new dosing regimen. Data are presented as median and range (continuous 
covariates) or incidence (dichotomous covariates). To explore continuous and dichotomous covariates 
between both cohorts, Mann-Whitney U test and χ² test were used respectively. n= number of 
observations; A p-value <0.05 was considered statistically significant. 
 
 
Continuous covariates 
 
Previous dosing regimen 
13
 
(n=193)  
New dosing regimen 
4
 
(n=101) 
p-value 
Gestational age (weeks) 32.86 (24.57-41.43) 32.14 (24.86-41) 0.9862 
Postnatal age (days) 13 (1-169) 12 (2-121) 0.4445 
Postmenstrual age (weeks) 34.71 (25.14-49.86) 35.29 (25.43-56) 0.5950 
Birth weight (gram) 1540 (420-4680) 1850 (440-4150) 0.3821 
Current weight (gram) 1818 (500-4715) 2060 (420-4863) 0.9237 
Albuminaemia (g/dl) 31.95 (17.40-50.40), N=164 31 (12.90-39.70), N=89 0.0290 
Creatininaemia (mg/dl) 0.43 (0.14-1.18), N=178 0.49 (0.13-1.19), N=93 0.0429 
    
 
Dichotomous covariates 
 
Previous dosing regimen 
13
 
(n=193) 
New dosing regimen 
4
 
(n=101) 
p-value 
Patent ductus arteriosus  12/153 5/80 0.8581 
Concurrent ibuprofen  10/193  6/101 0.9985 
Concurrent dopamine  22/193 11/101 0.9494 
Positive blood culture  64/192 30/101 0.6163 
Respiratory support  130/193 71/101 0.7020 
Invasive respiratory support  80/193 42/101 0.9183 
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Table 3b: Indications to start vancomycin therapy. Data are presented as incidences (%) for both 
dosing regimens included in the study and are further stratified by early (i.e. ≤72h after birth) versus 
late (>72h after birth) age at start of therapy. Differences in incidences between both dosing regimens 
were explored using χ² test. A p-value <0.05 was considered statistically significant. EOS: Early-onset 
sepsis, LOS: late-onset sepsis. n= number of observations. 
 
 
Clinical characteristics associated with (sub)optimal trough levels 
Overall, 205/294 (69.73%) of vancomycin trough levels were <10 mg/L, while 89/294 
(30.27%) reached levels ≥10 mg/L. Clinical characteristics of both groups (i.e. trough level 
<10 versus ≥10 mg/L) are presented in Table 4. Lower age (GA, PMA), lower weight (BW, 
CW) and higher PNA were significantly associated with suboptimal trough levels and these 
covariates were considered for inclusion in a logistic regression analysis. High correlation 
coefficients (r) were documented between PMA and GA (r =0.83), and between BW and CW 
(r =0.89). Since PMA combines GA (representing prenatal maturation) and PNA 
(representing postnatal maturation), GA was retained for inclusion instead of PMA. Since 
vancomycin is usually not administered in the first days of life, CW was chosen instead of 
BW. The final covariates entered in the logistic regression analysis were GA, PNA, CW and 
dosing regimen. Results of the analysis are presented in Table 5.  
 
Vancomycin indication 
 
Previous dosing regimen 
13
 
(n=193) 
New dosing regimen 
4
 
(n=101) 
p-value 
    
Early ( ≤ 72h after birth) 26/193 (13.47%) 15/101 (14.85%) 0.8830 
§ Foreign body material 4 (2.07%) 3 (2.97%) 0.9388 
§ Prophylaxis 2 (1.04%) 2 (1.98%) 0.8939 
§ (Suspected) EOS 16 (8.29%) 10 (9.90%) 0.8059 
§ (Sub)cutaneous 
wound infection 
4 (2.07%) 0 0.3541 
    
 Late ( > 72h after birth) 167/193 (86.53%) 86/101 (85.15%) 0.8830 
§ Prophylaxis 3 (1.55%) 1 (0.99%) 0.8939 
§ (Suspected) LOS 150 (77.72%) 82 (81.19%) 0.5880 
§ (Sub)cutaneous 
wound infection 
4 (2.07%) 2 (1.98%) 0.7031 
§ Pneumonia 8 (4.15%) 1 (0.99%) 0.2564 
§ Unknown 2 (1.04%) 0 0.7799 
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Table 5: Logistic regression analysis with vancomycin serum trough levels <10 mg/L (=1) or ≥ 10 
mg/L (=0) as dependent variable, based on 294 vancomycin serum trough levels. OR= Odds Ratio, 
SE= Standard error. Degrees of freedom was equal to 1 for all covariates. A p-value <0.05 was 
considered statistically significant (*).  
 
Covariates Coefficient B SE p-value OR OR 95% CI 
Constant 2.8523 1.6130 0.0770 17.327  
Gestational age -0.0486 0.0616 0.4296 0.9525 0.8443 to 1.0747 
Postnatal age 0.0220 0.0088 0.0113* 1.0222 1.0050 to 1.0397 
Current weight -0.0005 0.0003 0.1049 0.9995 0.9990 to 1.0001 
Dosing regimen 0.6363 0.3008 0.0344* 1.8895 1.0478 to 3.4075 
 
 
Discussion 
 
Up to 70% of vancomycin serum trough levels in neonates and young infants, achieved using 
2 published dosing regimens for intermittent intravenous vancomycin administration, were 
below the target level of 10 mg/L. This finding illustrates the urgent need for optimization 
with subsequent prospective validation of suggested vancomycin dosing regimens (Table 1) 
in this specific population.  
 
We documented that weight (BW, CW) and age (GA, PMA, PNA) - both reflecting ontogeny 
- were major covariates associated with vancomycin serum trough levels in neonates (Table 
4). This can be explained by the fact that developmental changes in physiology are most 
prominent in early life and influence drug disposition (pharmacokinetics) 
16,17
. Especially 
small (low BW, CW) and immature (low GA, PMA) babies showed vancomycin trough 
concentrations below 10 mg/L. Their higher body water content, resulting in a larger 
distribution volume for hydrophilic drugs (e.g. vancomycin) compared to older neonates, 
infants and adults, can in part contribute to the low TDM values observed. Besides changes in 
body composition with increasing age, also renal function (i.e. the combination of glomerular 
filtration and renal tubular functions), and consequently renal drug clearance, displays 
maturation. Although the maturation of glomerular filtration is well described and relates to 
conditions at birth (e.g. BW, GA) and conditions after delivery (e.g. PNA, ibuprofen 
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administration, perinatal asphyxia) 
18,19
, the role of renal tubular functions on neonatal drug 
clearance, and more specific on vancomycin clearance, is at present not yet unveiled.  
 
The same holds true for the impact of specific diseases on vancomycin disposition in 
neonates. To illustrate this, the vancomycin trough value of 37.8 mg/l (outlier on Figure 2) 
was documented in a girl with GA 39 weeks and PNA 4 days, during the rewarming phase 
after hypothermia therapy for severe perinatal asphyxia. Since C-reactive protein increased 
while receiving amikacin and amoxicillin, vancomycin was added on day 3. Serum creatinine 
was normal and amikacin trough level was only slightly elevated (4.1 mg/L). Vancomycin 
prescription, administration and TDM sampling times were in line with our local procedures, 
but an error in drug handling prior to administration cannot be excluded. Although asphyxia 
itself can impair renal function and hypothermia can reduce renal blood flow (and 
consequently renal drug clearance) 
20,21
 the impact of these events on neonatal vancomycin 
disposition is at present unknown.  
Therefore, we anticipate that optimized neonatal vancomycin dosing regimens should take 
into account covariates representing maturation but also disease characteristics 
22
 and co-
administration of drugs influencing renal function, but that these covariates are not yet well 
considered in the currently proposed dosing regimens (Table 1). 
 
Besides the above mentioned patient-specific characteristics, also the absence of optimal 
vancomycin efficacy targets, drug-specific characteristics and quantification assays used can 
contribute to variability in neonatal vancomycin exposure and can complicate the 
development of adequate dosing regimens 
23,24
. First, there is no clear relationship between 
clinical response and indices of systemic vancomycin exposure in neonates. Based on studies 
in adults, an AUC0-24/MIC ratio ≥400 has been recommended to achieve effectiveness. In 
clinical practice, vancomycin trough concentrations are used as surrogate marker and should 
be kept above 10 mg/L to correspond with an AUC0-24/MIC ratio ≥400, if the MIC is <1 mg/L 
3,24,25
. This assumption is derived from adults receiving 12-hourly vancomycin dosing. 
Moreover, trough concentrations depend on dose frequency 
26
. In neonates, it is unknown 
what the optimal trough targets should be. Although some authors recommend to monitor 
directly AUC, the optimal parameter for vancomycin efficacy in neonates and young children 
remains unresolved 
26-29
.  
It should be emphasized that the staphylococcal targets (CONS) for vancomycin use in 
neonates and their corresponding local MIC values are not comparable with the adult setting 
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in which vancomcyin is predominantly used to cure methicillin-resistant Staphylococcus 
aureus (MRSA) infections 
30
. Second, vancomycin is bound to albumin and immunoglobulin 
A in plasma and only the unbound drug is pharmacologically active. However, data in 
neonates concerning the extent of protein binding as well as the disposition of vancomycin in 
deep body compartments are limited. We would like to stress that these pharmacokinetic 
aspects need further research in order to improve insight into the behaviour of vancomycin in 
neonates. Finally, currently used analytical methods for vancomycin quantification contribute 
to variability in TDM results and limit the transferability of vancomycin pharmacokinetic 
models 
31
, and subsequently model-derived dosing regimens, to other centres 
31,32
. Therefore, 
the introduction of a more precise method, such as liquid chromatography-tandem mass 
spectroscopy (LC-MS/MS), which is considered to be the gold standard reference method, 
should be considered 
33,34
. The high specificity, sensitivity and accuracy of LC-MS/MS makes 
it more suitable for e.g. pharmacokinetic studies compared with immunoassays, which in 
general suffer from non-specific interference from related compounds or matrix effects 
33,35,36
 
or, in case of vancomycin, its crystalline degradation products. High instrument costs, greater 
technical complexity, speed and turnaround of sample analysis, are considered as the main 
disadvantages of LC-MS/MS. However, careful choice of sample preparation method and 
internal standard, and validation of assays should be able to avoid the majority of pitfalls 
33
. 
Bijleveld et al 
36
 recently reported that LC-MS/MS documented slightly lower vancomycin 
concentrations than FPIA (Fluorescence Polarization Immunoassay). However, the 
applicability of their LC-MS/MS was only tested in 3 neonatal patients 
36
. Therefore, paired 
analysis of neonatal vancomycin plasma concentrations using immunoassay versus LC-
MS/MS in a large neonatal cohort is currently not yet available, but could be of relevance to 
optimize neonatal vancomycin dosing. 
 
During the past decade, several neonatal vancomycin dosing regimens have been proposed in 
literature. The previous dosing regimen used in our unit seemed to be slightly better than the 
Neofax
®
 regimen, but both were unable to reach sufficient median vancomycin trough levels. 
Nevertheless, as soon as preliminary results of our study were available, we decided to re-
introduce the previous approach (based on PMA and serum creatinine) until prospectively 
validated improved dosing appear. Our observations are, to a certain extent, in line with 
Badran et al 
37
, who documented that only 51% of neonates attained a predefined vancomycin 
trough level between 5-10 mg/L using the Neofax
®
 vancomycin dosing regimen and 33% of 
their trough concentrations were below 5 mg/L 
37
.  
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We are aware that our analysis is only based on trough levels quantified after initiation of 
therapy, since we aimed to achieve drug levels in the target range within a short time. We 
consider our covariate analysis as exploratory. More precise and predictive analyses require a 
population pharmacokinetic modelling approach in which available pharmacokinetic data can 
be used for the exploration of the most optimal vancomycin PD target in neonates, as well as 
for Monte Carlo simulations exploring different vancomycin administration modes (e.g. 
loading dose in intermittent dosin ) to achieve early targeted vancomycin exposure. However, 
this is beyond the intention of the current study. Nevertheless, the large study size and the 
comparison of 2 ‘recently’ published vancomycin dosing regimens to document the 
emergence of prospective validation of neonatal vancomycin dosing are relevant strengths. 
We hereby also would like to highlight the importance of international collaborative 
initiatives to improve neonatal vancomycin therapy like the NeoVanc research project 
(http://cordis.europa.eu/project/rcn/110198_en.html) which, besides the development of a new 
age-appropriate vancomycin formulation, aims to document the best vancomycin PD target 
and dosing regimen for neonates. 
 
We conclude that 66.3% and 76.2% of vancomycin trough levels in neonates achieved using 2 
published dosing regimens did not reach the target of 10 mg/L. This is a relevant, but just one 
of the problems related to vancomycin treatment of neonates. As future perspectives, 
prospective validation of vancomycin dosing regimens, but also further exploration of PK 
[e.g. protein binding, impact of renal (tubular) functions on clearance] and PD (e.g. optimal 
exposure targets) aspects of vancomycin in neonates are urgently needed.  
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Abstract  
 
Introduction Amikacin efficacy is based on peak concentrations and the possibility to reach 
therapeutic levels at the infection site. This study aimed to describe amikacin concentrations 
in the epithelial lining fluid (ELF) through bronchoalveolar lavage (BAL) in newborns. 
 
Methods BAL fluid was collected in ventilated neonates treated with intravenous (IV) 
amikacin. Clinical characteristics, amikacin therapeutic drug monitoring serum concentrations 
and the concentrations of urea in plasma were extracted from the individual patient files. 
Amikacin and urea BAL fluid concentrations were determined using liquid chromatography 
with pulsed electrochemical detection (LC-PED) and capillary electrophoresis with 
capacitively coupled contactless conductivity detection (CE-C
4
D), respectively. ELF 
amikacin concentrations were converted from BAL fluid concentrations through 
quantification of dilution (urea in plasma/urea in BAL fluid) during the BAL procedure.  
 
Results Twenty two observations in 17 neonates [postmenstrual age 31.9 (range 25.1-41) 
weeks, postnatal age 3.5 (range 2-37) days] were collected. Median trough and peak amikacin 
serum concentrations were 2.1 (range 1-7.1) mg/L and 39.1 (range 24.1-73.2) mg/L, the 
median urea plasma concentration was 30 (8-90) mg/dL. The median amikacin concentration 
in ELF was 6.5 mg/L, the minimum measured concentration was 1.5 mg/L and the maximum 
(peak) was 23 mg/L. The highest measured ELF concentration was reached between 6-14.5 
hours after IV amikacin administration, and an estimated terminal elimination half-life was 8-
10 hours.  
 
Conclusions The median and highest (peak) ELF amikacin concentrations observed in our 
study population were, respectively, 6.5 and 23 mg/L. Despite the frequent use of amikacin in 
neonatal (pulmonary) infections, this is the first report of amikacin quantification in ELF in 
newborns. 
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What is already known on this topic 
 
 
§ Knowledge of amikacin disposition in deep body compartments of neonates is limited to 
observations in cerebrospinal fluid. 
 
§ Epithelial lining fluid (ELF) is considered as the site (compartment) of antibiotic activity 
against infections of the lung caused by extracellular pathogens.  
 
§ Aminoglycosides cross the blood-alveolar barrier by non-saturable, passive diffusion. 
 
 
What this study adds 
 
 
§ This is the first report of amikacin disposition in bronchial ELF in neonates. 
 
§ Quantification of amikacin concentrations in neonatal bronchial ELF is feasible, with urea 
as endogenous marker to correct for the bronchoalveolar lavage-related dilution. 
 
§ The peak amikacin ELF concentration in neonates is reached 6-14.5h after intravenous 
administration, which is delayed compared to observations in adults.  
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Introduction 
 
Aminoglycosides like amikacin are frequently administered in the treatment of suspected or 
proven Gram-negative infections in neonates, often in combination with penicillins. Due to a 
concentration-dependent killing combined with a postantibiotic effect, the bactericidal 
efficacy of amikacin relates to its peak serum concentration. Consequently, therapeutic peak 
levels at the infection site will define the effectiveness of antibiotic therapy. Renal side effects 
and ototoxicity relate to the trough serum amikacin concentration, based on the saturation of 
renal and cochlear cell-binding sites. The pharmacokinetics (PK) of amikacin displays 
extensive interindividual variability, which makes it difficult to achieve an effective and safe 
administration in the individual patient, including the neonate 
1
. Based on maturational 
differences in body composition and renal immaturity in early life, differences in both 
distribution volume (Vd, L/kg) and clearance (CL, mL/kg/min) of this hydrophilic drug have 
been observed. Because of the higher water content in preterm infants, and thus a higher 
distribution volume for hydrophilic drugs, a relatively higher amikacin dose is necessary in 
this population 
2,3
.  
 
Since pulmonary infections are a major cause of neonatal morbidity and mortality, antibiotic 
levels in bronchial secretions and bronchial and alveolar epithelial lining fluid (ELF) are of 
specific interest. Measuring antibiotic concentrations in the lung is not easy and is usually 
represented by ELF concentrations. Keeping the anatomy of the blood-bronchial barrier in 
mind, one can imagine that to reach the ELF, the antibiotic must pass through the epithelial 
lining cells linked by tight junctions 
4
. Consequently, biochemical characteristics like the 
degree of protein binding, the lipophilicity and diffusibility of the antibiotic will influence 
antibiotic concentrations in interstitial fluid and in ELF. In adults, we are aware of studies to 
assess the blood-alveolar barrier after parenteral administration of amikacin. Dull et al 
5
 
showed that, after intramuscular (IM) administration, the highest amikacin serum 
concentration correlated significantly with the highest bronchial secretion concentration of 
that individual and that elimination of amikacin from serum and bronchial secretions occurred 
at approximately the same rate with a peak concentration that is blunted in the alveolar 
compared to the blood compartment 
5
. Since data in neonates are lacking, the aim of this 
study is to describe amikacin concentration in the bronchial epithelial lining fluid (ELF) of 
newborns.   
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Methods 
 
Clinical characteristics and drug administration 
From March 2009 to June 2009, bronchoalveolar lavage (BAL) fluid samples were 
prospectively collected in ventilated neonates, to whom amikacin was administered for 
clinical indications. All the patients were enrolled in the Neonatal Intensive Care Unit (NICU) 
of the University Hospitals of Leuven, Belgium, following approval by the Medical Ethical 
Committee of the hospital (B32220084581, S51291) and signed parental consent. The latter 
was specifically obtained to collect and analyze the BAL fluid samples and to integrate the 
results with individual clinical characteristics [postmenstrual age (PMA), postnatal age 
(PNA), birth weight, amikacin therapeutic drug monitoring (TDM) and urea plasma 
measurements] and treatment [amikacin dosing regimen and duration between intravenous 
(IV) administration and BAL procedure]. 
 
Bronchoalveolar lavage aspirates were collected using an endotracheal suctioning method as 
described earlier in literature 
6
. Samples were collected when bronchial suctioning was 
performed based on perceived clinical need to perform bronchial suctioning.  
The amikacin dosing regimen used in the study, was implemented in 2002 based on the 
suggestions of Langhendries et al 
1,7
. In this regimen, dosing depends on PMA as follows: 
PMA of <28 weeks, 20 mg/kg/42 h; PMA of 28 to 30 weeks, 20 mg/kg/36 h; PMA of 31 to 
33 weeks, 18.5 mg/kg/30 h; PMA of 34 to 37 weeks, 17 mg/kg/24 h; and PMA of >37 weeks, 
15.5 mg/kg/24 h, with an additional dosing interval increase of 6 h if ibuprofen was co-
administered or if neonates had suffered asphyxia or hypoxia. Amikacin (Amukin, 50mg/mL 
pediatric vial; Bristol Myers Squibb Belgium) was given as an IV infusion over 20 min via 
syringe driver (SIMS; Graseby, Watford, United Kingdom).  
 
Amikacin assay in serum and BAL fluid  
Serum 
Blood samples for TDM were collected by arterial line or venous puncture just before 
(“trough”) and 1 h after the initiation of administration (“near peak”) of the second dose of 
amikacin, approximately 40 min after the 20-min IV infusion 
1,7
. Amikacin serum 
concentration was determined using a fluorescence polarization immunoassay (TDxFLx, 
Abbott Laboratories, Diagnostics Division, Abbott Park, IL, USA) following sample 
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collection and are expressed in mg/L 
1
. Drug recovery from extraction was 100% (standard 
deviation [SD]=2.6%) over a tested expected concentration range of 3 to 35 mg/L. The 
precision was assessed at 5, 15 and 30 mg/L. These concentrations yielded, respectively, a 
within-run coefficient of variation (CV) of 2.1, 1.4, and 1.8%, a between-day CV of 0, 1.5, 
and 1.7%, and a total CV of 3.2, 2.6, and 2.5%. The minimal quantifiable concentration was 
0.8 mg/L as defined by a CV of <20% (information from Abbott Laboratories). The CV was 
typically <5% based on an internal quality assessment covering a concentration range of up to 
50 mg/L 
8
. For quantification of concentrations between 50 to 200 mg/L, a manual dilution 
(4-fold dilution with dilution buffer TDX) is needed. 
 
BAL fluid 
Measurements of concentrations in deep bronchial secretions were performed on the 
supernatant after it was processed as described by Santré et al 
9
. Following collection, 
samples were frozen (-20°C) until completion of the study. After thawing, secretions were 
diluted in an equivalent sterile water volume and then centrifuged after incubation at 37°C for 
18 h to provide better viscosity.  
 
Supernatant was collected to determine the amikacin concentration. Quantification was 
performed by liquid chromatography with pulsed electrochemical detection (LC-PED) based 
on the method described by Brajanoski et al. for determination of amikacin in cerebrospinal 
fluid (CSF) 
10
. A few modifications were done: as column, a reversed-phase C18 Hypersil 
BDS (100 mm by 2.1 mm; 3 µm particle size) was used, and the flow rate was 0.3 mL/min. 
The quantification limit for amikacin base was found to be 0.06 mg/L. Good linearity was 
obtained for amikacin base in the concentration range from 0.06 mg/L to 4.0 mg/L, with a 
correlation coefficient greater than 0.995. The precision (relative standard deviation [RSD], 
n=3) on the peak area of a 1.0 mg/L amikacin base reference solution was 0.1%. The recovery 
was found to be 99.1 % and 100.9 % for BAL fluid spiked with amikacin base at 
concentrations of 0.2 mg/L and 2.0 mg/L, respectively. 
 
Since BAL fluid only in part reflects bronchial epithelial lining concentrations, we used urea 
concentration in plasma and in the BAL fluid to correct the bronchial epithelial lining 
amikacin concentrations for the BAL procedure-related dilution. When the urea concentration 
in plasma and the urea quantity in a lavage sample are known, VELF (ELF volume) can be 
calculated, using following equation: VELF = (Volume BAL fluid x [urea BAL fluid]/[urea plasma], 
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where [urea BAL fluid] is the urea concentration in BAL fluid and [urea plasma] is the urea 
concentration in plasma. As urea is a free low-molecular-weight substance that diffuses 
readily through the alveolar capillary membrane barrier, it may be assumed that [urea plasma] = 
[urea ELF] (Figure 1). To calculate amikacin concentration in ELF, [amikacin ELF], the 
following equation can be used: [amikacin ELF] = [amikacin BAL fluid] x ([urea plasma]/[urea BAL 
fluid]) 
4,11
.  
 
       
 
Figure 1: Schematic diagram of the blood-alveolar barrier (adapted from Kiem et al 
4
) which is 
composed of 2 membranes: the capillary wall and the alveolar wall. They are separated by the 
interstitial space.  Amikacin need to diffuse across the alveolar capillary wall, the interstitial fluid, and 
the alveolar epithelial cells to reach ELF. Urea readily diffuses through the blood-alveolar barrier. 
 
 
Urea determination in plasma and BAL fluid 
Plasma 
Urea determination in plasma was performed by a modular urea/blood urea nitrogen (BUN) 
Cobas system (Roche/Hitachi, IN, USA). The measuring range in plasma is 5 to 400 mg/dL 
urea with 5 mg/dL as detection limit. Precision was determined using human samples and 
Alveolar 
space 
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controls in an internal protocol. Repeatability (n=21) showed a CV of 0.8% at a concentration 
of 198 mg/dL. Intermediate precision yielded a CV of 3.4% at a concentration of 31 mg/dL.  
 
BAL fluid 
Samples were collected as mentioned above and kept in the freezer until analysis by capillary 
electrophoresis with capacitively coupled contactless conductivity detection (CE-C
4
D) was 
performed. Since coelution of urea and sodium was observed in the CE-C
4
D system, urease 
was added to the sample to hydrolyze urea and quantify it as ammonium 
12
. BAL fluid was 
centrifuged for 2 min at a speed of 14500 rpm using a Mini-Spin Plus (Eppendorf, Hamburg, 
Germany). A volume of 100 µL of supernatant of the BAL fluid sample was pipetted into a 
1.5 mL Eppendorf vial. A total of 100 µL of 0.1 mg/mL lithium hydroxide as an internal 
standard and 100 µL of 0.2 mg/mL urease (type IX from jack beans; 50000-100000 units/g of 
solid) were added and completed to 1000 µL with water. The mixture was incubated for 20 
min at 37
o
C by using a Thermomixer comfort system (Eppendorf, Hamburg, Germany). Next, 
the solution was centrifuged for 10 min at room temperature at a speed of 14500 rpm. The 
supernatant (100 µL) was transferred into a microsample vial and directly injected in CE-C
4
D 
instrument for quantification. The background electrolyte (BGE) for analysis of ammonium 
contained 30 mM malic acid, adjusted to pH 4.1 by L-arginine, and 10 mM 18 Crown-6 ether. 
The 10 mM 18 Crown-6 ether was added to the BGE to enhance the separation of ammonium 
from potassium ions, two cations of similar size, by partial complexation. A voltage of 30 kV 
was applied on a fused silica capillary with 75 µm internal diameter and total length of 65 cm 
(41 cm to C
4
D). The experiments were performed on a P/ACE MDQ capillary electrophoresis 
instrument (Beckman Coulter, Inc. Fullerton, CA, USA), coupled with an eDAQ C
4
D system 
(eDAQ, Denistone East, Australia). The eDAQ C
4
D detector was employed at a peak-to-peak 
amplitude of 100 V and the frequency was 1200 kHz. This method provided conditions 
without interference of matrix components and the recovery was found to be 97.9% and 
99.3% for BAL fluid spiked with urea at concentrations of 1.8 mg/L and 7.2 mg/L, 
respectively. For the CE-C4D method, the intraday precision is 0.7% (n=6) and the interday 
precision is 1.4 % (n=18, representing 3 days with 6 analyses/day). 
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Results 
 
Twenty two observations were collected in 17 neonates: 19 in male and 3 in female neonates. 
Median postmenstrual age (PMA) at inclusion was 31.9 (range 25.1-41) weeks, median 
postnatal age (PNA) 3.5 (range 2-37) days, and median birth weight was 1715 (range 550-
3540) grams. All observations were collected in ventilated neonates, with 19 collected during 
conventional mechanical ventilation and 3 collected during high-frequency oscillation. The 
median oxygenation index was 3.6 (range 1.2-7.9). Median creatinaemia and serum urea 
were, respectively, 0.6 (range 0.4-1) mg/dL and 26.5 (range 8-90) mg/dL. The median trough 
and peak amikacin concentrations in serum were 2.1 (range 1-7.1) mg/L and 39.1 (range 24.1-
73.2) mg/L, respectively (Figure 1).  
 
Median time of bronchoalveolar lavage was 13.5 (range 1.5-23.5) h after amikacin 
administration. Amikacin ELF concentrations of 16 samples were available. During analysis, 
one observation with an ELF amikacin concentration of 89 mg/L was excluded since this was 
an extreme outlier. In this patient, BAL fluid sampling occurred at 18 h after amikacin 
administration. Median amikacin concentration in ELF was 6.5 mg/L, the minimum measured 
concentration was 1.5 mg/L, and the maximum was 23 mg/L. The highest measured 
concentration in our study was reached between 6 and 14.5 hours after iv amikacin 
administration, and a subsequent estimated elimination half-life was 8 to10 h (Figure 2). 
Figure 2 illustrates the amikacin ELF concentrations for different time points.  
 
 
Discussion 
 
To prevent antibiotic resistance, antibiotics need to be administered based on 
pharmacokinetics (PK) and pharmacodynamics (PD). Therefore, it is useful to measure the 
concentrations of antibiotics at infection sites, because the distribution of antibiotics may be 
different among a variety of tissues, in part depending on disease characteristics, maturational 
changes or tissue characteristics 
4
. Amikacin is a commonly administered aminoglycoside to 
treat neonatal bacterial infections, but data about its concentrations in neonatal bronchial 
secretions are not yet described. In this study we showed that  maximum (peak) and median 
concentrations of, respectively, 23 and 6 mg/L can be reached in the epithelial lining fluid, 
after intravenous administration of amikacin in neonates (Figure 2).  
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Figure 2: Amikacin disposition in bronchial epithelial lining fluid (ELF) and serum. The X- axis 
shows the time (hours) after the start of intravenous amikacin administration. The Y-axis shows the 
amikacin concentration (mg/L). For ELF, each symbol represents a unique observation. For serum, 
median peak and trough concentrations of the study population are represented, with an accompanying 
trend line assuming a one-compartment model with instantaneous input and first-order output 
1,3
. 
 
 
To compare our data with already published evidence, we performed a systematic literature 
search on aminoglycoside [amikacin 
5,9,13-15
, tobramycin 
14-19
, gentamicin 
20,11
, and netilmicin 
21
] quantification in BAL fluid after parenteral (iv or im) administration of the antibiotic drug. 
Twelve studies were selected (Table 1), and they were all conducted in adults (11/12 studies) 
or children (1/12 studies), not in neonates. A literature search, using the same terms, was 
repeated in July 2014 but no additional papers could be included. Five of 12 studies used 
amikacin, either in a once-daily (n=1), twice-daily (n=1), or three times a day dosing regimen 
(n=2). One study (n=1) compared once- versus twice- daily dosage. Even within the adult 
population variability in sample material (sputum, bronchial secretions, BAL fluid) and 
antibiotic dosage regimen was found. The anatomic site of sample collection is of importance 
since earlier reports mentioned that aminoglycoside concentrations in the whole lung tissue, 
sputum, and bronchial secretions approximate respectively 50%, 20-60% and 20% of serum 
levels 
11
. It is also known that bronchial secretions cannot be used to predict ELF 
concentrations of aminoglycoside 
21
. The introduction of BAL as sampling procedure resulted 
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in more standardized measurements. When considering the different dosage schedules, higher 
maximum serum and bronchial amikacin concentrations can be detected with a once-daily iv 
drug administration regimen than with a twice-daily or continuous infusion regimen 
15
. Based 
on the data retrieved, Valcke et al registered the highest peak aminoglycoside concentration in 
ELF (14.7 mg/L) after iv administration of 450 mg netilmicin once daily in adults with 
pneumonia 
21
. Our study was performed only in neonates after an extended antibiotic interval 
and with the BAL procedure to collect samples. 
 
To reach (higher) therapeutic aminoglycoside concentrations in bronchial secretions, one can 
assume that aerosol-delivered drug administration directly into the bronchial tree is preferable 
to iv administration. No data can be found on neonates. Nebulised amikacin in mechanically 
ventilated adults with Gram-negative ventilator-associated pneumonia resulted in amikacin 
ELF concentrations more than 10-fold the MIC90 for micro-organisms responsible for 
nosocomial pneumonia 
22
. Specific characteristics of nebulised antibiotic administration are 
the heterogeneous drug disposition within different anatomical parts of the lung and major 
interindividual variability in achieved drug concentrations. Aerosol-delivered drug 
administration also results in low systemic drug absorption. This is important in neonates, 
since amikacin is frequently used to treat (suspected) systemic infections.  
 
When comparing amikacin disposition in other deep, extravascular compartments in neonates, 
only one report can be found concerning amikacin quantification in cerebrospinal fluid (CSF) 
with a median value of 1.1 mg/L. Besides serum, EFL, and CSF, further research on amikacin 
disposition in different body compartments is necessary for optimal treatment of neonatal 
infections.  
 
Although the endotracheal suctioning method used to collect BAL samples in neonates is part 
of the routine medical care in ventilated neonates, the quantification of amikacin in ELF is 
technically more complex. We showed that amikacin concentrations in ELF are relatively 
low, but detectable. As mentioned above, we used the urea concentration in plasma and in the 
BAL fluid to correct the ELF amikacin concentrations for the BAL procedure-related dilution. 
Urea, as an endogenous marker, is small, relatively nonpolar and its concentration is 
considered the same in ELF as in serum, implying complete distribution. Significant diffusion 
of urea across the epithelium during the BAL procedure does not occur 
5,23
. In literature, 
albumin and secretory component of immunoglobulin A (scIgA) are also presented as 
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denominators for BAL fluid constituents, but they are less appropriate markers. This is in part 
attributed to variation in concentrations, related to ontogeny and/or disease states, of these 
markers 
24-27
.  
 
In addition to already mentioned factors (protein binding, lipophilicity and capacity for 
passive diffusion of the drug) influencing the penetration capacity of antibiotic drugs through 
the blood-bronchial barrier, it has been postulated that inflammation, infection and disease 
severity also influence this passage. Canis et al investigated the pharmacokinetics of once-
daily iv amikacin (35 mg/kg/day) administration during the first treatment day in children 
(mean age 9.8 years) with cystic fibrosis. Amikacin sputum concentrations ranged from 5.1 to 
19.9 mg/L at 1 hour. The highest concentrations were obtained at 2 h (mean 10.9 ± 7.5 mg/L) 
13
. Our study aimed to describe population specific amikacin kinetics in ELF, but was not 
powered to elaborate on the potential impact of covariates on amikacin bronchial disposition. 
Based on the reported range in PK serum estimates within the neonatal population, we assume 
that further exploration of these covariates within the neonatal population will be extremely 
difficult and of limited add-on value.  
 
We conclude that amikacin concentrations in neonatal epithelial lining fluid after intravenous 
administration, can be quantified. During analysis, urea has to be used to correct 
concentrations for the BAL procedure dilution. The median and highest (peak) ELF amikacin 
concentrations found in our study population were respectively 6.5 and 23 mg/L. Despite its 
frequent use in neonatal (pulmonary) infections, this is the first report of amikacin 
quantification in ELF in newborns. 
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Abstract  
 
Introduction Propofol, is metabolised by hydroxylation with a limited contribution of 
glucuronidation in early life. Clearance variability in neonates is in part explained by 
postmenstrual age (PMA) and postnatal age (PNA). The aims of this study were to further 
explore propofol pharmacokinetics (PK) (i.e. covariates of metabolism and clearance), and to 
perform a preliminary dose-finding study with pharmacodynamic (PD) assessment of 
propofol for endotracheal intubation in neonates. 
 
Methods In 32 neonates receiving an intravenous propofol bolus, urine was collected during 
24 hours to determine propofol metabolites. The impact of clinical covariates on the urinary 
metabolic profile of propofol was examined. To assess the impact of hyperbilirubinaemia on 
propofol clearance, indirect serum bilirubin was introduced in a previously published propofol 
PK model based on 25 neonates. Non-linear mixed effect modeling was used for this analysis. 
In the prospective dose-finding study (n=35), propofol ED50 doses were calculated based on 
the method of Dixon, with simultaneous assessment of clinical observation scores, vital signs 
as well as cerebral oxygenation.  
 
Results Median total propofol metabolite recovery was 40.95 (2.01-129.81) % with a 
propofol glucuronide/quinol glucuronides ratio of 0.44 (0.01-5.93). Late PNA (≥ 10 days) 
resulted in a higher urinary PG fraction. Covariates PMA and PNA explained 67% of the 
inter-individual variability in propofol clearance compared to 45% by PMA and bilirubin. 
Using a propofol dose range of 0.5-4.5 mg/kg, and aiming for successful intubation [as well 
as extubation in case of INSURE (intubation, surfactant, extubation) cases], median ED50 
range for preterm neonates <10 days PNA was 0.480-1.287 mg/kg. Clinical recovery was not 
yet fully attained 21 minutes after propofol administration. A median decrease in mean 
arterial blood pressure between -29.41% and -39.09% from baseline was documented. 
Variability in blood pressure and in peripheral and cerebral oxygenation, could not be 
explained by weight, age or propofol blood concentrations (at 3 and 12h after propofol bolus). 
 
Conclusion Age 10 days (PNA) is pivotal in early life propofol metabolism. Also for 
neonatal propofol clearance, age (PMA and PNA) remains the key to explain variability. 
Compared to literature, lower (mg/kg) propofol doses can result in a sedative effect sufficient 
for intubation, while clinical recovery takes more time and is accompanied by a moderate 
decrease in blood pressure and a short decrease in peripheral and cerebral oxygen saturation. 
Chapter 4 
 
66 
 
What is already known on this topic 
 
 
 
§ Ontogeny, reflected by postmenstrual (PMA) and postnatal (PNA) age, only in part 
explains variability in propofol metabolism and clearance in neonates. 
 
§ Controversy exists concerning the safety of propofol (especially its hypotensive effect) to 
recommend its routine use for procedural sedation in neonatal intensive care units. 
 
§ The timing of dose-finding studies with drugs frequently used in neonates, but lacking 
appropriate and validated dosing regimens, is a question applicable to most compounds 
administered to neonates since off-label use is common practice.  
 
 
What this study adds 
 
 
 
§ Propofol glucuronidation in neonates is mainly driven by PNA, while hyperbilirubinaemia 
was not a useful biomarker of both metabolism and clearance.  
 
§ Propofol ED50 values for endotracheal intubation are provided for preterm neonates <10 
days of age.  
 
§ Using initial and total propofol dose ranges of 0.5-2 and 0.5-4.5 mg/kg, respectively, only 
a moderate decrease in blood pressure was noticed.  
 
§ Continuous vital sign measurements are of add-on value and are feasible for evaluation of 
pharmacodynamic effects. However, validated reference values as well as threshold 
values are urgently needed to adequately interpret the available data and to assess safety in 
neonates.  
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Introduction 
 
Current recommendations indicate that (semi-)elective procedures (e.g. endotracheal 
intubation, chest tube removal) in neonates should be performed after premedication. Optimal 
premedication should eliminate pain, discomfort and physiological instability. Furthermore, it 
should provide conditions for safe and efficient performance of the planned procedure with 
fast recovery of the sedative effect and without adverse effects 
1
. At present, treatment 
strategies (drug selection and dosing) vary 
2,3
.  
 
Propofol (2,6 di-isopropylphenol), a short acting anaesthetic, is one of the frequently used 
drugs in neonates for procedural sedation. After intravenous (iv) administration, it is 
characterized by rapid distribution to the subcutaneous fat and central nervous system, with 
subsequent redistribution and metabolic elimination. The main routes of propofol metabolism 
are glucuronidation [through UDP-glucuronosyltransferase (UGT)1A9 resulting in propofol 
glucuronide (PG)] and hydroxylation [through cytochrome P450 (CYP)2B6 resulting in 1- or 
4-quinol with subsequent glucuronidation to 1- and 4-quinol glucuronide (1-QG and 4-QG) or 
sulphation]. In adults, also CYP2C9 contributes to the metabolism of propofol 
4
. Due to a 
reduced glucuronidation capacity in early life, a significantly lower contribution of PG 
metabolite (34% versus 77%) and significantly higher contribution of QG metabolite (65% 
versus 22%) on urinary propofol metabolite profile were observed in neonates compared to 
adults 
5,6
. However, the impact of various covariates explaining inter-individual variability in 
neonatal propofol metabolism remains to be established. Therefore, we first aimed to describe 
urinary propofol metabolite profile during early life and to define covariates of neonatal 
propofol biotransformation, based on 24 hours (h) urine collections.  
 
The differences in maturation of metabolism, more specifically glucuronidation, throughout 
age are also reflected by the extensive interindividual variability in propofol clearance (range: 
3.7-78.2 ml/kg/min) within the neonatal population 
7
. In a previous study, postmenstrual age 
(PMA) was identified as the most important covariate to explain this variability. An additional 
impact of postnatal age (PNA) ≥10 days (dichotomous) on propofol clearance was identified. 
This probably reflects ontogeny of glucuronidation activity, which is activated in the first 
month of life 
7,8
. Besides ontogeny (reflected by age and weight), the influence of other 
covariates such as disease characteristics 
9,10
 on neonatal drug metabolism should be 
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considered. Since the presence or absence of jaundice is a relevant disease characteristic in 
early life, and since both bilirubin and propofol undergo metabolic elimination though 
conjugation, we aimed - in the second part of this chapter- to document if indirect bilirubin 
further improves predictability of propofol clearance in neonates and if it can serve as a 
clinically useful biomarker of reduced propofol clearance in this population. 
 
Determination of new covariates of propofol clearance can help to optimize individual dosing 
and safe administration. However, besides insight into the pharmacokinetic (PK) behavior of 
a fast acting drug like propofol, also pharmacodynamics (PD), including safety, is needed to 
develop adequate dosing regimens. At present, propofol PD data in neonates are limited. 
Ghanta et al 
11
 documented a shorter time until sleep or muscle relaxation and shorter time to 
achieve successful intubation when using propofol compared to a 
morphine/atropine/suxamethonium regimen in preterm neonates needing semi-elective 
intubation. Furthermore, our team reported a modest and short-lasting decrease in heart rate 
and in peripheral oxygen saturation, a short-lasting decrease in cerebral tissue oxygenation 
index and a slight increase in fractional tissue oxygen extraction after a single bolus propofol 
(3 mg/kg) administration in neonates. In contrast, a relevant and long-lasting (up to 60 min.) 
impact on mean arterial blood pressure (MABP) was seen 
12
. Significant hypotension (defined 
as MABP <25 mmHg using oscillometric measurement) was documented by Welzing et al 
13
 
investigating propofol 1 mg/kg in preterm (gestational age 29-32 weeks, PNA <8h) neonates 
undergoing an INSURE procedure [(semi-) elective intubation, intratracheal administration of 
surfactant followed by immediate extubation 
14,15
]. This resulted in preliminary termination of 
their study 
13
. Although the hypotensive effects of propofol were also described by other 
authors 
16-18
, reports describing the absence of profound impact on MABP can also be found 
11,19
. Due to the gaps in knowledge on propofol dosing and PD effects in newborns, we aimed 
- as a final step - to combine an exploratory dose-finding approach with the collection of PK 
and PD data in neonates receiving an iv single propofol bolus for short pre-intubation 
sedation. The primary objective was to define the ED50 (i.e. the effective dose for 50% of 
patients) for successful INSURE procedure or successful intubation in non-INSURE 
conditions. In case of intubation for an INSURE procedure the combined outcome of 
successful intubation and successful extubation needs to be taken into account. This 
necessitates a balanced approach in defining the optimal dose. Additionally, we aimed to 
explore the propofol PD data as a safety analysis, to define PD covariates, to link PD with 
propofol plasma concentrations, and to compare our data with previous reports 
11-13
. 
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4.1. Urinary metabolites and its covariates after intravenous propofol bolus 
in neonates 
 
Methods 
 
Clinical characteristics, ethics, procedural sedation, and sampling 
Neonates were included after approval of the study by the ethical board of the University 
Hospitals Leuven, Belgium, and after informed written consent was signed by the parents 
(internal study number S33070). Neonates to whom propofol (1-3 mg/kg iv bolus, Diprivan®, 
AstraZeneca, Belgium) was prescribed for procedural sedation to facilitate endotracheal 
intubation or elective chest tube removal were considered for inclusion only if a urinary 
bladder catheter was present for medical reasons.  
After iv bolus administration of propofol, urine was collected for 24 h in four consecutive 6 h 
aliquots. For every collection period, the urine volume was registered and a 5 ml urine sample 
was stored at -20°C until analysis. Just before the start of the procedure, propofol was 
administered in addition to the analgesics already administered by continuous (fentanyl or 
tramadol) or intermittent (acetaminophen) infusion 
5
.  
Clinical characteristics recorded at inclusion were PMA (weeks), PNA (days), body weight 
(kg), congenital cardiopathy (yes/no) and clinical diagnosis requiring intubation and/or chest 
tube placement (i.e. cardiac, respiratory or other conditions). Serum creatinine (mg/dL) and 
indirect serum bilirubin concentrations (mg/dL, in a time interval of 24 h before or after iv 
propofol bolus administration) were extracted from clinical files. Subsequent dichotomous 
partitioning of indirect serum bilirubin concentrations was based on fixed cut-off values (as 
reported earlier to explore the impact of bilirubin on paracetamol clearance in neonates) 
9,20
 
according to PNA, in order to adapt for the normal postnatal transient increase with 
subsequent decrease of bilirubinaemia in neonatal life (Table 1).  
 
Drug assay 
The glucuronides of propofol and its quinol metabolites in urine were determined by high 
performance liquid chromatography (HPLC) after a dual-step solid phase extraction (SPE) 
combined with ultraviolet (UV) and fluorescence detection. The method was based on earlier 
published techniques 
21,22
 and applications 
23-25
 but further modifications and improvements 
were made. To five- or tenfold diluted urine with PBS (phosphate buffer saline) + 0.1% BSA, 
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Table 1 : Cut-off values for dichotomous partitioning of indirect serum bilirubin adapted from 
Allegaert 2011 
9
 and Palmer 2008 
20
, as applied to search of covariates of paracetamol clearance, a 
drug that also undergoes glucuronidation. Bilirubin conversion used: µmol/L x 0.0585 = mg/dL. 
 
Postnatal age (days)        Indirect bilirubin threshold in µmol/L and mg/dL 
0-1           115 µmol/L     6.728 mg/dL 
2-5           155 µmol/L     9.068 mg/dL 
6-12           120 µmol/L     7.020 mg/dL 
13-19           80  µmol/L     4.680 mg/dL 
20-26           45  µmol/L     2.633 mg/dL 
>27           10  µmol/L     0.585 mg/dL 
 
 
20 µL of a mixture of two internal standards [Phenyl-beta-D-glucuronide (PDG) and 
nitrophenyl-beta-D-glucuronide (NP-DG); 200 and 40 µg/mL respectively] and 300 µL of 50 
mM potassium dihydrogenphosphate buffer pH 7.0 were added. 
Calibration curves were prepared by addition of standard dilutions of PG, 1-QG and 4-QG to 
PBS +0.1% BSA in the range of 1.56 to 25 µg/mL. Calibrators and samples were applied to 
the first SPE column (Oasis MAX 30 mg
–1
 mL, Waters Corporation, Milford, MA, USA). 
Elution of the glucuronides from the columns was performed by two times 0.5 mL of a 
mixture of acetonitrile and methanol (75/25, v/v) + 2% formic acid. The eluates were 
lyophilized and the residues were dissolved in 0.2 mL of PBS + 0.1% BSA and 0.3 mL of 
0.15 M phosphoric acid. For further purification, this mixture was applied to an Oasis HLB 30 
mg
-1
 mL column (Waters Corporation, Milford, MA, USA). Elution of the glucuronides from 
this column was performed with two times 0.5 mL methanol + 2% ammonia. After 
lyophilisation, the residues were dissolved in a mixture of acetonitrile and 0.1 M ammonium 
acetate buffer pH 5 (85/15, v/v). 
 
Aliquots of 20 to 70 µL were injected on the Atlantis HILIC 5µ column, 250 x4.6 mm I.D 
(Waters Corporation, Milford, MA, USA). Chromatographic separation was performed with a 
mobile phase consisting of a mixture of acetonitrile and 0.1 M ammonium acetate buffer 
(90/10, v/v) at a flow rate of 1 mL/min. Detection was performed simultaneously with UV 
and fluorescence at 265 nm and 270/310 nm respectively. The peaks of PG, 4-QG, 1-QG, NP-
DG and PDG were detected at 10.30, 11.81, 13.35, 15.46 and 19.51 minutes, respectively. 
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Recovery (mean ±SD) of PG, 4-QG, 1-QG, NP-DG and PDG was 75.4 ± 10.8, 75.8 ± 7.0, 
80.1 ± 5.6, 75.4 ± 5.3 and 35.2 ± 13.0% respectively. The internal standard NP-DG has no 
fluorescence properties, but could be used with high recovery after the dual-SPE extraction 
only with UV detection. The second internal standard PDG has UV and fluorescence 
properties, but could be used with high recovery only after the MAX columns. In this study 
PG was detected and quantified by UV and 4-QG and 1-QG by fluorescence detection.  
Intra-assay precision and accuracy were lower than 15% over the entire calibration range from 
1.56 to 25 µg/mL for all propofol glucuronides. Inter-day precision was measured by the 
variation of slopes of the calibration curves: 0.013 ± 0.002 (CV%=16.6, n=27) for PG, 0.060 
± 0.010 (CV%=18.0, n=29) for 4-QG and 0.031 ± 0.004 (CV%=12.9, n=29) for 1-QG. The 
lower limit of quantification (LLOQ) for PG, 4-QG and 1-QG was set at 0.75 µg/mL using 
UV detection and at 0.25 µg/mL using the fluorescence detection for 4-QG and 1-QG. 
 
Data reporting, exclusion criteria and statistics 
Urine propofol metabolite concentrations (µg/mL) were converted based on their molecular 
weight (molecular weight propofol=178.27, PG=354.39, and 1-QG or 4-QG=370.38) to 
calculate total urine mg propofol equivalent elimination and the proportional contribution of 
each of the metabolites to overall renal propofol excreted over the 24 h period. Total urinary 
recovery of propofol equivalents (%) was calculated as [(total urinary mg propofol 
equivalents)/(mg propofol administered)]×100. Urinary PG/QG ratio was determined as PG 
metabolite (mg propofol equivalents) divided by QG metabolite (mg propofol equivalents). 
Patients were excluded from the analysis when 24 h urine collection failed or when metabolite 
recovery exceeded 130% due to HPLC related technical interference. To avoid censoring of 
data below LLOQ, these concentrations were set to LLOQ/2 as suggested in literature 
26
. 
Statistical analysis was performed using Medcalc®12 software (Mariakerke, Belgium). 
Urinary metabolite observations and clinical characteristics were reported by median and 
range when non-normal distribution (Kolmogorov-Smirnov test) was documented. Spearman 
correlation was used to explore the impact of continuous variables on PG/QG ratio. To 
determine the impact of different continuous (PMA, PNA, body weight, propofol dose, 
creatinaemia) and dichotomous variables (PNA early/late, hyperbilirubinaemia yes/no, 
cardiopathy yes/no) on subgroups of study patients, Mann-Whitney U test (MWU) and Chi-
square test (χ
2
) were used, respectively. A p-value <0.05 was considered significant. 
Chapter 4 
72 
 
Results 
 
Descriptive statistics  
Data of 40 patients were collected, of whom 32 were available for analysis and 8 neonates 
were excluded (4/8 had an incomplete 24 h urine collection and in 4/8 cases propofol recovery 
exceeded 130%). Male/female distribution was 25/7. Propofol was administered for 
endotracheal intubation (n=19) or chest tube removal (n=13). Clinical characteristics of the 
included study population are provided in Table 2. Median total urinary recovery of propofol 
equivalents after single iv bolus administration of propofol in the 24 h urine collection was 
40.95 (2.01-129.81)%. The contribution of PG and QG to overall propofol metabolite 
elimination was 30.50 (0.80-85.60)% and 69.50 (14.40-99.20)% respectively, resulting in a 
PG/QG ratio of 0.44 (0.01-5.93). 
 
Covariate analysis 
PG/QG ratio did not correlate significantly with PNA (rho=0.292, p=0.105), PMA 
(rho=0.050, p=0.787), body weight (rho=-0.022, p=0.906) or creatinaemia (rho=-0.176, 
p=0.335). A significant correlation of %PG (PG metabolite in urine/propofol dose 
administered) with PNA was revealed (rho=0.433, p=0.013), but not between %QG (QG 
metabolite in urine/propofol dose administered) and PNA (rho=0.038, p=0.839). PG/QG ratio 
differed significantly between neonates with early PNA, compared to late PNA. Analysis with 
PNA 10 days as cut-off point for early neonatal life (MWU test, p=0.010) was hereby more 
significant compared to PNA 7 days (MWU test, p=0.013). There was no significant 
difference in urine propofol metabolite profile (PG/QG ratio) between neonates with or 
without cardiopathy (MWU test, p=0.843), also hyperbilirubinaemia was no determinant 
explaining inter-individual variability in urine metabolite profile (MWU test, p=0.817). 
PG/QG ratio did not differ with gender (MWU test, p=0.438). Differences in clinical 
characteristics between neonates with PNA <10 days compared to PNA ≥10 days are 
presented in Table 3, differences in PG/QG ratio, %PG and %QG are presented in Figure 1.  
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Table 2: Clinical characteristics, reported by median and range or number of cases, of included 
patients (n=32) in this study.  
 
Clinical characteristics Value 
Postmenstrual age (PMA, weeks) 36.5 (28 - 43) 
Postnatal age (PNA, days) 10 (1 - 32) 
Body weight at inclusion (kg) 2.675 (1.070 – 3.965) 
Propofol dose administered (mg/kg) 2.094 (0.990 – 4.505) 
Creatinaemia (mg/dl) 0.420 (0.190 – 1.340) 
Preterm (PMA <37 weeks)  16 
Term (PMA ≥37 weeks) 16 
Early neonatal life (PNA <10 days) 15 
Late neonatal life (PNA ≥10 days) 17 
Indirect hyperbilirubinaemia  7 
Clinical diagnosis 
 
          Cardiac 
                     Coarctatio aortae 
                     Univentricular heart 
                     Abnormal pulmonary venous return 
                     Critical aortic valve stenosis 
                     Persistent ductus arteriosus 
 
          Respiratory 
                     Pneumothorax 
                     Congenital diaphragmatic hernia 
                     Meconium aspiration 
                     Other causes of respiratory failure  
 
          Other 
                      Pierre Robin sequence 
   
 
     11, of whom 
 5 
 2 
 1 
 1 
 2 
 
     20, of whom 
 4 
 6 
 1 
 9            
 
 
 1             
 
 
In an attempt to further define reliable covariates of propofol metabolism in neonates, the 
population was divided in 2 groups, according to low (≤10%) versus high (>10%) %PG 
metabolite recovery in urine (Table 4). Again, incidences of early and late neonatal life 
differed significantly between both groups. Significance was more pronounced with PNA 10 
days (χ² test; p=0.022) as cut off point for early neonatal life compared to PNA 7 days (χ² test, 
p=0.043). The incidence of cardiopathy (χ² test, p=0.773) or hyperbilirubinaemia (χ² test, 
p=0.681) did not differ significantly between both groups. 
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Table 3: Clinical characteristics, reported by median and range or number of cases, of study patients 
with postnatal age (PNA) < 10 days compared to patients with postnatal age ≥ 10 days. Mann-Whitney 
U test (continuous variables) and Chi-square test (dichotomous variables) were used for comparison of 
both groups. * Statistical significant at p<0.05. 
 
Clinical characteristics PNA <10 days (n=15 ) PNA ≥10 days (n=17 ) P-value 
Postmenstrual age (PMA, weeks)  36 (28-40) 39 (28-43) 0.131 
Postnatal age (PNA, days) 2 (1-8) 17 (10-32) <0.001* 
Body weight (kg) 2.850 (1.070-3.900) 2.500 (1.130-3.965) 0.895 
Propofol dose (mg/kg) 2.105 (1.015-4.505) 2.083 (0.990-4.140) 0.584 
Creatinaemia (mg/dl) 0.660 (0.260-1.050) 0.330 (0.190-1.340) 0.001* 
Hyperbilirubinaemia (yes / no) 3 / 12 4 / 7 0.025* 
PG/QG ratio 0.028 (0.008-3.512) 1.117 (0.017-5.928) 0.010* 
% propofol glucuronide (%PG) 0.791 (0.260-89.320) 25.803 (0.715-93.615) 0.002* 
% quinol glucuronides (%QG) 29.607 (1.323-83.029) 18.375 (4.650-86.894) 0.769 
 
 
Table 4: Clinical characteristics, reported by median and range or number of cases, of all included 
study patients (n=32) are presented according to low (≤10%) or high (>10%) %PG metabolite 
retrieved in urine. Mann-Whitney U test (continuous variables) and Chi-square test (dichotomous 
variables) were used for comparison of both groups. %PG represents the ratio of PG metabolite (mg 
propofol equivalents) on propofol dose administered (mg), PG: propofol glucuronide. * Statistical 
significant at p<0.05.  
 
Clinical characteristics %PG ≤10% (n=20) %PG >10% (n=12) P-value 
Propofol dose (mg/kg) 2.070 (0.990-4.505) 2.393 (1.724-4.140) 0.206 
Body weight (kg) 2.430 (1.070-3.900) 2.945 (1.130-3.965) 0.243 
Postmenstrual age (PMA, weeks)  36 (28-42) 38 (28-43) 0.284 
Postnatal age (PNA, days) 5.5 (1-32) 15 (1-21) 0.105 
Creatinaemia (mg/dl) 0.590 (0.190-1.050) 0.350 (0.200-1.340) 0.220 
Early / late neonatal life (PNA 7 days) 12 / 8 2 / 10 0.043* 
Early / late neonatal life (PNA 10 days) 13 / 7 2 / 10 0.022* 
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Discussion 
 
Based on 24 h urine collections in neonates after single iv propofol bolus, we documented a 
median total propofol metabolite (converted to propofol equivalents) recovery of 40.95 (2.01-
129.81)% with only limited contribution of PG metabolite [median 30.50 (0.80-85.60)%] 
compared to QG metabolite [median 69.50 (14.40-99.20)%]. This resulted in a median 
PG/QG ratio of 0.44 (0.01-5.93). These observations are in line with earlier published results 
in a cohort of 8 neonates 
5
 and confirm overall low glucuronidation capacity in early life 
27
. 
However, this study aimed to further unveil covariates of propofol metabolism in the neonatal 
age range.  
PMA, body weight, cardiopathy and indirect hyperbilirubinaemia did not significantly 
influence urinary propofol metabolite profile. In contrast, PNA (dichotomous 7 days as well 
as 10 days) was a significant covariate of PG/QG ratio. Late PNA more frequently resulted in 
high urinary PG fraction. Analysis with PNA 10 days as cut-off point for early neonatal life 
was hereby more significant compared to PNA 7 days. The PNA of 10 days is pivotal in early 
life propofol metabolism. The present study hereby also validates the importance of PNA on 
propofol glucuronidation. This differs from the hydroxylation pathway since %QG 
(eliminated/administered dose) does not increase with PNA. To further illustrate the clinical 
impact, we recalculated clearance values for different PMA and an additional value for 
neonates with PNA ≥10 days (Table 5). It was earlier documented that introduction of age 10 
days in a PK model, predicting neonatal propofol clearance, improved the model 
8
.  
 
Table 5: Propofol clearance values calculated for neonates with different postmenstrual age (PMA) 
based on clearance equation [CLstd·(PMA/38)
11.5
], with standardized propofol clearance (CLstd) at 38 
weeks postmenstrual age (PMA) = 0.029 L/min. For neonates with postnatal age (PNA) ≥10 days, 
equation [CLstd·(PMA/38)
11.5
 +0,03] was used, as described by Allegaert et al 8. The results of these 
calculations illustrate the important role of 10 days PNA in early life propofol biotransformation. 
 
PMA (weeks) Clearance (L/min) Clearance for PNA ≥10 days (L/min) 
26 <0.001 0.030 
30 0.002 0.032 
34 0.008 0.038 
38 0.029 0.059 
42 0.092 0.122 
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Interestingly, no impact of indirect bilirubinaemia on propofol metabolism was found. 
Although propofol and bilirubin both undergo hepatic elimination, indirect 
hyperbilirubinaemia does not seem to influence the metabolic profile of propofol. Taking 
earlier propofol clearance results 
8
 and the present urine data into account, age (PMA+PNA) 
remains the most important clinical parameter when administering propofol to neonates. An 
additional analysis on the previously published PK model, to explore if bilirubin (instead of or 
in addition to PNA) could further improve propofol clearance, will be described in the next 
section of this chapter (section 4.2).  
 
When comparing our neonatal propofol data with reports of propofol metabolism in adults, 
some similarities (e.g. large variability) but also some differences (e.g. covariates) can be 
found, taking into account the discrepant methodology (i.e. in vitro versus in vivo, single 
propofol bolus versus continuous infusion) 
28
 often seen in adult studies. The clinical practice 
to administer propofol (off-label) in neonates is limited to (single) iv bolus. In line with 
neonates, an extensive inter-subject variability (median PG/QG ratio 3.46, range 2.57-13.3) of 
propofol biotransformation following iv bolus administration, is also observed in adults 
6
. 
This variability can in part be explained by polymorphisms, gender and advanced age 
29
. 
Urinary glucuronide and sulfate conjugates of 4-hydroxypropofol were found on average in 
60, 47, 25 and 24% of total propofol metabolites in urine of 4 unidentified patients, 6 male 
Caucasian volunteers, 8 Japanese patients and 6 male Caucasian patients respectively 
30
. Until 
now, evidence exploring the role of genotype is not consistent. In vitro study of human liver 
microsomes revealed CYP2B6 as principal determinant of inter-individual variability (19-
fold) of propofol hydroxylation 
29
. Loryan et al. documented no significant effects of 
CYP2B6 and UGT1A9 single nucleotide polymorphisms (SNPs) on adult propofol 
metabolism 
31
. However, Kansaku et al. recently described that CYP2B6 and UGT1A9 
genotype were determinant factors of propofol pharmacokinetics and pharmacodynamics 
29,31
. 
Since PNA explained only 8.5% (R²) of propofol metabolism in our cohort, quantification of 
the impact of polymorphisms on neonatal propofol metabolism would be interesting. 
However, since both iso-enzymes (CYP2B6 and UGT1A9) display ontogeny, the impact of 
polymorphisms might be even much lower in neonates compared to adults 
32
. Nevertheless, 
this will probably depend on the ontogenic patterns of possible polymorphisms and still needs 
to be studied.  
Not age, but gender had significant impact on the formation of propofol metabolites in adults 
after single iv bolus. In particular, mean values of weight-corrected area under the plasma 
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concentration-time curve for all propofol glucuronides were significantly higher (1.7-2.1-fold) 
in women 
31
. In neonates, gender was not yet a determinant of propofol metabolism.  
 
The strengths of the present analysis are the relevant study size (n=32), the urine collections 
during 24 h and the modified propofol quantification technique used. Urine collection up to 
24 h provides optimal metabolite recovery and allows comparison with adult data 
6
. Our 
urinary metabolites were determined by HPLC after a dual-step solid phase extraction (SPE) 
combined with UV and fluorescence detection, which is more specific than analyses used in 
the past (i.e. HPLC without previous purification of the samples or HPLC with only one 
detection mode). Furthermore, this is the first report of the analytical modifications used to 
quantify urine propofol metabolites in neonates.  
 
However, we are aware of limitations of the study. In adults, Hiraoka et al defined the kidneys 
as the major site of extrahepatic propofol metabolism, contributing for one third to total body 
propofol clearance 
33,34
. The presence and impact of renal metabolism in neonatal propofol 
elimination is unknown and cannot be determined based on urinary metabolite measurements 
only. However, plasma propofol metabolite data nor organ-specific arterial-venous propofol 
concentrations are available for neonates. The current data in neonates reflect ‘whole body’ 
propofol metabolism. Drug metabolite ratios can be affected by urine pH 
35
. In neonates, data 
on the impact of urine pH or even tubular functions on propofol elimination are unknown. In 
adults, tubular reabsorption of propofol and its metabolites is described. In early life, overall 
renal tubular functions are less effective and renal drug clearance almost completely depends 
on glomerular filtration rate (GFR). At birth, GFR is low and increases during the first two 
weeks of life, to reach adult values at the age of 8-12 months. These maturational aspects 
need to be considered when evaluating neonatal urinary drug elimination. To estimate GFR in 
neonates, serum creatinine is a frequently used marker. Since we revealed no significant 
correlation between creatinaemia and PG/QG ratio, we assume that metabolite profile does 
not depend on renal function. However, further investigation is needed. 
 
In conclusion, based on 24 h urine collections in neonates after single iv propofol bolus, we 
observed a median total metabolite (converted to propofol equivalents) recovery of 40.95 % 
and a PG/QG ratio of 0.44 (0.01-5.93) We confirmed PNA 10 days as pivotal time point of 
propofol metabolism in early life. This is in concordance with earlier reported propofol 
clearance studies in neonates. To define new determinants of inter-individual variability of 
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neonatal propofol metabolism, further research needs to be encouraged. Finally we want to 
emphasize that this was the first report of the analytical modifications used to quantify urine 
propofol metabolites in neonates. 
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4.2. Is indirect hyperbilirubinaemia a useful biomarker of reduced propofol 
clearance in neonates ?  
 
Methods 
Reported study population and propofol assay 
The analysis was based on 235 arterial propofol concentration-time points collected in 25 
neonates, up to 24 h after single bolus intravenous (IV) administration of propofol (3 mg/kg, 
10 seconds) for procedural sedation (elective chest tube removal or placement, endotracheal 
intubation) 
8
.  
The propofol assay was based on a reversed phase high performance liquid chromatography 
(HPLC). The chromatographic system consisted of a waters 600E pump, combined with a 
Waters autosampler 717 plus and a fluorescence detector (hitachi F-1000) with excitation and 
emission wavelengths set at 270 and 310 nm, respectively. For further details on bio-
analytical techniques (including its variability) and ethical consent procedures, we refer to the 
initial publication 
8
. 
 
Serum bilirubin assay  
Total bilirubin concentration was determined using a colorimetric DPD (2,5-dichlorophenyl 
diazonium tetrafluoroborate) method on Roche/ HITACHI – MODULAR (BIL-T Cobas, 
Roche Diagnostics, Mannheim, Germany). The measuring range was 1.71-513 µmol/L with 
1.71 µmol/L as lower limit of detection. Intra- and interday coefficients of variance (CV) 
were 1.3% and 1.9% respectively. Direct bilirubin concentration was determined using 
Roche/ HITACHI - MODULAR P (D-BIL Cobas, Roche Diagnostics, Mannheim, Germany) 
based on a colorimetric assay (Jendrassik-Grof procedure). The measuring range was 1.71-
171 µmol/L with 1.71 µmol/L as detection limit and with calculated extended upper range up 
to 342 µmol/L. Intra-and interday CV were 0.6% and 2.0%, respectively. Conversion factors 
for bilirubin quantification are µmol/L x 0.0585= mg/dL; mg/dL x 17.1= µmol/L. Indirect 
serum bilirubin was calculated as total serum bilirubin minus direct serum bilirubin. 
 
Population pharmacokinetic analysis 
Previously developed model  
As previously published 
8
, a three-compartment model adequately described the propofol 
pharmacokinetics. The covariates PMA, PNA, gestational age, body weight, gender and renal 
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function (serum creatinine) were evaluated in the model-building process using forward 
inclusion and subsequent step-wise backward deletion to confirm the contribution of each 
covariate. In the final model, all covariates associated with a significant increase in objective 
function after elimination (i.e. PMA and PNA) were maintained. In the final model, reported 
standardized propofol clearance (Clstd) at 38 weeks PMA was 0.029 L/min using the equation 
[Clstd . (PMA/38)
b
] with a power scaling parameter b of 11.5. The addition of a fixed value in 
neonates with a PNA of ≥ 10 days further improved the model and resulted in the equation 
[Clstd . (PMA/38)
11.5
 + 0.03] L/min 
8
. For further details we refer the reader to the initial 
publication 
8
. 
 
Current covariate analysis 
The model performance was assessed after introduction of unconjugated bilirubin into the 
previously developed model with PMA as the primary covariate for clearance. Indirect serum 
bilirubin concentrations (as collected in a time interval of 24 h before or after iv propofol 
bolus administration for clinical reasons) were retrospectively extracted from clinical files. 
Subsequent dichotomous partitioning of indirect serum bilirubin was based on fixed cut-off 
values (Table 1) according to postnatal age, to adapt for the normal postnatal transient 
increase with subsequent decrease in neonatal life, as explained in section 4.1 
9,20
. 
Hyperbilirubinaemia was implemented as dichotomous or continuous covariate (both age 
normalized) into the equation for clearance parameterized as a linear fraction or reduction. 
Discrimination between different covariate models was made by comparison of the objective 
function. A value of p <0.005, representing a decrease of 7.8 points in the objective function 
(χ² distribution), was considered statistically significant. In the backward deletion a more 
stringent p-value (p <0.001) was applied. In addition, goodness-of-fit plots were used for 
diagnostic purposes. 
 
Data analysis 
The current PK analysis was performed using non-linear mixed effect modeling 
36
 
(NONMEM, GloboMax LLC, Hanover, MD, USA, version 6.2) by use of the first-order 
conditional estimation (Method1) with η-ε interaction. S-plus (Insightful software, Seattle, 
WA, USA, version 6.2) was used to visualize the data.  
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Results 
 
Of the 25 neonates, with median weight of 2930 (range 680-4030) g, PMA of 38 (range 27-
43) weeks and PNA of 8 (range 1-25) days, serum indirect bilirubin concentrations were 
available in 23 patients, of which 8 cases had hyperbilirubinaemia, defined as values above 
age-dependent normal indirect bilirubin values (Table 1, Figure 2). 
 
 
Figure 2: Individual indirect serum bilirubin values, collected in a time interval of 24 hours before or 
after propofol administration for 23 out of 25 study patients. The data illustrate the postnatal 
dependent fluctuation in indirect bilirubinaemia. Hyperbilirubinaemia cases are presented by □, cases 
showing no hyperbilirubinaemia are presented by ●. 
 
 
Comparison of propofol clearance between cases with or without indirect hyperbilirubinaemia 
is represented in Table 6. The model using PMA and age normalized dichotomized bilirubin, 
implemented as a fraction or reduction resulted in a higher objective function compared to the 
model using PMA and PNA (Table 7). This was also reflected in the goodness of fit plots in 
which in particular observed versus population predicted concentrations worsened. Evaluation 
of bilirubin implemented into the model as an age normalized continuous variable did not 
improve the model. Finally implementation of bilirubin on other pharmacokinetic parameters 
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proved not statistically significant. While the covariates PMA and bilirubin explained 45% of 
the inter-individual variability, the covariates PMA and PNA explained 67% of the inter-
individual variability of propofol clearance. Introduction of bilirubin, into the PMA+PNA 
model did not further improve the model (p >0.05). 
 
Table 6: Comparison of propofol clearance (L/min) between cases with and without  indirect 
hyperbilirubinaemia. Data are represented by minimum, 25
th
 percentile, median, 75
th
 percentile and 
maximum clearance values for both groups.  
 
Propofol clearance value 
Cases without 
hyperbilirubinaemia 
(L/min) 
Cases with 
hyperbilrubinaemia 
(L/min) 
Minimum  0.0011 0.0012 
25
th
 percentile 0.0299 0.0024 
median 0.0767 0.0090 
75
th
 percentile 0.1029 0.0642 
Maximum 0.1286 0.0869 
 
 
Discussion  
 
Since raised bilirubin is considered as an indicator of deficient hepatic glucuronidation 
capacity in neonates, we hypothesized that indirect hyperbilirubinaemia could be a predictive 
biomarker and useful bedside tool to anticipate further reduced propofol clearance in 
neonates. However, introduction of dichotomous bilirubin values in our propofol PK model, 
with PMA and PNA as known covariates for clearance, did not further improve clearance 
predictability.  
Besides body weight, propofol clearance variability in humans mainly relates to phenotypic 
variability in phase 1 and phase 2 iso-enzymes. Propofol undergoes both phase 1 
(hydroxylation) as well as phase 2 (glucuronidation) metabolism. In vitro studies revealed the 
CYP450 isoform CYP2B6 as the principal determinant of inter-individual (19-fold) 
variability of propofol hydroxylation 
30,37,38
. However, median in vitro CYP2B6 expression 
itself increases with age (0.6 pmol/mg microsomal protein in fetal and neonatal hepatic 
samples; 1.6 pmol/mg for infant to adolescent samples and 4 pmol/mg in adult samples) 
32
. 
Glucuronidation of propofol occurs by UGT1A9.  
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Table 7: Model-based pharmacokinetic parameters estimates for the different models. 
Parameters PMA+PNA model 
PMA+bilirubin  
(fraction) 
PMA+bilirubin 
(reduction) 
    
Objective function (points) -269.026 -240.408 -241.021 
Fixed effects   - 
CL= CLp x (PMA/median)
o
 + 
p (if PNA >10) 
0.0289 - - 
o 12 - - 
p 0.0305 - - 
CL= CLp x (PMA/median)
o
 x p 
(if dichotomous bilirubin =1) 
- 0.0494 - 
o - 6.51 - 
p - 0.299 - 
CL= CLp x (PMA/median)
o
 – p 
(if dichotomous bilirubin =1) 
- - 0.046 
o - - 8.38 
p - - 0.00635 
V1 1.42 1.41 1.78 
Q2 0.0391 0.0381 0.0364 
V2 15.9 15.9 15.7 
Q3 0.0842 0.0875 0.0962 
V3 1.18 1.21 1.27 
Interindividual variability    
CL 0.582 1.07 1.15 
V1 0.581 0.486 1.2 
Q2 0.354 0.278 0.344 
Residual variability    
Proportional 0.0403 0.0404 0.0403 
 
CL= Clearance (L/min) ; CLp= Population value for clearance (L/min); o:Power scaling parameter; p: 
Plus clearance constant if postnatal age ≥ 10 days; PMA: Postmenstrual age; PNA: Postnatal age; Q2: 
Intercompartmental clearance between central and peripheral 1 (L/min); Q3: Intercompartmental 
clearance between central and peripheral 2 (L/min); V1: Central volume (L); V2: Peripheral volume 1 
(L); V3 = Peripheral volume 2 (L).  
 
 
In neonates, phenotypic maturation in glucuronidation activity mainly reflects age-dependent 
phase 2 iso-enzyme maturation 
27,39
. This impact of ontogeny on glucuronidation, was also 
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confirmed by Knibbe et al who defined body weight as most predictive parameter for 
glucuronidation capacity of morphine under the age of 3 years with a large group of preterm 
and term neonates in the dataset 
40,41
. Although the iso-enzymes involved for conjugation of 
bilirubin (UGT1A1) and propofol (UGT1A9) are different, they display a similar maturational 
pattern. Adult activity levels of UGT1A1 and UGT1A9 are reached at 3-6 months 
42
 and 4 
months 
43
 after birth, respectively. Besides ontogeny it is to be anticipated that disease 
characteristics also play a contributing role in phenotypic drug (metabolic) elimination 
clearance. Based on the link between phenotypic glucuronidation and propofol clearance, a 
focused search on the applicability of indirect bilirubinaemia as biomarker for further reduced 
propofol clearance was reasonable.  
Biomarkers (defined as characteristics that can be measured and evaluated as indicators of 
normal biologic and pathogenic processes) are increasingly being integrated into clinical 
practice 
44
, since, to a certain extent, they reflect disease status. In this study, we focused on 
raised indirect bilirubinaemia, a characteristic frequently present in the neonatal population. 
Furthermore, serum bilirubin is routinely quantified in clinically icteric newborns. However, 
we failed to document that indirect hyperbilirubinaemia is a useful biomarker of reduced 
propofol clearance within this age group. In adults, Song et al reported that there was no 
influence of obstructive jaundice on propofol pharmacokinetics compared with patients 
without obstructive jaundice 
45
. We have to be aware that the mechanism of jaundice in 
obstructive pathology (resulting in elevated direct serum bilirubin) differs from neonatal 
jaundice (mainly elevated indirect serum bilirubin). 
We claim that our negative findings are probably due to the fact that jaundice in the first days 
of life is the phenotypic result of an imbalance between (indirect) bilirubin synthesis (e.g. 
hemolysis) and bilirubin clearance (e.g. conjugation by the iso-enzyme UGT1A1) capacity 
46
. 
Consequently, jaundice can be present in the setting of increased synthesis despite effective 
conjugation capacity, while in the absence of bilirubin synthesis, deficient conjugation 
capacity will remain subclinical. Besides this claimed explanation, one may also suggest that 
hyperbilirubinaemia affects propofol clearance through an increase in free propofol 
concentration, since both compounds bind to human serum albumin (HSA). However, Zhou 
and Liu described no overlap in HSA binding sites for bilirubin and propofol 
47
, instead of, for 
example cefazolin (see chapter 5) and ibuprofen displaying competition for albumin binding 
places 
48,49
. In addition, neonates frequently display hypoalbuminaemia during the first days 
of life, possibly resulting in a significant increase in free propofol concentration.  
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The main aim of evaluating biomarkers and other covariates of neonatal propofol clearance in 
PK models is to increase individual clearance predictability. This knowledge can be 
introduced in anaesthetic applications such as target controlled infusion systems 
50
. At 
present, only 67% of propofol clearance variability in neonates can be explained by PMA and 
PNA. Since indirect bilirubinaemia has no major influence, a search for other covariates 
and/or biomarkers is warranted, although we are unsure about the markers to focus on. 
Propofol is a high extraction ratio drug and, as determined in adults, clearance depends on the 
liver blood flow. While there are no good data on hepatic blood flow in relation to age, 
hepatic blood flow in infants is suggested to be comparable to adult values 
51
. This means that 
rather than hepatic blood flow, maturational aspects (immature metabolizing enzymes) limit 
propofol clearance in neonates. Considering polymorphisms of metabolizing enzymes 
(CYP2B6, UGT1A9) 
32
, there is only a limited impact of these polymorphisms in adults. 
Since both iso-enzymes display ontogeny, the impact of these polymorphisms in neonates are 
assumed to be much lower. As mentioned earlier (section 4.1), this still needs to be studied. 
30,32,37-39
.  
  
Conclusion  
Although only based on observations collected in 25 neonates, we conclude that ontogeny 
itself, reflected by PMA and PNA, is a more relevant clinical predictor of reduced propofol 
clearance in neonates than hyperbilirubinaemia, a specific disease characteristic potentially 
reflecting deficient conjugation capacity. Such observations are also of clinical relevance 
since propofol has become a popular intravenous drug for induction and maintenance of 
anesthesia, even in neonates. Based on the current observations, propofol doses should be 
reduced in early (PNA of <10 days) life, independent of the presence or absence of indirect 
hyperbilirubinaemia 
52
. 
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4.3. Exploratory dose finding study in neonates receiving a single 
intravenous propofol bolus for (semi-) elective endotracheal intubation: 
preliminary analysis 
 
Methods 
Study population, inclusion criteria and ethics 
Neonates admitted to the Neonatal Intensive Care Unit (NICU) of the University Hospitals 
Leuven who need short procedural sedation for (semi-) elective intubation were considered 
for inclusion, after informed written consent of the parents. Patients considered for inclusion 
had to be hemodynamically stable and did not receive sedative or analgesic agents (with 
exception of paracetamol) during the previous 24 hours. INSURE (intubation-surfactant-
extubation) procedures in the UZ Leuven NICU are mainly performed in neonates below 34 
weeks of gestation, with a spontaneous respiratory drive, but characterized by an oxygen need 
>30% Fi02 while receiving nasal continuous positive airway pressure (nCPAP) and evidence 
of respiratory distress syndrome. The study (EudraCT nr 2012-002648-26) was registered at 
ClinicalTrials.gov and approved by the ethical board of our hospital. At present, the data 
collection of the 50 patients is completed. This chapter contains results of the first 35 patients 
as a preliminary safety analysis.  
 
Clinical characteristics at birth [gestational age (GA, weeks), birth weight (BW, grams), 
Apgar score at 1 and 5 minutes, gender (male/female)] and at moment of propofol 
administration [postnatal age (PNA, in days and in hours after birth), postmenstrual age 
(PMA, weeks), current weight (CW, grams), propofol indication (INSURE versus non-
INSURE), initial propofol dose (mg/kg) and total propofol dose (mg/kg)] were collected from 
the patient medical files. In case of an INSURE procedure, surfactant dose, time to surfactant 
administration, time to extubation and the need for reintubation (within 12 hours after the 
procedure) were also recorded.  
 
Drug administration  
Propofol (Diprivan 1%, AstraZeneca, Brussels, Belgium) is used as routine sedative agent for 
(semi-)elective intubation, including INSURE procedures, in the UZ Leuven NICU. Propofol 
is administered as intravenous bolus, immediately followed by NaCl 0.9% 1 ml/kg during 30 
seconds. 
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Efficacy 
Dose finding approach 
Based on available pharmacokinetic (PK) data on propofol in neonates, PMA and PNA < or ≥ 
10 days are defined as major covariates of propofol clearance 
8
. Therefore, neonates included 
in the current study were stratified according to PMA [group 1: <28 weeks, group 2: 28-31 
6/7 weeks, group 3: 32-36 6/7 weeks and group 4: ≥37 weeks] and PNA (<10 days versus ≥10 
days) as presented in Table 8. Eight stratums were hereby considered. 
 
 
Table 8: Stratification of included study patients in 4 groups and 8 strata. 
 
Group 
Postmenstrual age 
(PMA) 
Postnatal age (PNA) Stratum 
Group 1 < 28 weeks 
PNA < 10 days 
PNA ≥ 10 days 
1 
2 
Group 2  28- 31 6/7 weeks 
PNA < 10 days 
PNA ≥ 10 days 
3 
4 
Group 3 32-36 6/7 weeks 
PNA <10 days 
PNA ≥ 10 days 
5 
6 
Group 4 ≥ 37 weeks 
PNA < 10 days 
PNA ≥ 10 days 
7 
8 
 
 
The first patient in each stratum received an initial propofol dose of 1 mg/kg. If sedation and 
relaxation of the patient, perceived by the treating physician, was unsatisfactory, additional 
propofol (i.e. second dose always 1 mg/kg, if still unsatisfactory titration up to satisfactory 
clinical condition was achieved) was administered. In order not to interfere with routine 
clinical practice, the decision to give additional propofol as well as the decision to start the 
intubation was made by the treating physician. In the UZ Leuven NICU, endotracheal 
intubation mainly occurs by nasal route. 
 
The initial propofol dose for the next patient in the same stratum was based on the outcome of 
the previous patient, using the up-and-down method 
53
. The minimum and maximum 
predefined initial doses were 0.5 and 4 mg/kg, respectively. Successful outcome was defined 
as an endotracheal intubation with satisfactory sedation and relaxation (assessed by the 
treating physician) without the need for additional propofol (and extubation within 1 hour 
after propofol administration in case of INSURE procedure). If additional propofol was 
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needed, the initial dose for the next patient in the same stratum was increased with 0.5 mg/kg. 
If no additional propofol was needed, a decrease (-0.5 mg/kg) in initial dose was applied for 
the next patient in the same stratum.  
 
Intubation procedure 
The number of intubation attempts, the time to successful intubation (i.e. time from propofol 
administration until the clinician who performs the intubation considers the tube to be in the 
correct endotracheal position based on clinical inspection of the patient and auscultation) and 
the physician performing the (final) successful intubation (registrar, fellow, neonatologist) 
were recorded. The UZ Leuven NICU is a university training center. When the tube is not in 
the correct position after 1-2 attempts, intubation is performed by the supervising 
neonatologist. 
 
Propofol whole blood concentrations 
Blood sampling  
Blood samples for quantification of propofol concentration were collected at 3 hours (h) and, 
if possible, at 12 h after propofol administration. Only neonates with an arterial line were 
included for blood sampling or alternatively samples were taken by venous puncture, when 
sampling for medical reasons was necessary. Blood samples (300-600 µL/sample) were 
collected in oxalate tubes (BD Vacutainer) and a maximum total blood volume of 1 mL/kg 
collected in each individual was respected.  
 
Drug assay 
Blood samples were stored at 4°C, for a maximum period of 4 weeks, until processing. To 1 
volume of whole blood, 0.1 volume of the internal standard (thymol, 5 µg/mL in 50:50 
methanol:water) and 2 volumes of acetonitrile were added. Subsequently, samples were 
vortexed 2 times for 15 seconds, before being centrifuged (20816 g) at 4°C for 10 min. The 
supernatant was transferred to a new recipient and stored at -20°C until analysis. At the day of 
analysis, the supernatant was thawed, vortexed and centrifuged (20816 g) at 4°C for 10 min. 
150 µl of each supernatant was transferred into a micro-insert for HPLC (high performance 
liquid chromatography)-vials and injected directly into the HPLC-system. The HPLC-system 
consisted of a Waters 600E pump, combined with a Waters 717plus autosampler (8°C) and a 
Waters 2475 multi l fluoresence detector (ex/em: 270/310 nm). The injection volume was 35 
µL. Chromatographic separation of propofol (RT: 9 min) and thymol (RT: 6 min) over a total 
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run time of 12 min, was performed on a Gemini® C18 column (3 µm, 4.6 mm x 150 mm, 
Phenomenex, Utrecht, The Netherlands) protected with a Gemini® C18 SecurityGuard® 
cartridge (3 µm, 4 mm x 3 mm, Phenomenex, Utrecht, The Netherlands) both maintained at 
30°C. The mobile phase consisted of a mixture of acetonitrile and water (0.1% v/v formic 
acid) (70:30, v/v) which was delivered to the system isocratically at a flow rate of 0.6 
mL/min. Calibration curves of propofol were constructed at 10X concentrations in a mixture 
of methanol in water (50% v/v). 20 µL of each concentration was transferred to 180 µL of 
whole blood, after which they were processed in the same manner as whole blood samples. 
Calibration curves were found to be linear in the range of 0.005-20 µg/mL. Quality control 
samples were prepared at concentrations of 0.05, 0.5 and 5 µg/mL, processed and stored at -
20°C. Intra- and interday coefficients of variation were lower than 10% and the LOD and 
LLOQ valued 0.0014 µg/mL and 0.0048 µg/mL, respectively.  
 
Propofol pharmacodynamics 
Relaxation and sedation scores  
Relaxation and sedation scores were collected by 1 of 2 observers using predefined scoring 
systems. The scores were only used for retrospective evaluation of sedation and relaxation 
status of the patient, without interfering with decisions taken by the treating physician during 
the intubation procedure. Scores were evaluated every 2 minutes, from 5 minutes before up to 
21 minutes after propofol administration. Additionally, at the moment of propofol 
administration (time=0) and 1 minute thereafter, scores were collected. Relaxation was 
evaluated by clinical evaluation of the tone in arms and legs. Four degrees of relaxation, 
adapted from Naulaers et al 
54,55
 were considered (grade 1: hypertonic, grade 2: normal tone, 
grade 3: mildly hypotonic, grade 4: hypotonic) with effective relaxation defined as a score > 
grade 2. The degree of sedation was assessed as the motor response to external stimuli. As a 
stimulus ‘heel-rubbing’ as described by Grunau et al 
56
 was used. Four degrees of sedation 
were considered (grade 1: moves spontaneously, grade 2: moves when touched, grade 3: 
moves when stimulated, grade 4: no reaction to stimulus) 
54,55
, with effective sedation defined 
as a score > grade 2. 
 
Intubation condition score 
The intubation conditions at the moment of the final intubation were retrospectively scored by 
the treating physician who finally performed the intubation. The intubation condition score 
(ICS) according to Viby-Mogensen (Table 9) 
1
 was hereby used. The score was only 
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documented for retrospective evaluation of the final intubation conditions and good condition 
was defined as a total ICS ≤ 10, without taking the subscores into account.  
 
Table 9: The Viby-Mogensen Intubation Condition Score (ICS) used in this study 
1
 
 
Intubation Condition Score 
1
 
 1 2 3 4 Total 
Laryngoscopy Easy Fair Difficult Impossible  
Vocal cords Open Moving Closing Closed  
Coughing None slight Moderate Severe  
Jaw relaxation Complete Slight Stiff Rigid  
Limb movement None Slight Moderate Severe  
Total  
 
 
Vital signs and cerebral oxygenation 
Vital signs [heart rate (HR, beats per minute, bpm), mean arterial blood pressure (MABP, 
mmHg), peripheral oxygen saturation (SaO2, %), respiration rate (RR, breaths per minute) and 
perfusion index (PI, %, a relative assessment of the pulse strength at a specific monitoring 
site, calculated as the ratio between pulsatile and non-pulsatile signals by the pulse oxymeter 
57
)] were measured using IntelliVue MP70 (Philips, The Netherlands) with Nellcor Pulse 
Oxymeter sensor from 2 minutes before up to 12 hours after propofol administration. Data 
were recorded simultaneously and continuously on a personal computer with a sampling rate 
of 2 Hertz using Rugloop® (RUG, Gent, Belgium) and subsequently converted using 
Rugloop Converter in Excel. MABP was measured invasively if an indwelling arterial line 
was present. If not, manual blood pressure was measured at least every 5 minutes as safety 
parameter after propofol administration, but was not used for further analysis. 
Near infra-red spectroscopy (NIRS) determined regional cerebral oxygen saturation (rScO2, 
%) was used as a reliable estimator for changes in regional cerebral oxygenation 
58
. An 
INVOS 5100 near infrared spectrometer (Somanetics Corp., Troy, Michigan, USA) was used 
to measure this parameter. The cerebral neonatal OxyAlert NIRSensor (Covidien) was 
attached to the fronto-parietal left side of the neonatal skull. To investigate the balance 
between oxygen delivery and oxygen consumption, the cerebral fractional tissue oxygen 
extraction (cFTOE) was calculated as [(SaO2-rScO2)/SaO2]. An increase of cFTOE might 
indicate a reduced oxygen delivery to the brain with a constant oxygen consumption of the 
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brain or higher oxygen consumption than oxygen delivery. A decrease of cFTOE suggests a 
decrease of oxygen extraction of the brain due to less oxygen use or a constant oxygen 
consumption of the brain with an increased oxygen delivery to the brain 
59,60
.  
 
Data analysis and statistics 
Descriptive statistics 
Clinical characteristics were reported for the 4 patients groups (as defined in Table 8) by 
median (range) or incidence. To explore continuous and dichotomous covariates between the 
patient groups, the Kruskal-Wallis test and Fisher exact test was used, respectively. For the 
patients receiving propofol for INSURE indication, time until in-and extubation were 
compared between ‘success’ versus ‘failure’ outcome (Mann-Whitney U test). A p-value 
<0.05 was considered statistically significant. Analysis was performed using SPSS (IBM 
statistical software, version 20.0, Armonk, New York, IBM Corp.) and Medcalc (Medcalc 
Statistical Software version 13.1.7, Ostend, Belgium).  
 
Covariates of observed propofol concentrations 
Whole blood propofol concentrations (µg/mL) at 3 h and 12 h after propofol administration 
were presented as median and range. To explore covariates of variability in propofol 
concentrations at 3 h and 12 h after propofol administration, univariate regression (continuous 
covariates) and Mann Whitney U test (dichotomous covariates) were used. Covariates 
significant in univariate analysis were entered in a multiple regression analysis.  
 
Propofol pharmacodynamics 
Signal processing of vital signs  
Data analysis was performed using MATLAB (MATLAB Release 2013a, The MathWorks, 
Inc., Natick, Massachusetts, USA). Data were filtered using a median filter with a length of 
10 samples. Remaining artefacts were detected manually and replaced by ‘not a number’ 
symbol (NaN). For each measured variable, its baseline value was computed as the median of 
the segment comprised by the 2 minutes prior to propofol administration. In addition, the 
MABP (mmHg) was corrected for PMA (weeks), using the following formula cMABP = 
MABP-PMA, where cMABP represents the corrected MABP. 
To explore individual changes in the included parameters, the minimum value for MABP, 
HR, SaO2, rScO2 and PI after propofol administration was computed as % change from 
baseline value using the following formula: ΔX[%] = 100*[min(X)-Baseline(X)] 
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/Baseline(X), where X represents the measured variable, min(X) represents the minimum 
value of X, and Baseline(X) represent the Baseline value computed for X. For the FTOE the 
absolute minimum and maximum value was computed. 
 
The extent and duration in fluctuations of vital signs was taken into account by calculating the 
area under the curve (AUC). The AUC for each measured variable was computed using 
trapezoidal numerical integration. This integration is calculated as the sum of all the data in a 
given signal X multiplied by the sampling period, which is the inverse of the sampling 
frequency. For AUC calculation of a given signal X related to a predefined threshold value 
(TH), trapezoidal integration was used by integrating the signal ΔX=X-TH, and replacing all 
the positive numbers in ΔX by 0 before integration. Using this approach, the AUC for 
cMABP, HR, SaO2 rScO2 and PI was computed using 0 mmHg, 100 bpm 
61
, 85% 
62
, 65% 
63,64
 
and 0.44% 
57
 as threshold, respectively. Since at present, no cut-off value for cFTOE in 
neonates is available, AUC and AAC (area above the curve) were calculated form the baseline 
value for each individual.  
 
Data were graphically presented for the 4 patient groups as defined in Table 8. Both a median 
trend line with interquartile range (p25-p75) as well as individual trend lines from the 
continuous measurements were plotted.  
 
To explore covariates of AUC cMABP, AUC SaO2 and AUC rScO2 after propofol 
administration, univariate linear regression (for continuous covariates) and Mann Whitney U 
test (dichotomous covariates) were performed using clinical characteristics and propofol 
concentrations at 3 h and 12 h. Covariates significant in univariate analysis could 
subsequently be included in a multiple regression analysis.  
 
Propofol ED50 calculation 
An up-and-down dose-response design was used to determine the propofol ED50 dose 
(mg/kg). The ED50 was calculated separately in each stratum with an effective sampling size 
of at least N=6, using the Dixon-Massey method 
53
 for small sample size. The effective 
sample size (N) is the number of trials reduced by one less than the number of similar 
responses at the beginning of the series. The ED50 is the average of the N doses with a 
correction factor added, as presented in equation 1: 
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The Xi‘s are the initial propofol doses of the final N trials. The correction factor is a weighted 
function [the weight equals the interval between dose levels (d= 0.5) divided by N] of two 
tabulated values, A and C. Value A is obtained as a function of the difference in ineffective 
(i.e. failed outcome) and effective (i.e. successful outcome) responses and value C is a 
function of the number of similar responses in the beginning of the series. The respective 
values for A and C were obtained as provided by Dixon (Table 10) 
53
. If there are no similar 
responses at the beginning of the series and there is no difference in ineffective and effective 
responses, the ED50 is simply the observed average of the used dose levels. Analyses have 
been performed using SAS software, version 9.2 of the SAS System for Windows.  
 
 
Table 10: Values for A and C to determine ED50 as described by Dixon 
53
. n□ = number of ineffective 
responses, n■= number of effective responses. C=0 for a series whose first part is a single □ or ■.  
 
 C for test series whose first part is 
      n□ - n■ A □□ □□□ □□□□ □□□□□ 
      5 10.8 0 0 0 0 
4 7.72 0 0 0 0 
3 5.22 0.03 0.03 0.03 0.03 
2 3.20 0.10 0.10 0.10 0.10 
1 1.53 0.16 0.17 0.17 0.17 
0 0 0.44 0.48 0.48 0.48 
-1 -1.55 0.55 0.65 0.65 0.65 
-2 -3.30 1.14 1.36 1.38 1.38 
-3 -5.22 1.77 2.16 2.22 2.22 
-4 -7.55 2.48 3.36 3.52 3.56 
-5 -10.3 3.5 4.8 5.2 5.3 
n■ - n□ - A ■■ ■■■ ■■■■ ■■■■■ 
     -C for test series whose first part is 
  
 
Results 
Descriptive statistics 
Study population 
Data were prospectively collected in 35 patients. Clinical characteristics for the 4 patient 
groups are provided in Table 11. Continuous registration of vital signs was available for 34/35 
patients, blood pressure was measured invasively in 28/35 patients. In 30 cases, the indication 
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for propofol administration was an INSURE procedure, in 5 cases a non-INSURE condition 
(e.g. renal biopsy, respiratory failure, clipping patent ductus arteriosus) was documented.  
 
Efficacy 
Intubation procedure 
Successful intubation was achieved after the first intubation attempt in 60% of the patients, 
25.7% was intubated after the second attempt and 14.3% of patients after the third attempt. Of 
those who were intubated after the first attempt, intubation was performed by registrars in 
42.9%, by fellows in 4.8% and by neonatologists in 52.4% of cases. Overall, in 31.4% of 
patients final successful intubation was achieved by registrars, in 2.9% by fellows and 65.7% 
of final intubations were performed by neonatologists.  
 
In 57.1% of cases the initial propofol dose was sufficient, in 25.7% 1 additional dose was 
administered (dosing according to protocol), in 5.7% 2 additional doses and in 11.4% up to 3 
additional propofol doses were needed for successful intubation. Total propofol dose (mg/kg) 
and time to intubation for the 4 patient groups are presented in Figure 3.  
 
 
Figure 3a      Figure 3b 
Figure 3: (a) Total propofol dose (mg/kg) and (b) time to intubation (minutes) after propofol 
administration presented as boxplots for the 4 patient groups as defined in Table 8. 
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Using the up-and-down dose finding approach, successful outcome (i.e. successful intubation 
with satisfactory sedation and relaxation as defined by the treating physician without the need 
for additional propofol, and in case of INSURE procedure, with subsequent successful 
extubation within 60 minutes) was achieved in 51.4% of cases (54.5% in group 1, 60% in 
group 2, 42.9% in group 3 and 0% in group 4). Of the 30 INSURE cases, 17 had a successful 
outcome, 13 failed. Of these 13 failed cases, 3 neonates were (still) intubated 60 minutes after 
propofol administration (2 were not yet extubated: 1 due to pneumothorax, 1 due to repeated 
bradycardia and desaturation events, additionally 1 patient needed reintubation 24 minutes 
after extubation). In 11 failed cases, additional propofol was needed to achieve sufficient 
sedation prior to intubation. 
 
Since most included neonates received propofol for INSURE indication, information 
concerning time to intubation, surfactant administration and extubation (all expressed as 
minutes after propofol administration) is presented in Table 12.  
 
 
Table 12: Time to intubation, surfactant administration and extubation (expressed as minutes after 
propofol administration) for patients receiving propofol for INSURE indication. Data are presented as 
median and range. Mann Whitney U test was used to compare cases with outcome success (i.e. 
successful intubation with satisfactory sedation and relaxation as defined by the treating physician 
without the need for additional propofol, and in case of INSURE procedure, also successful extubation 
within 60 minutes) versus failure.  
 
                         INSURE 
Parameter All patients 
(n=30) 
Outcome success 
(n=17) 
Outcome failure 
(n=13) 
p-value 
Time to intubation (min) 4 (0-14) 2 (0-7) 7 (2-14) 0.0002 
Time to surfactant (min) 6 (1-17) 4 (1-8) 9 (3-17) 0.0006 
Time to extubation (min) 10 (4-2687) 8 (4-14) 15 (7-2687) 0.0011 
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Propofol whole blood concentrations  
Median (range) propofol concentration at 3 h after propofol administration, based on 28 
collected samples, was 0.200 (0.034-1.110) µg/mL. At 12 h after propofol administration, 19 
samples were available and median (range) concentration was 0.093 (0.035-0.467) µg/mL.  
 
Taking all samples into account, total propofol dose (mg/kg) was significantly associated with 
concentrations achieved at 3 h (p=0.0003) and at 12 h (p=0.0001). Neonates with a successful 
outcome, displayed significantly lower median propofol concentrations at 3 h and 12 h 
compared to those with a failed outcome (at 3h 0.101 µg/mL versus 0.274 µg/mL, p=0.010; at 
12 h 0.068 µg/mL versus 0.163 µg/mL, p=0.041). This can be explained by the fact that most 
cases with a failed outcome were due to the need of insufficient sedation after the initial 
propofol dose (n=11/13), requiring additional propofol administration. In a multiple 
regression analysis, only total propofol dose remained significant to explain variability in 
propofol concentrations at 3 h and 12 h after administration. 
 
When exploring covariates of propofol concentrations in the subgroup receiving a total 
propofol dose <2 mg/kg, propofol concentrations at 3 h were significantly associated with 
weight (BW and CW), age (GA and PMA) and total propofol dose (mg/kg). Since both BW 
and CW, and GA and PMA are highly correlated, only PMA and total dose were included in a 
multiple regression analysis. Both remained significantly associated with concentrations at 3 
h. Concentrations at 12 h were significantly associated with weight (either BW or CW).  
 
Propofol pharmacodynamics 
Relaxation, sedation and intubation condition scores 
Evolution of relaxation and sedation scores achieved in the 35 patients are presented in Figure 
4 and 5 respectively. Median (range) intubation condition score was 7 (5-13), 6 (5-10), 9 (6-
10) and 8 (7-9) for group 1, 2, 3 and 4 respectively and did not differ significantly across the 4 
groups (p=0.231). 
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Figure 4: Relaxation scores, adapted from Naulaers et al 
54,55
, collected in the 35 patients from 5 
minutes before up to 21 minutes after propofol administration (time=0). Y-axis: number of patients. 
 
 
 
 
 
Figure 5: Sedation scores, as reported previously 
54,55
, collected in the 35 patients from 5 minutes 
before up to 21 minutes after propofol administration (time=0). Y-axis: number of patients. 
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Vital signs and cerebral oxygenation 
In Table 13, a summary of the analyses for MABP, HR, SaO2, rScO2, FTOE and PI is 
presented. When exploring the age-corrected MABP values (cMABP), median (range) of the 
lowest values was -3 (-5, 1), -3 (-6,7.5), 2 (-9, 5) and -5.5 (-7, -4) for group 1, 2, 3 and 4 
respectively. During the first 24 h after propofol administration, 5 patients received a fluid 
bolus (normal saline or colloids), with initiation between 8.5 h and 21.5 h after propofol 
administration.  
 
For MABP, HR, SaO2, rScO2, FTOE and PI a median trend line with interquartile range (p25-
p75) up to 720 minutes after propofol administration for the 4 patients groups (as defined in 
Table 8) is presented in Figures 6a, 7a, 8a, 9a, 10a and 11a respectively. To provide more 
details concerning the first hours after propofol administration, individual trend lines were 
plotted up to 240 minutes after propofol administration (Figure 6b, 7b, 8b, 9b, 10b and 11b).  
 
Optimal interpretation of the vital signs requires review of the values provided in Table 13, 
since they cover the full 12 h period, as well as visual inspection of the graphs. The latter are 
of add-on value to unveil short-lasting changes immediately after propofol administration.  
 
Univariate regression revealed no significant association between either AUC cMABP, AUC 
SaO2 or AUC rScO2 and clinical covariates (age, weight, total propofol dose) or propofol 
concentrations at 3 h or 12 h. Furthermore, AUC cMABP, AUC SaO2 or AUC rScO2 was not 
significantly associated with gender or outcome (success/failure).  
 
Propofol ED50 calculation 
Stratum 1, 3 and 5, as defined in Table 8, contained an effective sample size sufficiently high 
to calculate the propofol ED50 value. The initial propofol dose (mg/kg) sequentially 
administered to the neonates included in these strata are visually presented in Figure 12. The 
ED50 (95% confidence interval) value was 0.749 (0.331-1.167) mg/kg, 0.480 (0.110-0.851) 
mg/kg and 1.287 (0.721-1.852) mg/kg for stratum 1, 3 and 5, respectively. 
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Figure 6a 
 
Figure 6b 
 
Figure 6: Mean arterial blood pressure corrected for postmenstrual age (cMABP) for the 4 groups. 
Patients with invasive monitoring (n=26) were included. (a) Median trend line and interquartile range 
(grey zone) up to 720 minutes and (b) individual trend lines up to first 240 minutes after propofol. 
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Figure 7a 
 
Figure 7b 
 
Figure 7: Heart rate (beats per minute, bpm) for the 4 patient groups. Data of 34 patients were 
included. (a) Median trend line with interquartile range (grey zone) up to 720 minutes and (b) 
individual trend lines up to first 240 minutes after propofol. 
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Figure 8a 
 
Figure 8b 
 
Figure 8: Oxygen saturation (SaO2,%) for the 4 patient groups. Data of 34 patients were included. (a) 
Median trend line with interquartile range (grey zone) up to 720 minutes and (b) individual trend lines 
up to first 240 minutes after propofol. 
Disposition of intravenous propofol bolus in neonates 
 
 
107 
 
 
Figure 9a 
 
Figure 9b  
 
Figure 9: Regional cerebral oxygen saturation (rScO2,%) for the 4 patient groups. Data of 34 patients 
were included. (a) Median trend line with interquartile range (grey zone) up to 720 minutes and (b) 
individual trend lines up to first 240 minutes after propofol. 
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Figure 10a 
 
Figure 10b  
 
Figure 10: Cerebral fractional tissue oxygen extraction (cFTOE, normalized units) for the 4 patient 
groups. Data of 34 patients were included. (a) Median trend line with interquartile range (grey zone) 
up to 720 minutes and (b) individual trend lines up to first 240 minutes after propofol. 
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Figure 11a 
 
Figure 11b  
 
Figure 11: Perfusion index (PI, arbitrary units) for the 4 patient groups. Data of 34 patients were 
included. (a) Median trend line with interquartile range (grey zone) up to 720 minutes and (b) 
individual trend lines up to first 240 minutes after propofol. 
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Figure 12a: Stratum 1 
 
Figure 12b: Stratum 3 
 
Figure 12c: Stratum 5 
Figure 12: Initial propofol dose (mg/kg) sequentially administered in a) stratum 1, b) stratum 3 and c) 
stratum 5, for which ED50 calculation was possible (i.e. effective sample size at least equal to 6).  
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Discussion 
 
The interest to use propofol for pre-intubation sedation in neonates is growing, but evidence 
concerning optimal dosing and safety is limited. We therefore performed an exploratory 
propofol dose-finding study in neonates needing pre-medication for endotracheal intubation. 
Besides data concerning intubation efficacy, we also explored propofol pharmacodynamics 
(sedation, relaxation and intubation condition scores, detailed and continuous vital sign 
measurements) as well as propofol blood concentrations, and finally provided propofol ED50 
doses.  
 
Efficacy 
Propofol is a short acting drug and administered to create optimal intubation conditions and 
fast recovery of awake status afterwards. Achievement of adequate sedation is needed for 
patient comfort and to avoid trauma, but it also facilitates the intubation procedure for the 
clinician. Throughout the present study, initial and total propofol bolus dose ranges of 0.5-2 
mg/kg and 0.5-4.5 mg/kg, respectively, were used. Simons et al 
16
, reported that a starting 
dose of 2 mg/kg for endotracheal intubation was only sufficient in 37% of cases (but 77% on 
the first day of life) and that success rate of the first intubation attempt was 49% 
6
. Compared 
to his observations, our initial propofol dose (median = 1 mg/kg) was lower but still had a 
comparable success rate in terms of predefined outcome as well as successful first intubation 
attempts. Importantly, the median PNA of the patients described by Simons et al was 5 days 
and no INSURE cases were included. The percentage of patients intubated at first attempt in 
our study is also in line with other reports (69% current study versus 60% by Welzing et al 
65
).  
 
Propofol whole blood concentrations 
As mentioned in the introduction of this chapter, propofol clearance in neonates increases 
with PMA. Due to immature glucuronidation capacity in early life, a PNA below 10 days 
additionally impairs metabolic elimination of this compound 
7,8
. The propofol concentrations 
collected in this study mainly cover the late distribution phase (3 h and 12 h sampling). In 
patients receiving <2 mg/kg total propofol dose, covariates weight and age in part explained 
variability in propofol concentrations, especially at 3 h. This regression analysis hereby 
confirms the relevance of maturational covariates earlier described in this chapter (section 4.1 
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and 4.2). As a future perspective, the currently collected data can be used to further validate 
the reported propofol PK models in neonates. 
 
Propofol pharmacodynamics 
Relaxation, sedation and intubation condition score  
Following the study of Ghanta et al 
11
 - one of the first reports of propofol (and its PD 
aspects) as induction agent for (semi)elective intubations in neonates - the drug became 
introduced in many neonatal intensive care units. One of the claimed advantages attributed to 
propofol is the continuation of spontaneous breathing and fast recovery of the sedative effect. 
However, we want to attenuate this clinical perception for use in neonates, since the suggested 
‘fast’ recovery strongly depends on the outcome measures assessed. At least in our hands, 
both sedation and relaxation scores were not yet returned to pre-sedation condition at 21 
minutes after propofol administration, as presented in Figures 4 and 5. In contrast, Ghanta et 
al 
11
 described a median time to recovery of 840 seconds (recalculated as time to sleep or 
muscle relaxation of 60 seconds plus time from sleep to return of spontaneous muscle 
movement of 780 seconds) (= 14 minutes) after administration of a 2.5 mg/kg propofol dose. 
However, it is questionable if spontaneous, voluntary muscle movement sufficiently covers 
the term ‘re’-covery, and in addition, to what extent this parameter reflects propofol effects in 
other body compartments (e.g. central nervous system). While it is not yet fully clear how 
propofol disrupts neural transmission, activation of the GABAA receptor is one of the 
mechanisms involved 
66
. Since GABAA in early life primarily displays excitatory function and 
only later in life changes into inhibitory signaling 
67,68
, understanding or estimating the 
sedative drug effects in early infancy (developmental PK/PD) becomes even more complex. 
The same holds true for other GABA-related phenomena like dissociative (the presence of 
peripheral but no central inhibition) effects in early life 
16
.  
 
One of the strengths of the current analysis is the continuous registration of vital signs over a 
relevant period (12 h) after propofol administration. When compared to baseline, a median 
MABP decrease between -29.41% and -39.09% was documented. This is in line with the 
mean blood pressure trend published by Simons et al 
16
. Based on the median values of mean 
arterial blood pressure prior to and after propofol administration, provided by Welzing et al 
11
, 
a MABP decrease of -36.8% (38 to 24 mmHg) after propofol bolus administration and -24% 
(37 to 28) mmHg after propofol administration over 60 seconds, was recalculated. Although 
the study of Welzing was stopped, the % decrease of MABP is comparable with our findings. 
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As commented by Lerman et al 
69
, it is open for discussion whether the early termination of 
the Welzing study was needed since systolic blood pressure within 10 minutes after intubation 
decreased, on average, only 20% from baseline and values >30% were only found in 23% of 
neonates. Similar to the assessment of sedation and relaxation, this reflects different opinions 
on how these trends in vital signs should be interpreted. To put these trends into perspective, 
we also determined of age-corrected blood pressure values and its AUC. Based on these age-
corrected blood pressure values (cMABP), a relevant proportion of patients indeed displayed 
hypotension (defined as cMABP <0), but mainly in the area considered as ‘permissive 
hypotension’ (defined as cMABP <0, without clinical signs of shock and no need for 
treatment) 
70,71
 (Table 13). Only a limited number of neonates (n=2) received a fluid bolus 
during the 24 h after propofol administration, with initiation at least 8 h after propofol, 
making the possibility of a causal link with this drug very unlikely. There was no need for 
inotropes. 
 
Based on the observations of Vanderhaeghen et al 
12
, persistence of a decrease in blood 
pressure beyond the first 60 minutes after propofol administration was anticipated. Visual 
inspection of groups 1, 2 and 3 on Figure 6a, suggests that the duration in blood pressure 
decrease is present up to 120-200 minutes after propofol administration. This transient 
decrease in blood pressure after propofol has been described in neonates, but also in older 
children and adults. It is hypothesized to be the result of a propofol-induced vasodilatation, 
which seems more relevant when the drug is administered in the first hours of life. At present 
there is evidence that preterm neonates, in general, can maintain cerebral blood flow (CBF) 
despite changes in hemodynamic parameters e.g. blood pressure 
72,73
. 
 
Irrespective of how clinicians assess the trends in blood pressure, this is only an indirect 
marker of blood flow and cerebral oxygenation 
58
. This is the reason that we simultaneously 
collected data on both vital signs and cerebral oxygenation and extraction. It is known that the 
sedative effect of propofol results in a decreased cerebral oxygen consumption by inhibition 
of the N-methyl D-aspartate receptors and activation of the GABAA receptors 
12
. Despite this 
reduced consumption, a mild and short-lasting decrease in rScO2 was seen in the first 20-30 
minutes after propofol administration in the current study (Figure 9). This decrease in rScO2 
can be caused by a decreased SaO2 (hypoxic hypoxia) or by a decrease in CBF secondary to a 
decreased MABP (ischemic hypoxia) when autoregulation mechanisms fail. Due to the brisk 
decreases in SaO2 with stable HR around the intubation procedure, we hypothesize the 
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decrease in rScO2 can be explained by hypoxic hypoxia since in most cases cFTOE remains 
stable (Figure 10a) 
74
. However, in some infants in group 1 and 2 an increase in cFTOE up to 
0.6 (Figure 10b) can be seen. We attribute this to decrease in SaO2 and MABP which will lead 
to higher oxygen extraction in order to provide sufficient oxygen delivery to the brain. This 
effect is short lasting (less than 30 minutes) and can be considered as safe 
75
. After recovery, 
the rScO2 value remains quite stable.  
A lower but more stable trend in cFTOE can be seen up to the first 200 minutes (Figure 10a, 
groups 1, 2 and 3) . This might indicate less oxygen consumption with stable supply or equal 
oxygen consumption with increased supply. Taking into account our study setting, we 
hypothesize this mainly indicates a decrease in cerebral oxygen consumption due to propofol, 
with intact neurovascular coupling. An exception can be seen in group 4 were a child with 
renal failure and hypertension displays a drop in cMABP with sustained increase of cFTOE. 
In our opinion, autoregulation in this patient has failed with an increased oxygen consumption 
due to impaired CBF during +/- 70 minutes. Although based on one observation, caution is 
warranted when administering propofol to neonates with hypertension. Interestingly, to the 
other patient in group 4 high oxygenation was applied, reflected by SaO2 and rScO2 values at 
the upper limit. The coincidental cFTOE hereby approximates 0. This illustrates the 
limitations of ‘calculated’ parameters like cFTOE (Figure 10b) or relates to the fact that the 
rScO2 parameter was measured by the neonatal OxyAlert NIRSensor, which gives rScO2 
values on average 10% higher compared to the small adult SomaSensor 
63
.  
 
After propofol administration, the PI displays an initial increase with subsequent decrease to 
0.5 % (Figure 10). This might be related to the propofol induced vasodilatation. PI is 
considered to be a valuable tool in clinical practice, providing information on e.g. illness 
severity and heamodynamic stability, but it needs to be combined with other parameters and, 
importantly, further validation in neonates is necessary 
57
. Therefore, we only describe the PI 
trend documented in this specific population. 
 
Although Welzing et al 
13
 described that both HR and SaO2 remained stable throughout an 
INSURE procedure with propofol (1 mg/kg) as premedication, a short-lasting and minor 
decrease in HR and SaO2 after propofol (3 mg/kg) for chest tube removal in neonates was 
previously reported 
11,12
. In our cohort, a modest decrease in HR persisted up to 200 minutes 
is documented (Figure 7a). Although the administration of propofol resulted in hypotension, 
no accompanying tachycardia was seen. This is probably due to the inhibitory effect of 
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propofol on the baroreceptor reflex 
12
. Since AUC for HR <100 bpm is equal to 0 in groups 1, 
2 and 3, no clinically significant bradycardia was noticed for these patient groups. Due to the 
older age of the patients in group 4 (n=2), lower HR values (up to 80 bpm) are clinically 
tolerated and considered as normal. This in part explains the higher AUC HR value for group 
4.  
The decrease in SaO2 after propofol administration was most pronounced during the first 
minutes after propofol administration, related to the intubation procedure, with a fast return to 
baseline (Figure 8). 
 
Within the propofol dose range applied in this study, variability in AUC cMABP, AUC SaO2 
and AUC rScO2, could not be explained by covariates representing ontogeny (weight, age), 
nor by propofol blood concentrations at 3 h and 12 h after administration. This is of relevance 
since clinicians still might be reluctant to use procedural sedation in especially the smallest 
and youngest neonates 
65,76
. 
 
Propofol ED50 calculation 
Besides reporting efficacy and propofol PD (including clinical scores, vital signs for safety 
evaluation and concentration-effect relationships) an important aim was to provide propofol 
ED50 values. We succeeded to determine these concentrations, effective in 50% of patients, 
for preterm neonates with PNA <10 days (i.e. strata 1, 3 and 5). Our results indicate that 
overall low propofol doses can be used to achieve successful outcome. We hereby want to 
stress that the majority of our patients (86%) were INSURE cases. The combined outcome of 
successful intubation and successful extubation hereby needed a balanced approach, i.e. 
tailored sedation. The fact that our patients, to a certain extent, still react during the intubation 
procedure, is also reflected in the ICS scores (overall range 5-13).  
We are aware that an ED50 value cannot be considered as a robust dosing recommendation, 
but at least provides a start to develop future dose-finding and validation studies. This is 
important, since simple extrapolation of dosing regimens from older children is likely 
incorrect since on can assume that besides propofol metabolism itself (PK), also transporters 
and/or receptors involved could be immature in neonates (PD) 
16
. In addition, the impact and 
maturational expression of polymorphisms of propofol metabolizing enzymes and receptors 
on its PK and PD in early life is unknown. In adults, polymorphisms studies are not 
conclusive and certainly cannot explain large variations in propofol effects 
66
.  
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Clinical reflection 
In contrast to some other reports 
13,16
, we used clinical scores already published previously 
1,54,55
 and succeeded to collect them systematically. As mentioned above, an additional 
strength of this study is the continuous registration of different vital signs. We are aware that 
these data include every minor as well as major fluctuation in vital signs, but this reflects the 
clinical setting of the intubation procedure with possible artefacts. Importantly, we hereby 
illustrated that this type of study is feasible within an intensive care patient setting. With 
exception of determination of the initial propofol dose, there was no interference with routine 
clinical practice during the intubation procedure itself. 
 
Although this study provides relevant data for safety evaluation of propofol use in neonates, 
there are some limitations. First of all, knowledge on neonatal vital sign trends, definitions, 
threshold values, validated reference values and the role of these vital parameters as 
biomarkers reflecting neonatal drug effects is very poor. Additionally, caution is needed when 
interpreting propofol effects of different reports. Besides variability in parameter criteria (e.g. 
hypotension) also blood pressure measurement frequency and techniques applied, as well as 
clinical characteristics of included patients will contribute to variability in the collected data. 
 
After providing the reader with an overview of our observations, including its limitations, we 
leave it to the individual clinician to decide whether or not the results are sufficiently safe to 
use a single propofol bolus in neonates. Based on both the clinical scores and safety PD 
analysis, we feel it appropriate to use this compound in the dose-ranges studied for neonatal 
intubation, especially INSURE conditions. At induction, the respective ED50 doses can be 
applied. Subsequently, since questions concerning the mechanism of action and covariates of 
neonatal propofol pharmacokinetics still remain, we strongly advise to only increase the 
propofol bolus dose by up-titration based on perceived clinical need instead of routinely use 
of higher initial propofol doses in neonates. Strict follow-up of vital signs in the first hours 
after propofol administration is compulsory.  
 
We conclude that a dose-finding study with intravenous propofol bolus as premedication for 
intubation resulted in ED50 values for preterm neonates below 10 days PNA. Simultaneous 
propofol PD data indicate that clinical recovery is not yet achieved at 21 minutes after 
propofol administration. Although a moderate hypotensive effect, considered as permissive 
hypotension, was confirmed, available PD data allow the safe use of propofol in neonates 
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within a total dose range of 0.5-4.5 mg/kg. As a future perspective, further propofol dosing 
exploration, based on the 50 patients included in this research project will be performed and 
subsequently need to be validated. 
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Abstract  
 
Introduction Pharmacokinetic data of cefazolin in neonates are limited and based on total 
drug concentrations. However, only the unbound drug is pharmacologically active. The aims 
of the study were to explore cefazolin protein binding and its covariates in neonates, to 
compare cefazolin protein binding between different populations and finally, to describe 
neonatal cefazolin pharmacokinetics (PK) based on both total and unbound concentrations.  
 
Methods In neonates (n=40) receiving intravenous cefazolin (50 mg/kg) for surgical 
prophylaxis, total and unbound cefazolin plasma concentrations were determined. Linear and 
multiple regression analyses were used to document covariates of unbound cefazolin fraction. 
To explore cefazolin protein binding across different populations, the neonatal data were 
pooled with observations of 3 other published cohorts (i.e. pregnant women, surgical adults 
and non-surgical adults). Kruskal-Wallis tests and multiple regression were applied. Finally, a 
population pharmacokinetic analysis (using non-linear mixed-effect modelling) with 
subsequent Monte Carlo simulations was performed using the neonatal dataset. 
 
Results In neonates, between- and within patient saturability of cefazolin protein binding 
were documented: 49.6% of neonatal unbound cefazolin fraction was explained by 
albuminaemia, total cefazolin concentration, indirect bilirubinaemia and postmenstrual age 
(PMA). Median unbound cefazolin fraction differed significantly across the observed 
populations. 76.8% of variability in unbound fraction was explained by total cefazolin 
concentration, unbound cefazolin concentration, albuminaemia but also patient subgroup. For 
the neonatal data, a one-compartment PK model was developed. Current bodyweight was 
identified as covariate for volume of distribution (Vd), birth weight and postnatal age for 
clearance (Cl) and albumin for maximal protein binding (Bmax), explaining 50%, 58% and 
41% of inter-individual variability in Vd, Cl and Bmax respectively.  
 
Conclusions The unbound cefazolin fraction in neonates is higher compared to adults. 
Besides alterations in albuminaemia, also subpopulation-specific characteristics determine 
variability in unbound cefazolin fraction across different populations. The concept of drug 
protein binding needs to be integrated in PK analyses to optimize drug dosing regimens. To 
illustrate this, a neonatal PK model taking into account total and unbound cefazolin 
concentrations was identified and a model-based cefazolin dosing regimen based on current 
bodyweight and postnatal age, documented as most important PK covariates, was proposed. 
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What is already known on this topic 
 
 
§ Cefazolin is highly and saturably bound to human serum albumin in adults. 
 
§ Only the unbound drug can have a pharmacological effect and is available for elimination. 
 
§ Neonatal cefazolin pharmacokinetic (PK) data are rare and based on total drug 
concentrations. Available neonatal cefazolin dosing regimens cover a 3-fold mg/kg range. 
 
 
What this study adds 
 
 
§ Median unbound cefazolin fraction in neonates is 0.39, which is higher than in adults. 
 
§ A one-compartment PK model taking into account both total and unbound cefazolin 
concentrations in neonates was developed. 
 
§ A neonatal model-based cefazolin dosing approach reaching a predefined exposure, but 
with a total daily dose reduction up to 67%, was presented. 
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Introduction 
 
Cefazolin, a first-generation cephalosporin, interferes with bacterial cell wall synthesis and 
covers especially gram-positive bacteria. Cefazolin is administered parenterally. Based on a 
European survey, 15% of antimicrobial use for surgical prophylaxis in children is accounted 
for by first generation cephalosporins 
1
. In a US point prevalence survey of patients in 
paediatric intensive care units and neonatal intensive care units, cefazolin was used in 17.6% 
and 1.2% of patients on the day of the survey, respectively 
2
. Indications for cefazolin 
administration in neonates are mainly prophylactic (72%), and to a lesser extent therapeutic 
(17%) (e.g. coagulase-negative staphylococcal sepsis) 
3
 or empirical (11%) 
2
. While the 
pharmacokinetics of cefazolin have been described in adults, information on cefazolin 
pharmacokinetics in early life is limited 
4-6
.  
 
In plasma, cefazolin is bound to human serum albumin (HSA) 
7-9
. Protein binding influences 
drug disposition but also drug action since only the unbound drug is pharmacologically active 
10
. Furthermore, unbound drug concentrations in plasma are assumed to reflect drug 
concentrations at the effect site, and are available for elimination. In vitro, cefazolin protein 
binding ranges from 73-92%, depending on variations in albumin concentrations in plasma as 
well as differences in methodology used to measure protein binding. In vivo, cefazolin protein 
binding has been documented separately in pregnant woman 
11
 and adult (surgical) patients 
12,13
. Within the adult population, important intra- and interindividual variability as well as 
concentration-dependency (saturability) of cefazolin protein binding has been documented 
11,13
. 
 
As highlighted in the general introduction of this thesis, drug disposition in neonates differs 
from adults based on their physiological characteristics, including protein binding (e.g. 
hypoalbuminaemia) as well as specific pathological processes. Furthermore, ontogeny 
(reflected by age and weight) needs to be considered. Since protein binding is of relevance 
both in the pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of cefazolin, the aim 
of the present study is first to describe cefazolin protein binding and its covariates in neonates.  
 
At present, there is little data defining whether cefazolin protein binding varies significantly 
across different human patient groups. Therefore, as a side step, the current neonatal data 
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were pooled with cefazolin protein binding observations of published cohorts of pregnant 
women and (surgical) adults to explore cefazolin protein binding across different human 
patient populations.  
 
The collected data on cefazolin protein binding in neonates were subsequently integrated to 
improve cefazolin pharmacokinetic estimates. 
 
Up to now, neonatal clearance (Cl) values for cefazolin are mainly based on total cefazolin 
concentrations, necessitating a neonatal cefazolin pharmacokinetic analysis integrating both 
total and unbound drug concentrations. Therefore, as a final aim, the neonatal cefazolin 
dataset was used to describe pharmacokinetics of cefazolin in (pre)term neonates based on 
both total and unbound cefazolin concentrations.  
 
Finally, these pharmacokinetic estimates taking into account protein binding, were integrated 
in a population PK approach with subsequent exposure evaluation.   
 
When an antimicrobial drug is administered to a patient, this is done with the intention to 
achieve optimal efficacy. For cefazolin, efficacy relates to the time unbound cefazolin 
concentrations exceed the minimal inhibitory concentration (MIC) for a given pathogen 
(T>MIC) 
14
. In neonates, often regarded as vulnerable and even immunocompromised patients, 
effective cefazolin therapy requires at least 60% of T>MIC 
15
. However, currently available 
cefazolin dosing regimens for neonates are variable (Table 1) 
16-22
, hereby inducing 
uncertainty of efficacy attainment. To illustrate exposure to cefazolin using our current dosing 
approach and to propose a model-based dosing regimen for (pre)term neonates resulting in 
unbound concentrations during >60% of T>MIC, Monte Carlo simulations were performed.  
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Table 1: Overview of cefazolin dosing regimens for neonates and young infants. The dosing regimen 
used in the current study as well as the dosing regimen provided by the Dutch Children’s Formulary 
and different handbooks are presented. Data are adapted to mg/kg/dose. PNA: postnatal age, PMA: 
postmenstrual age, g:grams, h:hours 
 
 
  
Reference          Age Weight 
Cefazolin dose  
and interval 
NICU UZ Leuven 
  
50 mg/kg/dose, q8h 
Dutch Children’s 
Formulary 
16
 
< 1 week PNA 
< 2000 g 
> 2000 g 
25 mg/kg/dose, q12h 
50 mg/kg/dose, q12h 
1-4 weeks PNA 
 
50 mg/kg/dose, q8h 
Neonatal and pediatric 
pharmacology, Yaffe 
and Aranda 2011 
17
 
0-4 weeks PNA < 1200 g 20 mg/kg/dose, q12h 
< 1 week PNA 
1200-2000 g 
> 2000 g 
20 mg/kg/dose, q12h 
20 mg/kg/dose, q12h 
≥ 1 week PNA 
1200-2000 g 
> 2000 g 
20 mg/kg/dose, q12h 
20 mg/kg/dose, q8h 
The Harriet Lane 
Handbook 2012 
19
 
≤ 1 week PNA 
 
20 mg/kg/dose, q12h 
> 1 week PNA 
≤ 2000 g 
> 2000 g 
20 mg/kg/dose, q12h 
20 mg/kg/dose, q8h 
Neofax 2011 
20
 
≤ 29 weeks PMA      0-4 weeks PNA 
                                  > 4 weeks PNA  
25 mg/kg/dose, q12h 
25 mg/kg/dose, q8 h 
30-36 weeks PMA    0-2 weeks PNA 
                                  > 2 weeks PNA  
25 mg/kg/dose, q12h 
25 mg/kg/dose, q8 h 
37-44 weeks PMA     0-1 week PNA 
                                   > 1 week PNA  
25 mg/kg/dose, q12h 
25 mg/kg/dose, q8h 
≥ 45 weeks PMA       all 
 
25 mg/kg/dose, q6h 
Nelson’s Textbook of 
Pediatrics 2007 
18
 
< 1 week PNA 
 
20 mg/kg/dose, q12h 
> 1 week PNA 
 
13-20 mg/kg/dose, q8h 
The Sanford guide to 
antimicrobial therapy 
2012-2013 
21
 
≤ 29 weeks PMA      0-4 weeks PNA 
                                  > 4 weeks PNA  
50 mg/kg/dose, q12h 
50 mg/kg/dose, q8h 
30-36 weeks PMA    0-2 weeks PNA 
                                  > 2 weeks PNA  
50 mg/kg/dose, q12h 
50 mg/kg/dose, q8h 
37-44 weeks PMA     0-1 week PNA 
                                   > 1 week PNA  
50 mg/kg/dose, q12h 
50 mg/kg/dose, q8h 
≥ 45 weeks PMA       all 
 
50 mg/kg/dose, q6h 
Redbook 2012 
22 
 
≤ 1 week PNA 
≤ 2000 g 
> 2000 g 
25 mg/kg/dose, q12h 
25 mg/kg/dose, q12h 
> 1–4 weeks PNA 
≤ 2000 g 
> 2000 g 
25 mg/kg/dose, q12h 
25 mg/kg/dose, q8h 
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5.1. Cefazolin plasma protein binding and its covariates in neonates 
 
Methods 
 
Ethics, drug dosing and clinical characteristics 
All patients were admitted to the Neonatal Intensive Care Unit of the University Hospitals 
Leuven, Belgium. The study was registered at ClinicalTrials.gov (NCT01295606) and 
approved by the ethical board of our hospital. After informed written consent of the parents, 
neonates were considered for inclusion if cefazolin (Cefazolin Sandoz®, Sandoz, Vilvoorde, 
Belgium) was intravenously administered over 30 min as routine prophylactic drug prior to a 
surgical procedure. At induction of surgery, a cefazolin dose of 50 mg/kg was administered. 
According to the local standard of care (depending on foreign body implantation or 
contamination risk of the procedure), additional cefazolin dose(s) of 50 mg/kg could be 
administered every 8 hour up to a maximum of 48 hours. Clinical characteristics recorded at 
inclusion were gestational age at birth (GA), postmenstrual age (PMA), postnatal age (PNA), 
birth weight, current body weight, cardiopathy (yes/no), gender and indication for cefazolin 
prophylaxis. Albuminaemia (g/L), indirect serum bilirubin concentrations (mg/dL) and serum 
creatinine (mg/dL) in a time interval of 24 h before or after the first cefazolin administration 
were extracted from clinical files. Threshold values for hyperbilirubinaemia are based on 
earlier reported cut-off values according to PNA, to adapt for the normal postnatal transient 
increase with subsequent decrease in neonatal life 
23
. Plasma free fatty acids concentrations 
(FFA, mmol/l) were additionally determined on study samples at the end of the study. 
 
Plasma sampling  
Blood samples were collected in lithium-heparin tubes at fixed time points, i.e. at 0.5, 2, 4 and 
8 h after the first cefazolin administration and subsequently at 8 h intervals prior to each 
scheduled cefazolin administration, to determine total and unbound cefazolin concentrations. 
However, the number of samples collected from each patient was limited since the predefined 
total volume of blood available for sampling per patient was maximized to 1 mL/kg 
bodyweight. Blood samples (0.6 mL/sample) were immediately centrifuged (5 minutes, 4500 
rpm at 4 °C) and the resulting 0.3 mL plasma was stored at -20°C in two aliquots of 0.15 mL. 
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Drug assay  
The initial High Performance Liquid Chromatography (HPLC) method was developed in our 
laboratory and reported in literature 
11
. The method was adapted for measurement of cefazolin 
in small volume plasma samples of neonates. 
To determine total cefazolin plasma concentration, to 0.1 mL plasma were added: 10 µL of 
standard cefazolin dilutions in water (final concentration range 0.1-100 mg/L), 10 µL of 
cefoxitin dilution (100 mg/L) in water and 0.1 mL 0.1 M ammoniumacetate buffer pH 4.0. 
After vortexing and centrifuging for 5 min at 1800xg these samples were ready for application 
to the solid-phase extraction columns (Oasis HLB 30 mg, 1 ml). 
The solid-phase extraction was performed with a Vac Elut SPS24 vacuum extraction system. 
The columns were activated with 2 times 1 mL methanol and 2 times 1 mL water, applying 
slight vacuum to the columns. The prepared standards, controls or samples were subsequently 
passed through the columns over a time period of 2 to 3 min. Then 1 mL water was applied 
and vacuum maintained for 2 min, followed by 1 mL methanol/water (80/20, v/v) and again 
vacuum maintained for more 2 min. Elution of the columns was performed with 2 times 0.5 
ml of methanol (+0.2 % triethylamine). The eluates were evaporated with an airstream in a 
water bath at 45° C and the dried residues dissolved in 200 µL mobile phase. Injection 
volumes varied between 20 and 50 µL. 
To determine the unbound cefazolin, to 0.1 mL of plasma was added 10 µL of 1M HEPES 
buffer pH 6.0. The samples were vortexed and incubated for 1 h in a water bath at 37 °C. 
Ultrafiltration was performed with Centrifree micropartition devices in a fixed rotor 
centrifuge for 30 min at 1100xg at room temperature (final temperature in centrifuge was 32 
°C). The volume of the ultrafiltrate was adjusted to 0.1 mL with 0.5 % BSA in 0.9 % NaCl. 
After addition of 10 µL of cefoxitin (100 mg/L) and 0.1 mL of 5 % trichloroacetic acid, 
vortexing for 15 s, and waiting for 10 min, the samples were centrifuged for 8 min at 
12000xg. Standard curves were prepared in 0.5 % BSA in 0.9 % NaCl, instead of plasma. A 
hundred µL of the supernatant was transferred to injection vials and injected onto the 
analytical column. The lower limit of quantification for cefazolin was 0.1 µg/mL, with a 
coefficient of variation lower than 20%. Intra-assay precision and accuracy averaged 3.9 and 
5.5% respectively. Inter-assay precision and accuracy averaged 5.7 and 6.8%, respectively. In 
this way, HPLC conditions remained the same and method performance showed the same 
recovery and reproducibility as earlier reported 
11
 and was in line with FDA analytical 
recommendations 
24,25
.   
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Biochemical assays 
Albumin (bromocresol green), indirect bilirubin and creatinine (enzymatic) were determined 
on Roche Modular P (Roche Diagnostics, Basel, Switzerland). Non-esterified fatty acids were 
determined with a kit from DiaSys (Diagnostic Systems, Holzheim, Germany).  
 
Statistical analysis 
Statistical analysis was performed using SPSS (IBM statistical software, version 19) and 
Medcalc® (Mariakerke, Belgium). Clinical characteristics were reported by median and range 
or incidence. Two separate treatment episodes with cefazolin, documented in the same patient 
at different postnatal ages (i.e. PNA 25 days and PNA 53 days) were considered as 2 distinct 
observations. Cefazolin plasma concentrations (mg/L) were also reported by median and 
range. Unbound cefazolin fraction was calculated as the ratio of unbound to total drug 
concentrations. The impact of continuous and dichotomous covariates on unbound cefazolin 
fraction was determined using linear regression and Mann Whitney U tests respectively. 
Significant results of monovariate linear regression were entered in a multiple forward 
regression analysis. Within patient comparison of unbound cefazolin fraction at peak versus 
trough cefazolin concentration was assessed using Wilcoxon signed rank test. For this paired 
analysis, only neonates with cefazolin concentrations on both peak (0-2 h after first cefazolin 
administration) and trough (>6 h after first cefazolin administration but before next cefazolin 
administration, if scheduled) times were included. For different clinical conditions (i.e. 
albuminaemia <35 versus ≥ 35 g/l, albuminaemia <30 versus ≥30 g/l, PMA <37 versus ≥37 
weeks, PNA <10 versus ≥10 days and indirect hyperbilirubinaemia versus no indirect 
hyperbilirubinaemia), relationship between unbound and total cefazolin concentration was 
expressed using regression equation. 
 
 
Results 
 
Forty neonates (male/female ratio 25/15) were included. Clinical characteristics and 
indications for cefazolin administration are provided in Table 2. Based on 131 samples, 
median (range) total and unbound cefazolin plasma concentrations were 100.63 (9.65-404.22) 
mg/L and 40 (2-261.38) mg/L, respectively. Median unbound cefazolin fraction was 0.39 
(0.10-0.73).  
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Table 2: Clinical characteristics of all included study patients (n=40), reported by median and range or 
number of cases. Indirect bilirubinaemia and plasma free fatty acids (FFA) values were available in 
39/40 patients. 
 
Clinical characteristics Median (range) or number of cases 
Postmenstrual age (PMA, weeks) 39 (25-45) 
Postnatal age (PNA, days) 9 (1-108) 
Body weight at inclusion (g) 2767 (830-4200) 
Albuminaemia (g/l) 34.70 (28.2-43.70) 
Indirect bilirubinaemia (mg/dl) 2.80 (0.10-11.13) 
Free fatty acids (mmol/l) 0.10 (0.00-0.84) 
Creatinaemia (mg/dl) 0.44 (0.21-1.03) 
Cefazolin dose (first administration) (mg/kg) 50.13 (30.70-55.25) 
Cardiopathy  23 
 
Indication for cefazolin prophylaxis 
 
          Percutaneous cardiovascular procedures  
          Cardiac surgery 
          Thoracic surgery 
          Gastrointestinal surgery 
          Neurosurgery 
          Prophylaxis uropathy 
 
 
 
21 
6 
6 
4 
2 
1 
 
 
 
 
Linear regression of unbound cefazolin fraction as a function of unbound cefazolin plasma 
concentration resulted in an R² value of 0.39 (p<0.001) and a slope significantly different 
from zero (p<0.001) (Figure 1). Linear regression analysis was significant between unbound 
cefazolin fraction and total cefazolin concentration (R²=0.10, p<0.001), PMA (R²=0.29, 
p<0.001), PNA (R²=0.17, p<0.001), GA (R²=0.04, p=0.018), albuminaemia (R²=0.12, 
p<0.001) and indirect bilirubinaemia (R²=0.10, p<0.001), but not between unbound cefazolin 
fraction and plasma FFA concentrations (R²=0.001, p=0.657). Unbound cefazolin fraction 
was not significantly influenced by cardiopathy (MWU-test, p=0.08), nor by gender (MWU-
test, p=0.31). In a multiple forward regression analysis, based on all (n=131) samples, 4 
independent covariates of unbound cefazolin fraction (PMA, albuminaemia, total cefazolin 
concentration and indirect bilirubinaemia) resulted in an R² value of 0.496 (p<0.001). Linear 
regression graphs of the 4 individual covariates retained, are shown in Figure 2 a, b, c and d.  
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Figure 1: Linear regression of unbound cefazolin fraction as a function of unbound cefazolin plasma 
concentration. Regression equation was expressed as y= 29.6 + 0.22x 
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Figure 2a 
 
 
 
Figure 2b 
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Figure 2c 
 
 
 
Figure 2d 
 
Figure 2: Linear regression of unbound cefazolin fraction as a function of (a) total cefazolin plasma 
concentration (R²=0.10), (b) indirect serum bilirubin concentrations (R²=0.10), (c) albuminaemia 
(R²=0.12) and (d) postmenstrual age (R²=0.29).   
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Paired plasma samples were available in 29 neonates. Median peak and trough sampling times 
and corresponding cefazolin concentrations are reported (Table 3). Median (range) unbound 
cefazolin fraction at peak level (0.46, 0.28-0.69) was significantly higher compared to trough 
level (0.36, 0.17-0.73) (p<0.001).  
 
 
Table 3: Paired unbound cefazolin (CFZ) plasma concentration, total cefazolin plasma concentration 
and unbound cefazolin fraction in 29 patients at peak (i.e. 0-2 h after first cefazolin administration) 
and trough (i.e. >6 h after first cefazolin administration but before next cefazolin administration, if 
scheduled) times. Data are represented by median and range. * Statistical significant difference. 
 
Parameter Peak Trough 
Sampling time (h) 1.00 (0.28-1.93) 8.00 (6.47-8.75) 
Unbound CFZ concentration (mg/L) 68.10 (35.47-165.04) 21.92 (2-67.74) 
Total CFZ concentration (mg/L) 155.60 (84.23-302.45) 60.42 (9.65-156.91) 
Unbound CFZ fraction * 0.46 (0.28-0.69) 0.36 (0.17-0.73) 
 
 
In Table 4 we estimated total cefazolin concentrations needed when an unbound cefazolin 
concentration of 8 mg/L is used as minimal inhibitory concentration (MIC) for susceptible 
pathogens e.g. CONS (Clinical and Laboratory Standards Institute MIC value) 
26
. Estimates 
were provided for different clinical conditions. Considering the total study population, 
unbound cefazolin concentration was ≥ 8 mg/L in 128 of 131 samples (97.7%). 
 
 
Table 4: Estimates of total cefazolin (CFZ) concentration (mg/L) needed for a time above minimal 
inhibitory concentration (T>MIC) of 100% if an unbound cefazolin concentration of 8 mg/L is used as 
MIC value for susceptible pathogens e.g. coagulase-negative staphylococci 
26
. Estimates are based on 
the regression equations of the unbound versus total cefazolin concentrations collected in our study 
population for different clinical conditions. Threshold values for hyperbilirubinaemia are >115 µmol/L 
if PNA<2 days, >155 µmol/L if PNA 2-5 days, >120 µmol/L if PNA 6-12 days, >80 µmol/l if PNA 
13-19 days, >45 µmol/L if PNA 20-26 days and >10 µmol/L if PNA ≥27 days, as reported in 
literature, to adapt for the normal postnatal increase and subsequent decrease of bilirubin in neonatal 
life 
23
. PMA: postmenstrual age, PNA: postnatal age. 
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Clinical 
inclusion criteria 
 
Total CFZ 
concentration (mg/L) 
 
Clinical 
inclusion criteria 
 
Total CFZ 
concentration (mg/L) 
Albuminaemia <35 (g/l) 30.38 
(y = -8.10 + 0.53x) 
Albuminaemia ≥35 (g/l) 48.74 
(y = -18.32 + 0.54x) 
Albuminaemia <30 (g/l) 24.76 
(y = -6.61 + 0.59x) 
Albuminaemia ≥30 (g/l) 38.90 
(y = -12.23 + 0.52x) 
PMA <37 weeks 29.89 
(y = -8.14 + 0.54x) 
PMA ≥37 weeks 39.29 
(y = -12.43 + 0.52x) 
PNA <10 days 35.76 
(y = -12.74 + 0.58x) 
PNA ≥10 days 30.76 
(y = -3.38 + 0.37x) 
Indirect 
hyperbilirubinaemia 
42.57 
(y = -17.97 + 0.61x) 
No indirect 
hyperbilirubinaemia 
25.87 
(y = -3.64 + 0.45x) 
 
 
Discussion  
 
Effective treatment with cefazolin requires integration of protein binding, which will affect 
disposition since only the unbound drug is responsible for antimicrobial action. We 
documented a median (range) unbound cefazolin fraction of 0.39 (0.10-0.73) in neonates and 
established between-patient as well as within-patient saturability of cefazolin protein binding. 
Neonatal unbound cefazolin fraction in our study is higher than reported values in adults 
(0.25, 0.14-0.41 in pregnant woman and 0.19, 0.10-0.51 in non-pregnant adults) 
11,13
. We 
hereby confirm the findings of Deguchi et al. who reported a mean unbound cefazolin fraction 
of 0.51 (± 0.17) in neonates and also referred to a significant difference in unbound cefazolin 
fraction between newborns and children (0.22±0.03, n=6) versus adults (0.11±0.02, n=12) 
4
.  
 
In addition to the paper of Deguchi et al., we explored covariates of the inter-individual 
variability in neonatal unbound cefazolin fraction. Albuminaemia, total cefazolin plasma 
concentration, indirect bilirubinaemia and PMA explained 49.6% of this variability. 
Covariates ‘albuminaemia’ and ‘total cefazolin plasma concentration’ are in line with findings 
in adults 
11
. Since neonates frequently display a lower albuminaemia compared to children or 
adults, an elevated unbound drug fraction can be expected. Within the neonatal population, 
albuminaemia increases with age reaching adult levels before the age of 5 months 
27
. The 
variation of unbound cefazolin fraction with total cefazolin concentration confirms that the 
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concept of cefazolin protein binding saturability is also applicable to neonates, but saturation 
is reached sooner compared to other populations because of a lower binding capacity 
13
.  
In addition to findings in adults, covariates ‘indirect bilirubinaemia’ and ‘PMA’ were specific 
for neonatal cefazolin protein binding. In early life, indirect hyperbilirubinaemia is common 
due to an increased production and decreased removal (by glucuronidation) of indirect 
bilirubin. Bilirubin displays an association constant 100 to 1000 times greater than most drugs 
for albumin 
27
. It can displace cefazolin from plasma albumin, resulting in an increased 
unbound drug fraction in case of an increased indirect bilirubin level. Additionally, the 
binding of bilirubin to albumin can induce an allosteric effect on albumin resulting in a 
decreased cefazolin binding percentage 
4,8
. However, cefazolin itself can also displace 
bilirubin from albumin binding sites 
28
, suggesting that the competition between bilirubin and 
cefazolin for albumin binding sites is a mutual interaction 
29
. Our observation is an illustration 
of this competitive binding concept. Structural changes of albumin in pathological conditions 
or the possible influence of unknown endogenous inhibitors on albumin binding need further 
research.  
PMA showed the strongest relation with unbound cefazolin fraction (R²=0.29). Changes in 
neonatal plasma profile and body composition can partly be attributed to PMA and can 
influence drug protein binding 
27
. The importance of age on neonatal protein binding was also 
documented for other compounds. Pullen et al. reported a significant correlation of neonatal 
flucloxacillin protein binding with age (gestational age, postconceptional age) 
30
.  
The impact of protein binding on cefazolin PK and PD needs special attention. Cefazolin 
elimination occurs by renal route (glomerular filtration and active tubular secretion). In 
general, higher protein binding is associated with lower drug elimination by tubular secretion 
and correlates negatively with glomerular filtration, because only the unbound drug is filtered 
31-33
. Since a higher unbound cefazolin fraction is documented in neonates, it is reasonable to 
postulate that clearance is proportionally higher compared to adults. However, the 
combination of an overall low glomerular filtration rate (GFR) and less effective renal tubular 
functions in neonates makes it difficult to predict the effect of protein binding on neonatal 
cefazolin clearance and needs further study.  
Protein binding also affects volume of distribution, because only the unbound drug can reach 
the extravascular space 
34
. Deguchi et al. documented that inter-individual changes in 
cefazolin volume of distribution per body weight in neonates are mainly due to individual 
differences in the unbound cefazolin plasma fraction 
4
.  
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The efficacy of cefazolin is related to the drug concentration at the receptor site (i.e. bacterial 
cell wall), but also to the time drug concentration exceeds the MIC for a given pathogen 
31,33,35
. Measurement of total cefazolin concentration without considering aspects of unbound 
cefazolin fraction is, therefore, not reliable for estimating PD effect. For prophylactic use, we 
aim for a T>MIC of 100%. In our study, 97.7% of samples had an unbound cefazolin 
concentration ≥8 mg/L, reflecting good prophylaxis for susceptible pathogens e.g. CONS 
26
. 
For different patient subgroups, we provided total cefazolin concentration needed to exceed 
an unbound concentration of 8 mg/L (Table 4). These estimates are based on the regression 
equation of the unbound versus total cefazolin concentrations collected in our study 
population and illustrate variability in different clinical conditions. To introduce these results 
in clinical practice, further population modeling is needed. Since the unbound cefazolin 
fraction is higher in neonates, lower doses (mg/kg) might theoretically be used to provide the 
same drug effect as in adults although final dosing guidelines should also consider cefazolin 
distribution and clearance. We did not focus on cefazolin PD but rather want to stress that the 
influence of protein binding on drug PD in neonates is of relevance beyond compound 
specific observations. In general, a minor decrease in protein binding -for very highly (e.g. 
>90%) protein bound drugs- will have a major effect on the free drug proportion. For drugs 
with a high toxicity profile, this can result in altered (side)effects and administration of lower 
drug doses have to be considered. For drugs with minor toxicity, like cefazolin, we have to be 
aware that dose adaptations may result in ineffectivity (drug dose too low) or increased free 
bilirubin (drug dose too high). Overall, data concerning protein binding, population specific 
PK/PD as well as drug characteristics have to be taken into account in future initiatives to 
optimize dosage regimens.  
 
Our study has its limitations, but also some strengths. Due to restrictions in blood volume 
available for sampling in neonates, we could not collect all predefined samples in each 
patient. FFA can influence drug-albumin interaction 
8,36
, however FFA were no significant 
determinant of cefazolin protein binding in our study and concentrations were lower than 
earlier reported values in neonates and infants 
27,37
. This can be due to interferences of co-
medication and parenteral nutrition and sample handling 
38
. Finally, review of individual 
patient data showed that the highest values of total (404.22 mg/L) and unbound (261.38 
mg/L) cefazolin concentration belong to the same patient. Chart review indicated this patient 
unintentionally received an additional cefazolin dose 1.8 h after the induction dose. These 
limitations reflect the difficult balance between research aims and clinical care in neonatal 
 143 
 
Disposition of intravenous cefazolin in neonates 
intensive care setting. We suggest that the strengths of our study are the relevant study size 
(40 neonates) and the repeated, focused sampling instead of opportunistic sampling strategies 
(e.g. Pullen et al, remnants), enabling paired analysis.  
 
We conclude that albuminaemia, total cefazolin concentration, indirect bilirubinaemia and 
PMA are the main covariates explaining 49.6% of inter-individual variability of neonatal 
cefazolin unbound fraction. Between- and within-patient saturability of cefazolin protein 
binding were also documented in neonates, but compared to adults a higher unbound 
cefazolin fraction was found in neonates. The integration of cefazolin protein binding aspects 
in PK/PD research is warranted to optimize neonatal cefazolin dosing regimens. Since 
neonatal PK studies often assume a fixed degree of protein binding, we recommend the 
measurement of protein binding, especially for highly protein bound and clinically relevant 
drugs. This need to be studied in sufficient numbers of patients to give a reliable point 
estimate for the neonatal population as well as a distribution for the extent of protein binding. 
How our data can be used to perform population pharmacokinetic modeling, will be 
illustrated in section 5.3. 
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5.2. Cefazolin plasma protein binding in different human populations 
 
Methods 
Study population and cefazolin plasma protein binding data 
Cefazolin plasma protein binding data of 4 published patient cohorts were collated. In total, 
the analysis consisted of total cefazolin concentrations, unbound concentrations and unbound 
fractions of 352 plasma concentrations-time points, collected in 124 patients.  
In a cohort of pregnant women (30 surgical interventions) 
11
 and a cohort of 40 neonates 
39
, 
both receiving cefazolin for surgical prophylaxis, respectively 130 and 131 blood samples 
were collected. In a cohort of 12 surgical adults undergoing (semi-)elective abdominal aortic 
aneurysm open repair with cefazolin as prophyaxis, cefazolin protein binding was determined 
in 36/104 plasma concentration-time points 
12
. Finally, data of a non-surgical adult cohort 
consisting of 31 adults treated with cefazolin either within a home antibiotic program or as in-
patients and of 12 other non-surgical hospitalized adults treated with cefazolin were included 
13
. In Table 5, general clinical characteristics, cefazolin dosing regimen and indication of the 4 
cohorts are presented. For further details we refer to the individual references 
11-13,39
.  
 
Table 5: Characteristics of included patient groups. n= number of patients 
 
Parameter Pregnant women 
11
 
(n=30)  
Neonates 
39 
 
(n=40)  
Surgical adults 
12
 
(n=12)  
Non-surgical adults 
13
 
(n=43) 
 
Median (range) 
age 
Childbearing age 9 (1-108) days 70 (62-81) years 19-91 years 
CFZ indication Prophylaxis Prophylaxis Prophylaxis Therapy 
CFZ Dosing 2 gr/8h  50 mg/kg/8h single 2 g bolus 2-6g/day, q8h or ct. 
 
Plasma samples 
 
130 131 36 55  
 
 
Drug assay 
Cefazolin was quantified using a validated liquid chromatography-tandem mass spectrometry 
(adult surgical cohort) or high performance liquid chromatography (other patients). 
Ultrafiltration was performed on all samples to determine unbound cefazolin fraction.  
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Statistical analysis 
To explore single continuous variables between the datasets, the Kruskal-Wallis test was 
used. For further data exploration 3 patient subgroups were defined i.e. pregnant women, 
neonates and (non-pregnant) adults. Each data point was considered as a unique observation 
of cefazolin protein binding. Observations with data on unbound cefazolin concentration, total 
cefazolin concentration and albuminaemia (n=237) were included in a multiple regression 
analysis to define covariates of unbound cefazolin fraction. A p-value <0.05 was considered 
statistical significant. Statistical analysis was performed using SPSS (SPSS, version 20.0, 
Armonk, New York, IBM Corp.) and Medcalc (Mariakerke, Belgium). 
 
 
Results 
Median total cefazolin concentrations, unbound concentrations and unbound fractions differed 
significantly between the 4 original populations (Kruskal-Wallis test, p<0.0001). For the 237 
observations retained, median (range) total [55.34 (1.96-148.26) mg/L, 100.63 (9.65-404.22) 
mg/L, 122 (2.30-547) mg/L] and unbound cefazolin concentrations [15.59 (0.31-46.69) mg/L, 
40 (2-261.38) mg/L, 18.98 (0.40-192.60) mg/L] for respectively pregnant women, neonates 
and adults as well as unbound fraction (Figure 3a) and albuminaemia (Figure 3b) differed 
significantly between the 3 subgroups (Kruskal-Wallis test, p<0.05). Albumin concentration 
in neonates hereby differed significantly from pregnant women, but not from non-pregnant 
adults probably due to the large range of albuminaemia in the non-pregnant adults. Seventy-
seven percent (R²=0.768) of the variability in unbound cefazolin fraction was explained by 
covariates total cefazolin concentration, unbound concentration, albuminaemia and patient 
subgroup (represented by 2 dummy variables). 
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Figure 3a 
 
 
Figure 3b 
 
Figure 3: (a) Unbound cefazolin (CFZ) fraction and (b) albuminaemia for different patient subgroups 
(1= adults, 2= pregnant women and 3= neonates). Only observations (n=237) with available total 
cefazolin concentrations, unbound cefazolin concentrations and plasma albumin concentrations were 
included.  
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Discussion 
Significantly higher median unbound cefazolin fractions were documented in pregnant 
women and neonates compared with adults. Since only the unbound drug can have a 
pharmacological effect, integration of the present observations in 
pharmacokinetic/pharmacodynamics (PK/PD) analyses may be useful to develop optimized, 
population-specific cefazolin dosage regimens. To explore whether this binding pattern also 
applies for other highly albumin-bound compounds across these populations, similar 
investigations are needed in the future.  
The impact of albuminaemia on unbound cefazolin fraction was anticipated. Both pregnancy 
and neonatal life display hypoalbuminaemia. During pregnancy, median albuminaemia 
decreases with increasing gestational age. In neonates, albumin concentration increases 
rapidly up to the age of 5 months. As illustrated in Figure 3, the differences in unbound 
cefazolin fraction between patient subgroups can, however, not solely be attributed to 
alterations in albumin concentrations (‘quantitative’ aspect), but also depend on the covariate 
‘patient subgroup’. This may in part be explained by an altered affinity constant for the drug-
albumin interaction (‘qualitative’ aspect) owing to endogenous agents (e.g. bilirubin, free 
fatty acids, urea) 
8
. Interference of these agents with drug-albumin binding is based on 
competition for albumin binding sites or by inducing structural albumin modifications. The 
variation of unbound cefazolin fraction with total cefazolin concentration confirms protein 
binding saturability, which was documented previously 
11,13,39
.  
 
As a highly protein bound, renally eliminated drug, of which dosing is not titrated to effect, 
alterations in protein binding of cefazolin may be clinically relevant, even if limited, since 
they can influence PK parameters and achievement of PD targets. To the best of our 
knowledge, this is the first pooled analysis of cefazolin protein binding data.  
 
In conclusion, cefazolin protein binding varies between different patient groups. This can not 
only be attributed to alterations in plasma albumin concentrations. Subpopulation specific 
characteristics also matter. These data can be considered in the optimization of cefazolin 
dosing regimens. Further exploration of whether the protein binding pattern described applies 
beyond compound specific observations would be of interest.  
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5.3. Population pharmacokinetic modeling of total and unbound cefazolin 
plasma concentrations as a guide for dosing in preterm and term neonates 
 
Methods 
 
Ethics, study population and drug dosing 
The patients included in this analysis are based on the cohort of 40 neonates and young 
infants described in section 5.1. Details on study approval, cefazolin dosing regimen, 
collection of clinical characteristics and laboratory data can be found in section 5.1. As in the 
present analysis only neonates with postnatal age (PNA) 1-30 days were included, patients 
with PNA 48, 51, 53 and 108 days) were excluded from the original dataset. Clinical 
characteristics of the study population are presented in Table 6.  
 
Blood sampling and drug assay 
Blood sampling procedure and quantification of total and unbound cefazolin plasma 
concentrations are extensively described in section 5.1. 
 
 
Table 6: Clinical characteristics of the neonates included in the pharmacokinetic analysis.  
 
Patient characteristics Median (range) or number of cases 
 Number of patients 36 
 Number of samples 119 
 Birth bodyweight (g) 2720 (540-4200) 
 Current bodyweight (g) 2755 (830-4200) 
 Postnatal age (PNA, days) 9 (1-30) 
 Gestational age (weeks) 37 (24-40) 
 Postmenstrual age (PMA, weeks) 38 (25-41) 
 Albumin (g/L) 34.5 (28.2-43.7) 
 Creatinine (mg/dL) 0.46 (0.26-1.03) 
 Free fatty acids (mmol/L) 0.08 (0-0.84) 
 Indirect bilirubin (mg/dL) 2.91 (0.1-11.13) 
 Gender (male/female) 22 / 14  
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Population pharmacokinetic analysis 
Model development 
The population pharmacokinetic analysis was performed using the non-linear mixed effect 
modeling software NONMEM version 6.2 (Globomax LLC, Hanover, MD, USA) using the 
first-order conditional estimation method with the interaction option (FOCE-I). Tools used to 
visualize and evaluate the model were S-Plus version 6.2.1 (Insightful software, Seattle, WA) 
with NM.SP.interface version 05.03.01 (© by LAP&P Consultants BV, Leiden, The 
Netherlands), PsN and R (version 2.10.1).  
The model building process was performed in a stepwise manner: (i) choice of the structural 
model, (ii) choice of the statistical sub-model, (iii) choice of the covariate model, (iv) model 
evaluation. Different diagnostic tools were used to discriminate between the different models 
40
. A decrease in objective function value (OFV) of ≥3.9 points was considered statistically 
significant (p<0.05 based on χ
2
 distribution, for nested models). Furthermore, the goodness-
of-fit plots were evaluated. Finally, the total number of parameters, visual improvement of 
individual plots, correlation matrix, confidence intervals of parameter estimates, ill-
conditioning 
41
 and shrinkage 
42
 were assessed.  
 
Structural and statistical sub-model 
A one and two compartment pharmacokinetic models was fitted to both total and unbound 
cefazolin concentrations using NONMEM VI, subroutine ADVAN6, TOL=3. Unbound 
cefazolin concentrations were related to total cefazolin concentrations by the following 
equation, taking into account non-linear protein binding 
43
: 
 
totalDDtotalDtotalunbound
CKKBCKBCC ´´+--+--´= 4)()(
2
1 2
maxmax  
                      (Equation 1) 
 
In this equation Cunbound represents the unbound cefazolin concentration, Ctotal the total 
cefazolin concentration, Bmax the maximum protein binding and KD the dissociation constant. 
For the statistical sub-model, the inter-individual variability was assumed to follow a log-
normal distribution. For the intra-individual variability and residual error, a proportional, 
additive and a combined error model were tested. 
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Covariate analysis 
The following covariates were evaluated in the covariate analysis: birth bodyweight [bBW  
(g), bodyweight on the day of birth], current bodyweight [cBW (g), bodyweight on the day of 
blood sampling], postnatal age [PNA (days)], gestational age [GA (weeks)], postmenstrual 
age [PMA (weeks), combination of GA and PNA in weeks], albuminaemia (g/l), 
creatininaemia (mg/dL), free fatty acids (mmol/L), indirect bilirubin (mg/dL) and gender. 
Potential covariates were separately implemented into the model using a linear or power 
equation (equation 2):  
 
k
Median
pi
Cov
Cov
PP )(´=             (Equation 2) 
 
In this equation Pi represents the individual parameter estimate of the ith subject, Pp equals the 
population parameter estimate, Cov is the covariate and k is the exponent which was fixed to 
1 for a linear function or was estimated for a power function. Covariates were considered 
statistically significant if the OFV decreased by ≥7.8 points (p-value <0.005). The covariate 
causing the largest reduction in OFV was chosen as a basis to sequentially explore the 
influence of additional covariates. The choice of the covariate models was further evaluated 
as discussed under Model development, whereby the results of the model validation were also 
considered. 
 
Model validation 
The stability of the final pharmacokinetic model was evaluated by a bootstrap analysis, in 
which the model building dataset was resampled 1000 times, in S-plus, version 6.2.1. 
(Insightful software, Seattle, WA) with NM.SP.interface version 05.03.01 (© by LAP&P 
Consultants BV, Leiden, The Netherlands). To evaluate the accuracy of the model the 
normalized prediction distribution error (NPDE) method was used. To perform this analysis 
the dataset was simulated 1000 times after which each observed concentration was compared 
with the simulated concentrations using the NPDE package in R 
44,45
. 
 
Monte Carlo simulations 
To evaluate T>MIC, the Clinical and Laboratory Standards Institute (CLSI) 2012 
26
 MIC 
interpretative criteria for susceptibility to cefazolin corresponding with the 5 bacterial species 
isolated most frequently from neonatal blood cultures from our department were used. 
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Therefore, all positive blood culture results (n=137) from our unit, for the period January - 
October 2012, were retrospectively collected. Identification of bacterial isolates was done by 
use of MALDI Biotyper (Bruker  Daltonics, Bremen, Germany). Staphylococcus species 
contributed for 94.4% of the top 5 isolates. Consequently, the CLSI MIC interpretative 
criterion for susceptibility to cefazolin of Staphylococcus species (8 mg/L) was used as target 
MIC (Table 7) 
26
. As effective cefazolin therapy is reported to require at least 60% of T>MIC, 
the probability of attaining unbound cefazolin concentrations during 60% of the dosing 
interval 
15
 above 8 mg/L was evaluated on the basis of Monte Carlo simulations using the 
final pharmacokinetic model. These Monte Carlo simulations were performed in 1000 
individuals to evaluate the exposure to cefazolin in (pre)term neonates following the currently 
used dosing regimen in this study and the dosing regimen proposed by the Dutch Children’s 
Formulary 
16
. The covariates identified in the final pharmacokinetic model were sampled from 
the original dataset taking into account their correlation. Albumin was randomly generated 
according to the observed distribution in these 36 neonates. For the simulations, cefazolin 
doses were administered over 30 minutes every 8 hours until 48 hours after the first dose. To 
evaluate the results of the Monte Carlo simulations, 4 different groups (group 1: PNA ≤ 7 
days and cBW ≤ 2000g; group 2: PNA ≤ 7 days and cBW > 2000g; group 3: PNA > 7 days 
and cBW ≤ 2000g; and group 4, PNA > 7 days, cBW > 2000g) were created. Based on these 
results, a new model-based dosing regimen was proposed. 
 
Table 7: The 5 bacterial species isolated most frequently from neonatal blood cultures (n=137) in the 
Leuven neonatal intensive care unit for the period January 2012 until October 2012. Corresponding 
CLSI MIC values are reported. 
 
Isolate 
Contribution to 
all positive blood 
cultures (%) 
Contribution to 
top-5 isolates 
(%) 
 
CLSI MIC values (mg/L) 
 
Susceptible Intermediate  Resistant 
      
1)  S. epidermidis 51.82 65.74 ≤ 8 16 ≥ 32 
2)  S. hominis 9.49 12.04 ≤ 8 16 ≥ 32 
3)  S. aureus 6.57 8.33 ≤ 8 16 ≥ 32 
4)  S. capitis 6.57 8.33 ≤ 8 16 ≥ 32 
5)  E. coli 4.38 5.56 ≤ 2 4 ≥ 8 
 
S.: Staphylococcus, E.: Escherichia, CLSI: Clinical and Laboratory Standards Institute, MIC: Minimal 
Inhibitory Concentration. 
Chapter 5 
152 
 
Results 
 
Patients 
The pharmacokinetic analysis was based on 119 plasma concentrations of cefazolin obtained 
in 36 (pre)term neonates with PNA 1-30 days. Median total and unbound cefazolin plasma 
concentrations, were 101.09 (range 17.44-404.22) mg/L and 41.15 (range 5.34-261.38) mg/L, 
respectively. The median unbound fraction was 0.40 (range 0.14-0.73). Clinical 
characteristics are presented in Table 6.  
 
Population pharmacokinetic analysis 
Structural and statistical sub-model 
A one compartment model was selected as structural model because a two compartment 
model was not superior over a one compartment model. The final one compartment 
pharmacokinetic model, taking into account total and unbound cefazolin concentrations, was 
parameterized in terms of clearance (Cl), volume of distribution (Vd), maximum protein 
binding Bmax and the dissociation constant KD (Figure 4).  
 
Figure 4: Schematic representation of the pharmacokinetic model using both total and unbound 
concentrations of cefazolin. KD = Dissociation constant, Bmax = Maximum protein binding, FU = 
unbound fraction of cefazolin, CLunbound = Clearance of unbound cefazolin 
 
By the determination of Bmax and KD, unbound cefazolin concentrations could be calculated 
from total concentrations (equation 1). Initially, a separate proportional error was estimated 
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for total and unbound cefazolin concentrations. Since these errors were not significantly 
different (p>0.05), the model was simplified by estimating one proportional error for both 
total and unbound concentrations. 
 
 
Covariate Model 
Current bodyweight was found as most important covariate on Vd. Initially, current 
bodyweight was implemented on Vd using a power function with an estimated exponent of 
0.94. However since the 95% confidence interval of this parameter included 1, a linear 
relationship between current bodyweight and Vd was used (p>0.05). Implementation of 
current bodyweight on Vd caused a significant drop in OFV of 46 points (p<0.005). Although 
for clearance, PMA was identified as most important covariate, a combination of the 
covariates birth bodyweight and PNA was preferred over PMA alone. First, both analyses 
resulted in a comparable improvement of the model (i.e. same reduction in OFV of 32 points, 
P< 0.005). Secondly, the combination of birth bodyweight and PNA allows to make a 
distinction between the antenatal (birth bodyweight) and postnatal (PNA) maturation 
component of cefazolin clearance. Birth bodyweight was implemented on clearance using a 
power function with an estimated exponent of 1.37, while PNA was implemented using a 
linear function with an estimated slope of 0.496 (Table 8). The model was further improved 
(reduction in OFV of 12 points, P< 0.005) by introducing albumin on Bmax using a linear 
function (Table 8).  
 
The parameter estimates of the simple and the final pharmacokinetic model and the values 
obtained from the bootstrap analysis are provided in Table 8. 
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Table 8: Model-based population pharmacokinetic parameter estimates and the values obtained after 
the bootstrap analysis. 
 
Parameter 
Simple model 
without 
covariates 
 
Value (CV%)  
Final 
pharmacokinetic 
covariate model 
 
Value (CV%) 
Bootstrap final 
pharmacokinetic 
model 
 
Value (CV%) 
    
Fixed effects 
CL (L/h) = CLp 0.229 (11.7) - - 
CLp in CL = CLp x (bBW/median)
m
 x 
(1+(PNA/median) x n) 
- 0.185 (12.8) 0.187 (13.3) 
       m - 1.37 (16.4) 1.41 (17.3) 
       n - 0.496 (38.5) 0.524 (44.5) 
V (L) = Vp 0.812 (3.0) - - 
Vp in V = Vp x (cBW/median) - 0.863 (3.55) 0.860 (3.63) 
Bmax (mg/L) = Bmaxp 143 (14.5) - - 
Bmaxp in Bmax = Bmaxp x (ALB/median) - 136 (12.6) 141 (14.5) 
Kd (mg/L) =Kdp 53.2 (22.9) 46.5 (20.9) 49.5 (24.1) 
Interindividual variability (ω
2
) 
ω
2 
CL 0.535 (33.6) 0.163 (35.1) 0.149 (38.0) 
ω
2
 V 0.14 (29.1) 0.0259 (38.6) 0.0258 (43.2) 
ω
2 
Bmax 0.102 (41.0) 0.0367 (54.0) 0.0368 (56.7) 
Residual variability (σ
2
) 
σ
2
 (proportional) 0.0332 (22.1) 0.0351 (21.5) 0.0342 (22.5) 
 
CL= clearance, CLp = population value for clearance for an individual with birth bodyweight of 2720g 
and postnatal age of 9 days, V = Volume of distribution, Vp = population value for volume of 
distribution for an individual with a current bodyweight of 2755g, Bmax = maximum protein binding, 
Bmaxp = population value for maximum protein concentration for an individual with an albumin 
concentration of 34.5 g/L, Kd = Dissociation constant of the drug, Kdp = population value of 
dissociation constant of the drug, bBW = birth bodyweight, cBW = current bodyweight, PNA = 
postnatal age, ALB = concentration of albumin 
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In Figure 5, the observed versus predicted concentrations are plotted for the total and unbound 
concentrations showing that the model adequately describes the data. In Figure 6, the inter-
individual variabilities in clearance, Vd and Bmax are plotted against the relevant covariates for 
the simple and the final pharmacokinetic model. A significant part of the interindividual 
variability is explained (Figure 6). This is also reflected in the decrease in the estimates of the 
interindividual variability when comparing the simple and the final pharmacokinetic model, 
which resulted in a decrease of 50% in the interindividual variability in Vd, 58% in clearance 
and 41% in Bmax (Table 8). In Figure 7 the observed and population predicted bound and 
unbound cefazolin concentrations are plotted from which Bmax and the value for the unbound 
concentration for which the binding was half-maximal (KD) can be derived. Variation in 
population predicted bound and unbound cefazolin concentrations can be explained by 
differences in current bodyweight, birth bodyweight and PNA of the subjects (Figure 7).  
 
 
 
Figure 5: Observed versus individual predicted concentrations (a,d) and population predicted 
concentrations (b,e) for total (upper panels) and unbound (lower panels) cefazolin concentrations. The 
histograms show the distribution of the normalized prediction distribution error (NPDE) methods for 
total (c) and unbound (f) cefazolin concentrations. 
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Figur 6: Interindividual variability (ETA) in a) clearance versus birth bodyweight, b) clearance (Cl) 
versus postnatal age, c) volume of distribution (V) versus current bodyweight, d) Maximum protein 
binding (Bmax) versus albumin for the simple (left) and final covariate model (right). 
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The number of binding sites on the albumin molecule was derived from Bmax, which was 
corrected for molecular weight of albumin (67000 g/mol) and cefazolin (454.5 g/mol) 
(Equation 3), and the median albumin concentration (34.5 g/L) (Equation 4) and was 
calculated to be 0.6.  
 
Lg
molg
molg
LgB /20)
/5.454
/67000
(/136.0max =´=    (Equation 3) 
 
Number of binding sites = 6.0)
/5.34
/20
( =
Lg
Lg
   (Equation 4) 
 
Model Validation 
The results of the bootstrap analysis (Table 8) show that the median estimated values based on 
the resampled dataset were within 10% of the values obtained in the final model. The NPDE 
histograms follow the normal distribution, indicating the accuracy of the final 
pharmacokinetic model (Figure 5). Furthermore, no trend was seen in the NPDE versus 
time or versus predicted concentrations. The number of ill-conditioning (74.6) was far below 
 
Figure 7: The relationship between the observed (square) and model-based predicted (circle) bound 
and unbound cefazolin concentrations (mg/L) in 36 (pre)term neonates. Bmax (protein binding defined 
as the maximum estimated concentration bound to albumin) and KD (dissociation constant defined as 
the unbound concentration which corresponds to 50% of the maximum binding capacity) are 
illustrated. 
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the critical number of 1000 indicating that the final pharmacokinetic model was not 
overparameterized. Finally, η-shrinkage expressed as a percentage was identified to be 9.8% 
for clearance, 21.2% for Vd and 30% for Bmax. 
 
Monte Carlo simulations 
Concentration-time profiles following the currently used dosing regimen, the dosing regimen 
proposed by the Dutch Children’s Formulary and the new model based-dosing regimen (Table 
9) were predicted based on Monte Carlo simulations using the final pharmacokinetic model 
(Figure 4). In Figure 9, box plots illustrate the median and interquartile ranges (5% to 95%) of 
the individual predicted concentrations at 60% of the dosing interval after the first dose and 
after the fourth or sixth dose. This illustrates that less than 10% of the individual predicted 
concentrations at 60% of the dosing interval are below a MIC of 8 mg/L. Relatively high 
cefazolin peak concentrations are reached, particularly in neonates in group 1, 2 and 3 
following the dosing regimen used in the current study and in group 3 following the dosing 
regimen proposed by the Dutch Children’s Formulary (Figure 8, 9). Therefore, a new dosing 
regimen was advised based on the dosing regimen proposed by the Dutch Children’s 
Formulary but including a lower dose for group 3 (Table 9). Using this dosing regimen, 0%, 
1.2%, 0.7% and 1.0% of the individuals of group 1, 2, 3 and 4, respectively, would be 
exposed to concentrations below 8 mg/L at 60% of the dosing interval (Figure 9B). 
 
 
Table 9: Dosing recommendations for cefazolin in preterm and term neonates according to dosing 
regimens used in the current study, the Dutch Children’s Formulary and a new model-based proposed 
dosing regimen. For concentration-time profiles of these dosing regimens for neonates with different 
clinical characteristics we refer to Figure 8. PNA = postnatal age, cBW = current bodyweight 
 
Guideline PNA (days) cBW (g) Dose (mg/kg) Interval (h) 
Used in the current study  - - 50 8 
Dutch Children’s Formulary 
≤ 7 days ≤ 2000g 25 12 
≤ 7 days > 2000g 50 12 
8-28 days  50 8 
Proposed dosing regimen 
≤ 7 days ≤ 2000g 25 12 
≤ 7 days > 2000g 50 12 
8-28 days ≤ 2000g 25 8 
8-28 days > 2000g 50 8 
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Figure 8: Concentration-time profiles based on 1000 Monte Carlo simulations using the final 
pharmacokinetic model following the dosing regimen used in this study (upper row), the dosing 
regimen proposed by the Dutch Children’s Formulary (middle row) and the new model-based 
proposed dosing regimen (bottom row) in 4 different groups based on current bodyweight and 
postnatal age. The black line represents the median of the simulated profiles and the grey area 
represents the 90% confidence interval of the simulated values. The black horizontal line corresponds 
to the minimal inhibitory concentration of 8 mg/L. The full vertical lines indicate the time at which 
60% of the dosing interval is reached (4.8 and 44.8 hours) for a dosing interval of 8 hours. The vertical 
dotted lines indicate the time at which 60% of the dosing interval is reached (7.2 and 43.2 hours) for a 
dosing interval of 12 hours. PNA = Postnatal age, cBW = Current bodyweight. 
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Discussion 
 
Neonatal cefazolin PK data and cefazolin dosing regimens (Table 1) are outdated since they 
are mainly based on total drug concentrations collected in a limited number of subjects. We 
aimed to characterize cefazolin pharmacokinetics and its covariates based on both total and 
unbound drug concentrations. In our study, the median cefazolin clearance value (coefficient 
of variation, %) for a neonate with a birth bodyweight of 2720 g and PNA 9 days was 0.185 
(12.8) L/h (i.e. 0.068 L/kg/h). This is slightly higher than the earlier reported values of 0.53-
1.10 mL/kg/min (i.e. 0.032-0.066 L/kg/h) in 11 neonates receiving 30 mg/kg cefazolin 
intravenously. Since only the unbound cefazolin is pharmacologically active and total drug 
concentrations only partially reflect unbound concentrations (Figure 7), we would like to 
emphasize that unbound concentrations need to be measured instead of using estimated 
unbound concentrations based on a fixed protein binding percentage. Especially in highly 
protein bound drugs this is of relevance.  
 
Postnatal age and birth bodyweight were the most important covariates of neonatal cefazolin 
clearance. This is in line with expectations, taking into account the elimination of cefazolin by 
renal route. Renal clearance displays maturation during early life and covariates birth 
bodyweight and PNA can hereby reflect the prenatal and postnatal maturation, respectively 
46
. 
Furthermore, age and bodyweight were earlier documented as clearance predictors of other 
beta-lactams in neonates 
47-50
. We can only hypothesize on factors affecting the remaining 
unexplained cefazolin clearance variability within the neonatal population. Possibly, 
maturation of the renal tubular activity is a contributing factor. Also for other beta-lactams 
(e.g. amoxicillin, flucloxacillin) the presence of other elimination pathways, in addition to 
glomerular filtration rate (GFR), such as tubular secretion or non-renal clearance routes was 
suggested earlier 
47,51
. Since only the unbound drug can be eliminated and since compound 
specific clearance depends on compound specific protein binding, we hereby want to stress 
that the mean (± standard deviation) protein binding of flucloxacillin (74.5±3.1%) and in 
particular amoxicillin (11.7±2.7%) is lower compared to cefazolin 
30,48
. Therefore, results of 
amoxicillin and flucloxacillin may not be directly applied to cefazolin. 
The number of binding sites for cefazolin on the albumin molecule based on this analysis was 
calculated to be 0.6 (equation 3 and 4), which corresponds well with the number of binding 
sites for cefazolin on albumin previously found in literature (0.7) 
8,52,53
. 
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We documented relatively high cefazolin plasma concentrations based on a 50 mg/kg/8h 
cefazolin dosing regimen, administered to all study patients. This is probably due to the 
absence of any bodyweight- and/or age- adapted dosing. Simulation of the dosing regimen 
proposed by the Dutch Children’s Formulary resulted in lower cefazolin concentrations. 
However, based on Figure 8 and 9, the dose administered to neonates in group 3 when using 
the Dutch Children’s Formulary, still needs further reduction. A new bodyweight- and age-
based dosing regimen is suggested, derived from the dosing regimen proposed by the Dutch 
Children’s Formulary, but with a dose reduction for group 3 in order to reach similar exposure 
in all four groups (Table 9). With this new model-based dosing regimen the target of 8 mg/L 
for 60% of the dosing interval was reached for >90% of the patients (i.e. 100%, 98.8%, 99.3% 
and 99% of the individuals of group 1, 2, 3 and 4, respectively). 
When compared to the dosing regimen used in this study, a total daily dose reduction of 67%, 
33% and 50% for patients in respectively group 1, 2 and 3 is proposed resulting in similar 
exposure in all groups. The proposed dosing regimen is hereby more in line with some of the 
recommendations presented in Table 1. As a consequence of cefazolin dose reduction, 
albumin binding places become available for other endogenous (e.g. bilirubin) or exogenous 
compounds competing for the same albumin binding places. In neonates, frequently showing 
hyperbilirubinaemia (increased bilirubin production and decreased glucuronidation) and/or 
receiving multidrug therapies, this is a relevant and population specific advantage. Recent 
pharmacokinetic reports of other beta-lactam antibiotics commonly used in neonatal intensive 
care units also suggested dose adaptations compared to previously used regimens. To further 
illustrate this, a reduction in drug dose and interval for amoxicillin 
47
 and an increase of initial 
dose with subsequent dose reduction depending on the microbiological isolate, for 
flucloxacillin 
51
 were suggested in neonates. This emphasizes the need for population specific 
pharmacokinetic studies in neonates. Since study methodologies can differ, a correct 
definition of the aimed pharmacokinetic target is required to achieve reliable dosing 
evaluations in this specific population 
15,54
. In general, we have to be aware that total daily 
dose reduction of an antimicrobial may lead to increased bacterial resistance and 
ineffectiveness 
55
. Prospective validation of the new dosing regimen is therefore necessary, 
but this was not the intention of the present study.  
The strength of our analysis is the measurement of both total and unbound cefazolin 
concentrations in a relevant neonatal cohort. Additionally, the final pharmacokinetic model 
can be used to optimize dosing regimens for other pathogens in different settings by changing 
the target MIC value and/or the T>MIC. However, there are some limitations. First, the MIC  
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Figure 9: Individual predicted concentrations based on Monte Carlo simulations in 1000 individuals 
versus 4 different groups based on current bodyweight (cBW) and postnatal age (PNA). Plot A 
represents the individual predicted concentrations at 60% of the dosing interval after the first dose 
which corresponds to 4.8 or 7.2 hours after the first dose for a dosing interval of 8 or 12 hours 
respectively. Plot B represents the individual predicted concentrations at 60% of the dosing interval 
after 4 or 6 doses which corresponds to 44.8 or 43.2 hours based on a dosing interval of 8 or 12 hours, 
respectively. The black horizontal line corresponds to the minimal inhibitory concentration of 8 mg/L. 
For each group 3 boxplots are shown following the dosing regimen applied in this study (left), the 
dosing regimen suggested by the Dutch Children’s Formulary (middle) and the new model-based 
proposed dosing regimen (right). Box plots illustrate median, interquartile range (5-95%) and outliers. 
The percentage of individuals with a concentration below 8 mg/L at 60% of the dosing interval is 
indicated for each dosing regimen per group. 
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values used were not prospectively determined. Secondly, the success of antibiotic 
prophylaxis depends not only on selection of the antimicrobial drug and drug dosing but also 
on correct, well-timed drug administration and subsequent tissue distribution. Direct 
measurement of drug concentrations in the surgical site tissues 
56,57
 may provide additional 
information to include in pharmacokinetic models, but is very challenging in this population 
58
.  
 
We conclude that total and unbound cefazolin concentrations in neonates could be described 
by a one compartment pharmacokinetic model which includes saturable protein binding. Birth 
bodyweight and PNA were defined as the most important covariates contributing to cefazolin 
clearance variability. A new model-based neonatal cefazolin dosing regimen was proposed, 
however prospective validation of this dosing regimen is needed.  
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Abstract  
 
Introduction A novel neonatal amikacin dosing regimen was previously developed based on 
a population pharmacokinetic model. The aim of the current study was to prospectively 
validate this model-derived dosing regimen in clinical practice. 
 
Methods First, early therapeutic drug monitoring (TDM) observations were evaluated. 
Secondly, all observed TDM concentrations were compared with concentrations predicted by 
the model, whereby the results of an NPDE (normalized prediction distribution error) were 
considered, after which Monte Carlo simulations were performed. Finally, remaining causes 
limiting amikacin predictability (prescription errors and disease characteristics of outliers) 
were explored. 
 
Results In 579 (pre)term neonates [median birth bodyweight 2285 (range 420-4850)g, 
postnatal age (PNA) 2 (1-30) days, gestational age 34 (24-41) weeks], 90.5% of the observed 
peak levels reached 24 mg/L and 60.2 % of the early trough levels was <3 mg/L (93.4% ≤5 
mg/L). All prospective observations were accurately predicted by the model without bias, 
which was confirmed by the NPDE. Monte Carlo simulations showed that peak 
concentrations >24 mg/L were reached in almost all patients. Trough values <3 mg/L were 
documented in 78-100% and 45-96% of simulated cases, respectively when ibuprofen was co-
administered or not, with largest percentages of trough levels >3 mg/L in patient subgroups 
with postnatal age <14 days and current weight >2000g.  
 
Conclusions Prospective validation of a model-based neonatal amikacin dosing algorithm 
resulted in optimized peak and trough concentrations in almost all patient groups. Slightly 
adapted dosing regimens for patient subgroups with suboptimal trough levels (PNA<14 days 
in combination with current weight >2000g) were proposed. This model-based approach 
substantially contributes to drug dosing individualization in neonates.  
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What is already known on this topic 
 
 
§ Extended interval dosing of amikacin contributes to achieve higher peak (‘more efficacy’) 
and lower trough (‘less toxicity’) amikacin concentrations in neonates. 
 
§ Neonatal amikacin clearance can be predicted by birth bodyweight (reflecting prenatal 
renal maturation), postnatal age (reflecting postnatal maturation) and co-administration of 
ibuprofen. 
 
§ A model-based amikacin dosing regimen for neonates was recently developed, and 
underwent both internal and external, but not yet prospective, validation. 
 
 
What this study adds 
 
 
§ Prospective validation of this model-based dosing regimen resulted in optimal peak and 
trough concentrations for a relevant proportion of neonates. 
 
§ In neonates with specific clinical conditions influencing amikacin pharmacokinetics, 
therapeutic drug monitoring remains of utmost importance. 
 
§ Prospective validation resulted in a further improvement of the current amikacin dosing 
regimen, for neonates with postnatal age <14 days in combination with a current weight 
>2000g. This illustrates the importance of validation studies. 
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Introduction 
 
Despite profound differences between neonates and adults, neonatal dosing regimens are 
usually derived from adult regimens using extrapolations based on bodyweight. However, this 
may lead to under- or overdosing 
1,2
 with subsequently therapeutic failure or occurrence of 
adverse drug effects. In order to establish rational and evidence-based dosing regimens for 
neonates, detailed information on population specific pharmacokinetics (PK) and 
pharmacodynamics (PD) is needed 
3
. Population PK and/or PD analysis using non-linear 
mixed effect modeling (NONMEM) is a useful tool to generate such knowledge and to 
improve neonatal dosing regimens. A crucial, but often missing part in the development of 
new model-derived dosing regimens is a thorough evaluation and validation of these dosing 
regimens in a large prospective clinical study 
3
.  
 
Amikacin is commonly recommended to treat (suspected) neonatal sepsis. In our department, 
co-treatment with amoxicillin (early-onset cases) or vancomycin (late-onset cases) is usually 
prescribed. Despite the frequent use of amikacin, currently used dosing regimens may lack 
efficacy or systematically reach the toxic range 
4
. Therefore, a model-based dosing regimen 
was recently developed in which neonatal amikacin dosing is based on current bodyweight [a 
covariate found for volume of distribution (Vd)], birth bodyweight, postnatal age and co-
administration of ibuprofen [covariates for clearance (Cl)] 
4
. This model-based dosing 
regimen was derived from a neonatal pharmacokinetic model that was based on amikacin data 
from preterm and term neonates (n=874) varying in age between 1 and 30 days, and was both 
internally and externally (n=239) validated 
4
. In July 2011, a simplified version of this dosing 
regimen (Table 1) was introduced in the neonatal intensive care unit of UZ Leuven, Belgium.  
 
The aim of the current study was to prospectively evaluate this model-based dosing regimen 
for amikacin in neonates in the same clinical setting. As such, we first defined the proportion 
of early therapeutic drug monitoring (TDM) results (i.e. first trough and peak samples) 
achieving target concentrations (trough <3 mg/L or ≤ 5mg/L, peak >24 mg/L). Secondly, 
using all TDM results, the predictive performance of the previously published model was 
evaluated based on a comparison of the observed versus the model-based predicted 
concentrations and an NPDE analysis after which Monte Carlo simulations were performed. 
Finally, we hypothesize that observations outside the target values can also be due to errors on 
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the application of the dosing regimen during clinical practice or due to covariates not covered 
by the current dosing approach 
4
. We consequently also reviewed prescription errors as well 
as outliers defined by visual inspection of the plots.  
 
 
Table 1: Original (1) and simplified (2) model-based dosing regimen of amikacin in neonates used in 
the current study 
4
. The dosing regimen proposed after the prospective validation (3) is also presented. 
The differences between dosing regimens 1 and 2 are highlighted in bold and italic, between 2 and 3 in 
bold, italic and grey. 
 
 
1. Original model-based  
dosing regimen 
2. Simplified model-based 
dosing regimen 
 
3. Final dosing regimen after 
prospective validation 
 
CW (g) PNA <14 days PNA ≥14 days PNA <14 days PNA ≥14 days PNA <14 days PNA ≥14 days 
0-800 
16 mg/kg/48h 
(group 1) 
20 mg/kg/42h 
 (group 2) 
16 mg/kg/48h  20 mg/kg/42h  16 mg/kg/48h  20 mg/kg/42h  
800-1200 
16 mg/kg/42h 
(group 3) 
20 mg/kg/36h 
 (group 4) 
16 mg/kg/42h  20 mg/kg/36h  16 mg/kg/42h  20 mg/kg/36h  
1200-2000 
15 mg/kg/36h 
(group 5) 
19 mg/kg/30h 
(group 6) 
15 mg/kg/36h  18 mg/kg/30h  15 mg/kg/36h  18 mg/kg/30h  
2000-2800 
13 mg/kg/30h 
(group 7) 
18 mg/kg/24h 
(group 8) 
15 mg/kg/30h  18 mg/kg/24h  15 mg/kg/36h  18 mg/kg/24h  
≥2800 
12 mg/kg/24h 
(group 9) 
17 mg/kg/20h 
(group 10) 
15 mg/kg/24h  18 mg/kg/20h  15 mg/kg/30h  18 mg/kg/20h  
 
Dosing interval was prolonged 10 hours when ibuprofen was co-administered or when asphyxia was considered by 
the treating physician. Duration of the  iv infusion was 20 minutes, PNA=postnatal age, CW=current bodyweight. 
 
 
 
Methods 
 
Patients 
All neonates admitted to the Neonatal Intensive Care Unit of the University Hospitals Leuven 
in whom routine amikacin TDM samples were available between July 2011 and December 
2012 were considered for inclusion in this study. The study was approved by the ethical board 
of our hospital. A simplified version of the previously developed model-based dosing regimen 
4
 was applied, and based on current weight and postnatal age 10 different patient groups were 
considered (Table 1). Patients were excluded from this analysis if initiation of amikacin 
administration was based on a previously used dosing regimen 
5
, when data (prescription or 
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clinical characteristics) were missing or if patients had a postnatal age above 30 days. Clinical 
characteristics at birth [gestational age (GA, weeks), birth bodyweight (grams), Apgar score at 
1, 5 and 10 minutes after birth, asphyxia (yes/no/initially suspected but not retained as final 
diagnosis at discharge)], as well as characteristics at the moment of amikacin TDM 
[postmenstrual age (PMA, weeks), postnatal age (PNA, days), current bodyweight (grams), 
concurrent ibuprofen (yes/no) or inotropic drugs (yes/no), respiratory support (i.e. continuous 
positive airway pressure or mechanical ventilation, yes/no), mechanical ventilation 
(conventional or high frequency, yes/no)] were retrospectively extracted from the patient files. 
Additionally, blood culture results at start of amikacin therapy were collected from the 
individual laboratory reports. The daily nursing progress reports were used to collect amikacin 
prescription (dose and interval) data. 
 
Drug administration and TDM sampling 
Amikacin (Amukin, Bristol Myers Squibb, Braine-L’Alleud, Belgium) was administered as 
an intravenous infusion over 20 minutes. As part of routine clinical care, blood samples for 
early amikacin TDM were collected just before (trough) and 1 hour after administration of the 
second dose (peak). In case of unexpected results or dosing adaptation, additional TDM 
samples were collected, based on the decision of the attending physician. 
 
Amikacin assay 
Up to May 31
th
 2012, amikacin concentrations were measured with fluorescence polarization 
immunoassay (Abbott TDx kit, Abbott Laboratories, Diagnostics Division, Abbott Park, IL 
60064 USA). The lower limit of quantification (LLOQ) was 0.8 mg/L. According to the 
insert, the coefficient of variation was <5% (assessed at 5, 15 and 30 mg/L). From May 31
th
 
2012, amikacin quantification was based on a kinetic interaction of microparticles in solution 
(KIMS) immunoassay (Roche/Hitachi Cobas c systems, Roche Diagnostics GmbH, 
Mannheim, Germany). Also in this assay, the LLOQ was 0.8 mg/L. According to the insert, 
the coefficient of variation was <4%. To avoid censoring of data below the LLOQ, these 
concentrations were replaced by LLOQ/2 (i.e. 0.4 mg/L) as suggested in literature 
6,7
. 
 
Prospective validation 
1. Early amikacin TDM observations 
To evaluate early amikacin exposure, trough and peak concentrations obtained just before and 
1 hour after the second dose of each amikacin treatment episode were considered. The 
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percentage of samples achieving target trough <3 mg/L and peak concentrations >24 
mg/Lwere defined. These targets were chosen since dosing regimen adaptation during clinical 
practice in our unit is considered if early trough concentrations exceed 3 mg/L and/or peak 
levels are below 24 mg/L. In addition, trough levels ≤5 mg/L were evaluated since this target 
is associated with toxicity. Descriptive statistics were performed using MedCalc®12 
(Mariakerke, Belgium).  
 
2. Pharmacokinetic analysis and Monte Carlo simulations 
2.1. Pharmacokinetic analysis 
To evaluate the predictive performance of the recently developed pharmacokinetic model 
4
, a 
pharmacokinetic analysis was performed using NONMEM VI in which model-based 
individual and population predicted concentrations were simulated for each observation in the 
prospectively collected dataset. These model-predicted concentrations were obtained by use 
of the recently developed pharmacokinetic model 
4
 in which all parameters were fixed to the 
final values with MAXEVAL = 0 and without covariance step. Subsequently, both the 
individual and population predicted concentrations were visually compared to the observed 
concentrations. Additionally, to evaluate accuracy, the recently developed pharmacokinetic 
model 
4
 was used to compute a NPDE (normalized prediction distribution error) 
8,9
 for each of 
the observations of the prospective dataset. A histogram of the NPDE distribution and 
scatterplots showing the NPDE versus time and versus predicted concentration were used as 
evaluation tools 
8,9
. Finally the parameters of the recently developed pharmacokinetic model 
4
 
were re-estimated based on the data of the prospective dataset.  
 
2.2. Monte Carlo simulations 
Monte Carlo simulations were performed to evaluate whether target peak (>24 mg/L) 
10
 and 
trough concentrations (<3.0 mg/L) 
11
 of amikacin were reached following the simplified and 
the original model-based dosing regimen (Table 1) 
4
. For these Monte Carlo simulations, 5 
consecutive doses of amikacin were administered over 20 minutes. For the peak values, 
concentrations <24 mg/L, between 24 – 35 mg/L 
10
 and >35 mg/L were evaluated. For trough 
values, concentrations between 1.5 - 3.0 mg/L were evaluated because this was the primary 
target of the model-based dosing regimen 
4
. In addition, the percentage of trough 
concentrations  <1.5, between 3.0 – 5.0 and >5.0 mg/L was evaluated. Results of the Monte 
Carlo simulations were compared among different neonatal dosing groups as defined in Table 
1. For these simulations, the covariates identified in the recently developed final 
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pharmacokinetic model 
4
 - birth bodyweight and PNA (covariates found on clearance) and 
current bodyweight (covariate found on volume of distribution) - were sampled from the 
prospective dataset taking into account their correlation. The Monte Carlo simulations were 
performed twice in 5000 individuals following the model-based dosing regimen (either or not 
with ibuprofen co-administration) 
4
.  
 
3. Remaining causes limiting amikacin exposure predictability 
To assess the performance of the dosing regimen implementation in clinical practice, 
prescription errors were evaluated based on chart review. Four categories of prescription 
errors were distinguished i.e. a) incorrect dose (>10% deviation of intended dose 
12
), b) 
incorrect interval, c) incorrect dose and interval, and d) incorrect interval adaptation in case of 
asphyxia or ibuprofen.  
In addition, based on visual inspection of the plots of the pharmacokinetic analysis and Monte 
Carlo simulations, outliers were identified and clinical characteristics were reviewed to search 
for remaining clinical causes impairing amikacin exposure predictability in neonates.  
 
 
Results 
 
Patients 
From July 2011 until December 2012, 701 neonates were evaluable for prospective evaluation 
of the model-based dosing regimen. In total, 122 patients were excluded from the analysis due 
to application of a previous dosing regimen (n=32), missing data (n=76) or PNA above 30 
days (n=14). A summary of the clinical characteristics of the patients included in the final 
prospective dataset (n=579) is presented in Table 2, as well as the clinical characteristics of 
the patients used for initial development of the pharmacokinetic model 
4
. In total, 579 
included patients underwent 701 amikacin treatment episodes, resulting in 1195 amikacin 
TDM observations. In 93/701 episodes, a bacterial species was isolated from at least one 
blood culture. Additional data on pathogens isolated and related MIC values are provided in 
Table 3 
10,13,14
.  
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Figure 1: Flowchart of included early trough and peak amikacin therapeutic drug monitoring (TDM ) 
observations. The number of trough observations <3 mg/L, between 3-5 mg/L and >5 mg/L and peak 
observations <24 mg/L, between 24-35 mg/L and >35 mg/L are presented. The percentage of 
prescription errors documented in suboptimal trough and peak observations are calculated. n= number 
of TDM observations. 
 
 
 
Early trough TDM 
n = 678 
n=1195 TDM observations  
collected in 579 patients  
n= 1067 ‘early’ TDM  
Excluded TDM observations (n= 128) 
-  First TDM collected too late (prior to and  
    after 3
rd
  amikacin administration) 
-  TDM collected after dosing adaptation 
Early peak TDM 
n = 389 
 <3 mg/L          3-5 mg/L       >5 mg/L     <24 mg/L    24-35 mg/L    >35 mg/L 
  n = 408          n =  225          n = 45         n = 37         n = 279            n = 73 
   270 suboptimal         37 suboptimal 
 
 
 
 
Prescription error         Prescription error  
  23/270 (8.5/%)             4/37 (10.8%) 
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Table 2: Clinical characteristics of neonates included in the recently published analysis on amikacin 
4
 
and in the current prospective analysis (median and range, or absolute number and incidence). 
 
Characteristics 
Recently developed  
amikacin model 
4
 
 
n= 874 
Current prospective 
amikacin analysis 
 
n= 579 
Gestational age (weeks) 32 (24-43) 34 (24-41) 
Postmenstrual age (weeks) 33 (24-43) 34 (24-45) 
Postnatal age (days) 2 (1-30) 2 (1-30) 
Birth bodyweight (g) 1750 (385-4650) 2285 (420-4850) 
Current bodyweight (g) 1760 (385-4760) 2100 (420-5040) 
Co-administration of ibuprofen (n (%)) 118 (13.5) 29 (5) 
 
 
Table 3: Pathogens isolated from blood cultures collected at start of the amikacin treatment episodes 
included in the prospective analysis. Isolates are ranked based on frequency.   
 
Blood culture result Number Percentage MIC reference values* 
Negative 601 85.7%  
 
Positive 
     1) Staphylococcus epidermidis 
     2) Escherichia coli 
     3) Staphylococcus aureus 
     4) Streptococcus mitis 
     5) Others 
 
93 
     32 
     23 
     6 
     5 
     27 
13.3% 
     34.4% 
     24.7% 
      6.5% 
      5.4% 
      29% 
 
1.5-12 
10
             
 
 
≤ 2 
13
, MIC90=1 
14
 
0.75-3
 10 
              
NA 
NA 
Unknown / Not available 7 1%  
Total 701 100%  
 
* MIC: Minimal inhibitory concentration. NA: not applicable.  
 
 
Prospective validation 
1. Early amikacin TDM observations 
Of the 1195 TDM observations, 678 early trough and 389 early peak samples were identified  
(Figure 1). Overall, 60.2%, 33.2% and 6.6% of first amikacin trough levels were <3 mg/L, 
between 3-5 mg/L and >5 mg/L respectively. Taking into account all first peak levels, 90.5% 
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reached 24 mg/L (71.7% between 24-35 mg/L, 18.8% exceeded 35 mg/L) (Figure 1). The 
percentages of first trough and peak TDM observations for the 10 different groups are 
presented in Table 4.  
 
 
Table 4: Early therapeutic drug monitoring (TDM) observations included in the prospective dataset 
(n=678 early trough and n=389 early peak observations). For the subgroups 1-10 as defined in Table 1, 
the percentages of trough samples <3 mg/L, between 3-5 mg/L and >5 mg/L and peak samples <24, 
between 24-35 and >35 mg/L are provided. Conc= concentration. 
 
Conc 
(mg/L) 
group 1 group 2 group 3 group 4 group 5 group 6 group 7 group 8 group 9 group 10 
Simplified model-based dosing regimen 
<3 74% 100% 66% 92% 72% 84% 44% 92% 48% 88% 
3-5 26% 0% 25% 8% 25% 16% 49% 0% 41% 12% 
>5 0% 0% 9% 0% 3% 0% 7% 8% 12% 0% 
<24 23% 0% 23% 0% 14% 8% 4% 0% 5% 0% 
24-35 71% 100% 68% 70% 76% 46% 71% 33% 74% 78% 
>35 6% 0% 9% 30% 10% 46% 25% 67% 21% 22% 
 
 
2. Pharmacokinetic analysis and Monte Carlo simulations 
2.1. Pharmacokinetic analysis 
Figure 2 shows the individual and population predicted concentrations versus concentrations 
observed in this prospective study, for the different dosing groups based on current 
bodyweight and postnatal age (Table 1). Both panels indicate absence of bias and an adequate 
prediction of the observed concentrations across the different groups. Moreover, the 
distribution of the data points around the line of unity of the observed versus predicted plot 
indicates that the interindividual variability is both acceptable and similar across the entire 
neonatal population. This is also reflected in Figure 3 in which the interindividual variability 
on clearance is plotted against birth bodyweight, postnatal age and co-administration of 
ibuprofen. Figure 3 illustrates that the pharmacokinetic model of amikacin is able to describe 
the prospective dataset accurately across the different covariates as no trend is seen in the 
interindividual variability on clearance versus these covariates. This result was obtained 
despite the fact that there were small differences in clinical characteristics between the dataset 
that was used to build the model 
4
 and the prospective dataset (Table 2). Table 5 gives an 
overview of the parameter estimates of the recently published final pharmacokinetic model 
4
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together with the parameter estimates obtained for the current prospective dataset in 579 
individuals. Based on the values in Table 5, fairly similar parameter estimates are obtained 
when comparing the prospective dataset with the previously obtained parameters, hereby 
indicating the stability of the model.  
 
Figure 2: Observed versus model-based individual and population predicted concentrations 
(logarithmic scale) for the 10 different dosing groups based on current bodyweight and postnatal age 
(Table 1) for the current prospective dataset. 
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Figure 3: Interindividual variability (eta) on clearance (CL) versus birth bodyweight (a), postnatal age 
(b) en co-administration of ibuprofen (c) for the current prospective dataset using the recently 
developed pharmacokinetic model 
4
. 
 
 
Figure 4 shows the results of the NPDE analysis. The histogram follows the normal 
distribution indicated by the black solid line. Additionally, no trend is seen in NPDE versus 
time and NPDE versus predicted concentrations indicating model accuracy. 
 
 183 
 
Prospective validation of a model-based amikacin dosing  regimen 
 
Figure 4: Results of the NPDE analysis performed for the prospective dataset using the recently 
developed pharmacokinetic model 
4
. Left panel: Histograms of the NPDE distribution with the solid 
line representing a normal distribution as a reference, Middle panel: NPDE versus time (hours); Right 
panel: NPDE versus observed concentrations (mg/L). 
 
 
2.2. Monte Carlo simulations 
Monte Carlo simulations were performed to illustrate the exposure to amikacin in two times 
5000 neonates (with and without ibuprofen administration) following the simplified model-
based and the original model-based dosing regimen 
4
 after 5 consecutive doses. In Table 6a 
the percentages of the individuals with simulated trough concentrations after 5 doses <1.5 
mg/L, between 1.5-3 mg/L, between 3-5 mg/L and >5 mg/L and peak concentrations after 5 
doses <24 mg/L, between 24-35 mg/L and >35 mg/L are given when ibuprofen is not co-
administered. In Table 6b, these simulated percentages are shown when ibuprofen is co-
administered. Both tables are graphically presented in Figures 5a and 5b. In both figures the 
upper panels (A) represent the trough concentrations while the lower panels (B) represent the 
peak concentrations. Based on the Tables 6a and 6b and Figures 5a and 5b, it can be seen that 
for the model-based dosing regimens (with and without ibuprofen) the percentages for trough 
concentrations between 1.5 and 3.0 mg/L are relatively constant across the 10 different age 
and weight groups. This confirms the predictions performed in the previously published 
analysis 
4
. Overall, these Figures and Tables show that trough concentrations <3 mg/L 
11
 are 
reached in most individuals of the different dosing groups upon the simplified (78-100% and 
45-96%) and original model-based dosing regimen (86-100% and 62-92%), when ibuprofen is 
co-administered or not, respectively. Trough concentrations >5 mg/L which are associated 
with oto- and nephrotoxicity, were observed in 0-20% and 0-9% of the individuals of the 
different dosing groups as defined in Table 1, for the simplified dosing regimen and the 
original dosing regimen 
4
 respectively (Tables 6a and 6b). Considering the peak 
concentrations, simulations using the simplified model-based dosing regimen result in peak 
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concentrations >24 mg/L in almost all individuals. For the original model-based dosing 
regimen 
4
, target peak concentrations are not reached in all individuals of one or more dosing 
subgroups.  
 
 
Table 5: Final parameter estimates and coefficients of variation (CV%) of the pharmacokinetic model 
that was recently developed on the basis of the original dataset (n=874) 
4
 and on the basis of the 
current prospective dataset (n=579). Clinical characteristics of the datasets are provided in Table 2. 
 
Parameter 
Recently developed  
amikacin model 
4
 
n=874 patients 
 
Value (CV%) 
Current prospective 
 amikacin analysis 
n=579 patients 
 
Value (CV%) 
   
Fixed effects   
CLp in CL = CLp x 
(bBW/median)
m
 x 
(1+ n x (PNA/median)) x o 
(ibuprofen) 
0.049 (2.21) 0.066 (3.2) 
m 1.34 (2.04) 1.30 (2.95) 
n 0.213 (9.81) 0.302 (9.34) 
o 0.838 (3.88) 0.846 (6.55) 
Vp in V1 = Vp x 
(cBW/median)
p
 
0.833 (1.34) 1.03 (1.47) 
p 0.919 (2.46) 0.863 (4.03) 
Q = r x CL 0.415 (12.3) 0.480 (13.5) 
V2=V1 V2=V1 V2=V1 
Interindividual Variability   
ω
2 
(CL) 0.0899 (14.9) 0.0921 (19.3) 
Residual Variability   
σ
2
 (proportional) 0.0614 (8.2) 0.0448 (22.3) 
σ
2
 (additive) 0.267 (27.2) 0.315 (16.3) 
 
CLp = population value for clearance (L/h), Vp = population value for volume of distribution of the 
central compartment (L), bBW = bodyweight at birth (g), cBW = current bodyweight (g), PNA = 
postnatal age (days), Q = intercompartmental clearance (L/h), V2 = Volume of distribution of the 
peripheral compartment (L), median values for the recently developed model for amikacin: bBW = 
1750g, PNA = 2 days, cBW=1760g; median values for the current prospective study: bBW = 2285g, 
PNA = 2 days, cBW = 2100g 
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3. Remaining causes limiting amikacin exposure predictability 
Prescription errors using the simplified model-based dosing regimen were found in 64/701 
(9.1%) of the amikacin treatment episodes. Of these errors, an incorrect dose was prescribed 
in 17/64 (26.6%) episodes, an incorrect interval was found in 20/64 (31.2%) errors. Dose and 
interval were both incorrect in 11/64 (17.2%) cases. Interval prolongation in case of asphyxia 
or ibuprofen use was not correctly implemented in 16/64 (25%) of the error cases. When 
suboptimal trough (>3 mg/L) or peak levels (<24 mg/L) were obtained, a prescription error 
was documented in respectively 8.5% and 10.8% of cases (Figure 1).  
Although no trend was seen in Figure 3, a subgroup of 7 patients presented an interindividual 
variability (eta) on clearance <-0.6. When exploring the individual characteristics, 2 cases 
displayed perinatal asphyxia, 1 course was suggestive for asphyxia, 2 neonates presented with 
hydrops foetalis at birth, 1 case suffered a fulminant septic shock and 1 patient was born at 35 
weeks and had toxic trough and peak samples without specific underlying disease.  
 
 
Discussion 
 
Recently, a population pharmacokinetic model and a model-based dosing regimen for 
amikacin in neonates aged between 1-30 days were developed 
4
. The main aim of this dosing 
regimen was to obtain trough concentrations of 1.5-3 mg/L and peak concentrations >24 mg/L 
across the entire neonatal population 
4
. As a final step to evaluate whether this model-based 
dosing guideline indeed results in the target amikacin concentrations aimed for in the clinical 
setting, a prospective clinical trial was conducted to validate this dosing regimen.  
 
For most patient groups, adequate amikacin peak and trough levels were achieved. The 
observed values (60.2% of trough values <3 mg/L, 93.4% ≤5 mg/L, and 90.5% of peak values 
>24 mg/L) hereby represent the early treatment phase, in which steady-state amikacin 
concentrations are not yet presumed. The results obtained by the Monte Carlo simulations 
(trough values <3 mg/L in 78-100% and 45-96% respectively when ibuprofen was co-
administered or not, and peak values >24 mg/L in almost all patients) more likely reflect 
steady-state condition, since simulations were performed up to 5 administrations. Overall, the 
prospective validation of the model-based dosing regimen resulted in better amikacin 
exposure when compared to evaluations of dosing regimens found in reference books as 
reported by De Cock et al 
4
. To further illustrate this, we performed Monte Carlo simulations 
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Table 6: The percentage of individuals of subgroups 1-10 as defined in Table 1 with trough 
concentrations after 5 amikacin doses <1.5 mg/L, between 1.5-3 mg/L, between 3-5 mg/L and >5 
mg/L and peak concentrations (grey background) after 5 doses <24 mg/L, between 24-35 mg/L and 
>35 mg/L following Monte Carlo simulations in 5000 individuals according to the simplified model-
based dosing regimen and the original model-based dosing regimen 
4
, when ibuprofen was not co-
administered (Table 6a) and when ibuprofen was co-administered (Table 6b). 
 
Table 6a 
Conc 
(mg/L) 
group 1 group 2 group 3 group 4 group 5 group 6 group 7 group 8 group 9 group 10 
Simplified model-based dosing regimen 
< 1.5 34% 55% 30% 65% 27% 58% 17% 53% 8% 58% 
1.5-3 45% 30% 45% 30% 45% 38% 45% 36% 37% 36% 
3-5 16% 15% 21% 5% 23% 4% 27% 11% 35% 6% 
> 5 5% 0% 4% 0% 5% 0% 11% 0% 20% 0% 
< 24 0% 0% 0% 0% 0% 0% 0% 3% 0% 0% 
24-35 95% 50% 94% 71% 97% 83% 90% 97% 81% 94% 
> 35 5% 50% 6% 29% 3% 17% 10% 0% 19% 6% 
Original model-based dosing regimen 4 
< 1.5 33% 55% 29% 43% 25% 56% 25% 60% 16% 61% 
1.5-3 41% 30% 48% 36% 47% 36% 47% 32% 46% 25% 
3-5 21% 15% 18% 14% 22% 8% 23% 5% 29% 11% 
> 5 5% 0% 5% 7% 6% 0% 5% 3% 9% 3% 
< 24 0% 0% 0% 0% 0% 0% 9% 3% 24% 9% 
24-35 96% 50% 93% 64% 97% 70% 91% 89% 76% 84% 
> 35 4% 50% 7% 36% 3% 30% 0% 8% 0% 7% 
 
Table 6b 
Conc 
(mg/L) 
group 1 group 2 group 3 group 4 group 5 group 6 group 7 group 8 group 9 group 10 
Simplified model-based dosing regimen 
< 1.5 34% 55% 30% 65% 27% 58% 17% 53% 8% 58% 
1.5-3 45% 30% 45% 30% 45% 38% 45% 36% 37% 36% 
3-5 16% 15% 21% 5% 23% 4% 27% 11% 35% 6% 
> 5 5% 0% 4% 0% 5% 0% 11% 0% 20% 0% 
< 24 0% 0% 0% 0% 0% 0% 0% 3% 0% 0% 
24-35 95% 50% 94% 71% 97% 83% 90% 97% 81% 94% 
> 35 5% 50% 6% 29% 3% 17% 10% 0% 19% 6% 
Original model-based dosing regimen 4 
< 1.5 33% 55% 29% 43% 25% 56% 25% 60% 16% 61% 
1.5-3 41% 30% 48% 36% 47% 36% 47% 32% 46% 25% 
3-5 21% 15% 18% 14% 22% 8% 23% 5% 29% 11% 
> 5 5% 0% 5% 7% 6% 0% 5% 3% 9% 3% 
< 24 0% 0% 0% 0% 0% 0% 9% 3% 24% 9% 
24-35 96% 50% 93% 64% 97% 70% 91% 89% 76% 84% 
> 35 4% 50% 7% 36% 3% 30% 0% 8% 0% 7% 
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using the Neofax 
15
 and BNFc 
16
 dosing regimen, to compare them with the simulations of the 
model-based dosing regimens as can be seen in Figure 5a and 5b.  
 
A ratio of peak concentration divided by the minimal inhibitory concentration of a given 
pathogen (peak/MIC) of at least 8-10 is recommended for effective amikacin therapy 
17
. 
While the amikacin peak concentration depends on the dose administered and the distribution 
volume of the individual patient, the peak/MIC also depends on the sensitivity of the specific 
pathogens targeted for. Taking the non-specified Staphylococcus species MIC values (0.75-3 
mg/L) as published by Sherwin et al 
10
 and the Escherichia coli MIC values (our department 
≤2 mg/L, Pacifici 2009 MIC
90
=1 mg/L) into account 
14
, a peak/MIC ratio ≥8 is obtained if 
peak concentrations reach 24 mg/L (Table 3). Consequently, the current extended interval 
dosing approach reaches sufficient high (≥8) peak/MIC values to treat pathogens causing 
neonatal infections in most patients, as documented in both early TDM, as well as in the 
Monte Carlo simulations (Table 6a and 6b). 
 
Besides the overall positive evaluation of the model-based dosing regimen, we anticipated 
that the exposure for some patient groups can be further improved. Considering observed 
trough levels, group 7 (current weight 2000-2800g, PNA<14 days) and 9 (current weight 
>2800g, PNA<14 days), had a relevant proportion of early trough observations (respectively 
50% and 41%) between 3-5 mg/L, and this elevated incidence was also confirmed in the 
Monte Carlo simulations (Table 6a and 6b) after 4-5 administrations. In the setting of peak 
levels on target, this indicates that an additional interval prolongation (+6h) for the subgroups 
7 and 9 may be of additional benefit to avoid toxicity. Based on these observations, we 
suggest a further adapted dosing regimen for these two subgroups. Since optimal peak 
concentrations are achieved using the simplified model-based dosing regimen, the 15 mg/kg 
dose can remain the same, but an interval of 36h instead of 30h, and 30h instead of 24h, for 
respectively group 7 and 9 can be considered, as presented in Table 1. At least, this illustrates 
the importance of prospective validation studies. Consequently, a new prospective validation 
is needed in these specific subgroups to evaluate whether lower trough concentrations could 
be obtained when the dosing interval is prolonged as suggested. 
 
In addition to dosing regimen validation, the predictive performance of the pharmacokinetic 
model was assessed. Based on the current results, it can be concluded that the final 
pharmacokinetic model is indeed able to predict the observed concentrations in the current 
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study without bias across the entire neonatal range (Figure 2). Moreover, the covariates birth 
bodyweight, postnatal age and co-administration of ibuprofen are correctly implemented on 
clearance as no trend is seen when plotting the interindividual variability on clearance versus 
the different covariates (Figure 3). When evaluating Figure 2 and Figure 3, we concluded that 
only random variability remained in the model while variability allocated to the explored 
covariates is explained. 
  
Finally, we also explored remaining causes of impaired amikacin exposure predictability. 
First of all, prescription errors were evaluated. In the current study, the extent of suboptimal 
early trough and peak amikacin levels associated with prescription errors (8.5% and 10.8% 
respectively) is in line with the extent of overall prescription errors (9.1%) in the prospective 
dataset, suggesting that this is not a major cause of unexplained variability per se. Overall, 
drug prescription errors are common and multifactorial. Efforts to reduce these errors, like 
computerized physician orders with electronically provided dosing regimens 
18
 as well as the 
development of care bundles (i.e. a combination of evidence-based practices to improve a care 
process) are gradually being introduced in neonatal departments 
19
 and improve patient safety. 
We therefore encourage that when new neonatal dosing regimens are introduced, a 
simultaneous evaluation on prescription and administration feasibility is performed. Secondly, 
we documented that amikacin exposure predictability was impaired in individual neonates 
with hydrops foetalis, perinatal asphyxia or severe septic shock. Although the impact of sepsis 
on the clearance 
20
 and volume of distribution of gentamicin in neonates are described, the 
influence of other clinical conditions on aminoglycoside disposition in neonates is not yet 
confirmed 
20,21
. Furthermore, robust parameters to define conditions like (suspected) asphyxia 
are lacking. Therefore we want to stress that TDM monitoring remains indicated to guide safe 
and effective amikacin therapy, at least in these specific cases.  
 
Following dosing regimen development, a prospective study was performed and confirmed 
the accuracy of the model. In addition, the covariate model itself was also validated, and this 
may be of relevance beyond the amikacin specific observations. This is because it was shown 
by two different groups that the pharmacokinetic covariate model of amikacin contains 
system-specific information on the developmental changes in glomerular filtration rate (GFR) 
throughout neonatal life. 
21,22
. Consequently, the covariate model on amikacin clearance with 
birth bodyweight, postnatal age and co-administration of ibuprofen as most important 
covariates could be used to predict the dosage regimens of other drugs excreted by GFR.  
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Figure 5a: Bar graphs to illustrate the percentages of individuals of the different dosing groups as 
defined in Table 1 with A/ trough concentrations after 5 doses <1.5 mg/L (light grey), between 1.5-3 
mg/L (white), between 3-5 mg/L (dark grey) and >5 mg/L (black) and B/ peak concentrations after 4 
doses <24 mg/L (light grey), between 24-35 mg/L (white) and >35 mg/L (dark grey) following the 
Monte Carlo simulations in 5000 individuals according to the different dosing regimens (1= simplified 
model-based dosing regimen, 2= original model-based dosing regimen 
4
, 3= Neofax 
15
, 4= BNFc 
16
) 
when ibuprofen was not co-administered.  
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Figure 5b: Bar graphs to illustrate the percentages of individuals of the different dosing groups as 
defined in Table 1 with A/ trough concentrations after 5 doses <1.5 mg/L (light grey), between 1.5-3 
mg/L (white), between 3-5 mg/L (dark grey) and >5 mg/L (black) and B/ peak concentrations after 4 
doses <24 mg/L (light grey), between 24-35 mg/L (white) and >35 mg/L (dark grey) following Monte 
Carlo simulations in 5000 individuals according to the different dosing regimens (1= simplified 
model-based dosing regimen, 2= original model-based dosing regimen 
4
, 3= Neofax 
15
, 4= BNFc 
16
) 
when ibuprofen was co-administered. 
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(netilmicin, tobramycin, gentamicin and vancomycin) in neonates 
21,22
. This semi-
physiological approach may be used to optimize sparse data analysis and may facilitate 
development of pharmacokinetic models and evidence-based dosing regimens following 
prospective validation 
23
.  
 
In conclusion, we documented that a large percentage of neonatal amikacin TDM 
observations achieved using a model-based dosing regimen reached predefined targets. 
Furthermore, we illustrated that population pharmacokinetic modeling facilitates the 
development of drug dosing regimens in neonates. Finally, we raised awareness on other 
causes possibly impeding amikcin exposure predictability in neonates.  
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General discussion 
 
The neonatal period is characterized by large and intriguing inter-and intra-individual 
variability in drug disposition and drug action. In this doctoral thesis, we aimed to improve 
pharmacotherapy in neonates based on pharmacokinetic (PK) and/or pharmacodynamic (PD) 
studies of frequently used -but still insufficiently understood- drugs in this population. The 
drugs selected for the studies represent a larger group of compounds with similar 
physicochemical characteristics and/or with similar metabolic or renal excretion pathways. 
Therefore, the drugs studied can be seen as ‘probe’ drugs, of which PK/PD results are of 
relevance beyond the compound specific observations.  
 
Research sequence and individual studies performed 
Throughout this doctoral thesis, a 3-step research sequence was used, illustrating how a 
pharmacology-related problem or question, arising during clinical care, can ultimately result 
in improved pharmacotherapy through validated drug dosing. Population pharmacokinetic 
modelling hereby needs to be considered as an advanced methodological tool turning neonatal 
drug therapy from explorative to confirmatory 
1
. First, to gain insight into the behavior of a 
drug in neonates, exploration of covariates contributing to variability in drug exposure 
and/or effect is warranted. Secondly, integration of these covariates in dosing regimens can 
improve prediction of drug exposure for the individual patient. Finally, new model-derived 
dosing regimens need prospective validation. For each research step, observations were 
collected using different probe drugs.  
 
Part 1: Problem identification and covariate exploration 
Although vancomycin is an old drug used in the treatment of neonates, suboptimal 
vancomycin dosing was presumed since low trough levels were often measured during 
clinical care. In chapter 2 we retrospectively assessed that indeed up to 70% of vancomcyin 
serum trough levels in our NICU patients were below the target of 10 mg/L. For this 
evaluation we used routine therapeutic drug monitoring (TDM) results achieved using 2 
published neonatal vancomycin dosing regimens. Especially the small [low birth weight 
(BW), current weight (CW)] and immature [low gestational age (GA), postmenstrual age 
(PMA)] neonates showed suboptimal trough concentrations, indicating ineffective or at least 
off target therapy. Besides confirming the impact of covariates reflecting ontogeny on 
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vancomycin exposure (which is in line with observations in literature 
2
), we hereby also 
illustrated the need for prospective validation of dosing regimens, preferably before 
publication 
3
. 
 
Measurement of drug exposure usually occurs in the blood compartment. However, the ability 
to reach therapeutic concentrations at the effect site is necessary for drug efficacy. In chapter 
3 we explored this PK aspect for amikacin by describing neonatal amikacin concentrations in 
a deep body compartment, i.c. the bronchial epithelial lining fluid (ELF). Quantification was 
feasible and required urea (introduced by Renard et al 
4
) to correct for bronchoalveolar lavage 
(BAL)-related dilution 
5
. The specific chromatographic and electrophoretic methods were 
developed and subsequently applied to neonatal samples 
5
. Median (range) amikacin ELF 
concentration was 6.5 (1.5-23) mg/L 
6
. Only 1 additional published observation on amikacin 
disposition in a deep body compartment (cerebrospinal fluid, CSF) in neonates could be found 
7
. To compare both (CSF, ELF) deep body compartment studies, we provide a summary of the 
clinical and biochemical characteristics in Table 1.  
 
Although we are aware that there are differences in sampling times, the ELF compartment 
attained significantly higher median amikacin concentrations (6.01 mg/L) than the CSF, 
where a median value of 1.08 mg/L in neonates was reported previously 
7
. In that study, 
amikacin CSF concentrations in neonates without meningitis were analysed. The lower 
amikacin detection in CSF illustrates that passing the blood-CSF barrier is more difficult for 
amikacin than passing the blood-ELF barrier, a finding similar to many other water soluble 
drugs 
8
.  
 
We are aware that primary respiratory tract infections are a rare indication for amikacin use in 
neonates. However, we encourage the investigation of drug penetration in ELF as well as 
other deep compartments in neonates since such data can be integrated in physiology-based 
pharmacokinetic models (PBPK) or by pooling of different data, in a population 
pharmacokinetic modelling analysis with Monte Carlo simulations. This allows to evaluate 
plasma and ELF concentrations with regard to the achievement of predefined PD targets. This 
is of relevance since -at present-, the relation between clinical outcomes (including efficacy, 
but also the potential to induce microbiological resistance) and deep compartment 
concentrations, including ELF concentrations, is under-studied 
9
. Unfortunately, such efforts 
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are laborious and demanding, resulting in overall small cohorts of patients as reflected in 
Table 1 of chapter 3.  
 
Table 1: Comparison of amikacin quantification in cerebrospinal fluid (CSF group 
7
) and epithelial 
lining fluid in neonates (ELF group 
6
). CSF: cerebrospinal fluid; ELF: epithelial lining fluid. Data are 
presented as median and range if not otherwise stated. *: Mean and standard deviation. °: Hours after 
amikacin administration. 
 
Clinical characteristics  
 and fluid analysis 
CSF group 
7
 
(n=43) 
ELF group 
6
 
(n=17) 
Clinical characteristics   
      Weight (kg) 2.430 (0.865-3860) 1.715 (0.550-3.540) 
      Postmenstrual age (weeks) 36 (26-41) 31.9 (25.1-41) 
      Postnatal age (days) 3 (1-29) 3.5 (2-37) 
      Creatinaemia (mg/L) 0.86 (0.48-1.26) 0.62 (0.35-0.98) 
   
Fluid analysis   
       Serum amikacin trough (mg/L) 3.8 +/- 2.5 * 2.1 (1-7.1) 
      Serum amikacin peak (mg/L) 35.7 +/- 5.9 * 39.1 (24.1-73.2) 
      CSF or ELF sampling (h)°  25 (2.5-93.7) 13.5 (1.5-23.5) 
      Amikacin concentration (mg/L) CSF: 1.08 (0.34-2.65) ELF: 6.01 (0.26-23.03) 
 
 
Comparable with many other drugs, the prescription of propofol in neonates is off-label. 
Available propofol PD data are conflicting and dosing recommendations in neonates are 
absent. In chapter 4, we first explored PK covariates of a single propofol bolus. Based on 24 
h urine collections, the median total urinary recovery of propofol equivalents was 40.95 (2.01-
129.81)% and PG/QG (propofol glucuronide/quinol glucuronides) ratio was 0.44 (0.01-5.93). 
In this analysis, postnatal age (PNA) was a significant covariate of propofol metabolic profile. 
A significant correlation between %PG and PNA as well as between early versus late PNA 
(10 days as cut-off point) and PG/QG ratio was documented 
10
.  
Secondly, we introduced bilirubin in a published propofol population PK model for neonates 
to explore if hyperbilirubinaemia is a valuable covariate explaining neonatal propofol 
clearance. It turned out that the model with PMA and PNA as covariates remained the most 
optimal. Although both UGT1A1 and UGT1A9 mature simultaneously, hyperbilirubinaemia 
can be the final result of either increased production or decreased elimination. This indicates 
that UGT activity is only one of the contributing factors to the newborn with jaundice 
11
. As 
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main conclusion of both covariate explorations on propofol metabolism, the clinician 
administering propofol to a neonate, has to be aware of the age (PNA + PMA) to estimate 
propofol clearance.  
Especially in the first days after birth, propofol induced vasodilatation and decrease in blood 
pressure might occur more often due to impaired clearance besides potential 
pharmacodynamic differences (more pronounced hemodynamic instability) 
12
. At this age, 
respiratory distress syndrome typically occurs, sometimes requiring endotracheal intubation 
or an INSURE procedure. Therefore, in a third study, we explored the propofol ED50 dose and 
simultaneously recorded PD aspects in neonates needing propofol for pre-intubation sedation. 
The initial and total propofol dose ranges administered were 0.5-2 and 0.5-4.5 mg/kg, 
respectively. Within this dose ranges a moderate decrease in blood pressure, considered 
permissive, and a short-lasting decrease in peripheral and cerebral oxygen saturation was 
seen. Since 86% of patients received propofol prior to an INSURE procedure, both successful 
in-and extubation are requested to consider the procedure as successful. This resulted in the 
use of overall low propofol doses and patients who still remained active to a certain level. 
Notwithstanding this tailored sedation approach, it was interesting to see that clinical recovery 
(sedation, relaxation state) takes time. At the end of our scoring period (i.e. 21 minutes after 
propofol administration) baseline scores were not yet reached. The ED50 propofol dose for 
neonates in stratum 1, 3 and 5 (as defined in Table 1 chapter 4) was 0.749, 0.480 and 1.287 
mg/kg respectively. We recommend to start with the respective ED50 doses and subsequently 
to increase the propofol bolus dose by up-titration based on perceived clinical need, combined 
with strict follow-up of vital signs, until validated dosing regimens become available.  
Besides propofol, also remifentanil, a short-acting opioid, has been suggested as suitable 
candidate for premedication prior to endotracheal intubation in neonates. Its metabolism by 
nonspecific tissue and plasma esterases theoretically results in a fast termination of its clinical 
effect. However, also for this compound, the impact on intubation conditions and vital signs 
vary across different reports 
13-16
. Since the time to extubation after remifentanil could be 
rather long, the appropriateness of its use for INSURE conditions is debatable 
17
. It should be 
stressed that whatever compound is used (propofol, remifentanil) in a specific NICU, one has 
to remain attentive for side effects. In our opinion, it is only once validated ED50 values for 
both drugs are available and their safety is assessed, that a randomized controlled trial can be 
performed to further compare both compounds in the search for the most optimal pre-
intubation medication.  
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Part 2: Drug exposure prediction  
After a drug has been administered to a patient, we may not simply assume that the total drug 
concentration measured in the blood (or another body compartment e.g. CSF, BAL fluid), is 
responsible for the drug effects. In essence, only the unbound drug can have an effect (PD), 
can diffuse to deep compartments or is available for elimination. Protein binding is one of the 
interfering covariates of this unbound drug concentration. Cefazolin is highly bound to 
albumin in plasma. However, available PK analyses in neonates are old and are based on total 
cefazolin concentrations. Therefore, in chapter 5, we first explored cefazolin protein binding 
in 40 neonates and subsequently developed a neonatal population PK model based on both 
total and unbound cefazolin concentrations. We documented a median unbound cefazolin 
fraction in neonates of 0.39 (0.10-0.73), which was higher compared to pregnant women and 
adults. Overall, 49.6% of variability in unbound cefazolin fraction could be explained by 
covariates PMA, albuminaemia, total cefazolin concentration and indirect bilirubinaemia 
18
. 
As a side step we compared cefazolin protein binding in neonates with published cohorts of 
other specific populations. Despite the limited number of clinical characteristics available for 
evaluation and despite the (minor) differences in analytical techniques used, this was -to the 
best of our knowledge- the first pooled analysis of CFZ protein binding data 
19
. Besides total 
and unbound cefazolin concentrations, variability in unbound cefazolin fraction across the 
populations also seemed to depend on albuminaemia and characteristics of the patient 
subgroup itself 
19
.  
According to literature, both pregnancy and neonatal life are typically characterized by 
hypoalbuminaemia. The decrease in albuminaemia during gestation is assumed to result from 
haemodilution, and is only in part compensated by an increase in the amount of circulating 
albumin 
20
. In the pregnant cohort included in the pooled analysis, median albuminaemia 
decreased with gestational age (GA), but did not appear to differ significantly from non-
pregnant adult values. This could be explained by the extensive range of albuminaemia, 
reflecting different pathophysiological conditions in the non-pregnant adults.  
As shortly announced in section 5.2, not only the number of albumin binding places (i.e. 
‘quantitative’ aspect, depending on the number of albumin molecules and on the presence of 
other compounds in competition for the same binding places), but also the drug-albumin 
binding affinity (i.e. ‘qualitative’ aspect) matters. Alterations in affinity can be due to the 
presence of endogenous substances [e.g. bilirubin, free fatty acids (FFA), urea] which by 
binding to albumin induce conformational changes of the albumin molecule with subsequent 
alterations in binding affinity 
21,22
. Elevated FFA are reported during pregnancy and the first 
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days of life, although robust reference values of the latter are lacking. Decreased protein 
binding of cefazolin, phenytoin and valproic acid has been shown in the presence of increased 
FFA concentrations 
21,23
. In uremic conditions, decreased drug binding (e.g. diazepam, 
salicylic acid) but also increased drug binding (e.g. doxycycline, metoclopramide) is reported 
24,25
. For cefazolin, binding in uremic conditions is yet to be described. As a highly protein 
bound, renally eliminated drug, where dosing is not titrated to effect 
26
, alterations in protein 
binding of cefazolin may be of -perhaps limited- clinical relevance. Because the concept of 
protein binding certainly matters, our neonatal data were subsequently, integrated in a 
population PK analysis using non-linear mixed effect modelling, to describe cefazolin 
disposition and to define covariates improving exposure predictability. A one-compartment 
PK model was developed. Current weight was identified as covariate for volume of 
distribution (Vd), birth weight and postnatal age for clearance (Cl) and albumin for maximal 
protein binding (Bmax), explaining 50%, 58% and 41% of inter-individual variability in Vd, Cl 
and Bmax respectively 
27
. Based on Monte Carlo simulations, an advanced statistical tool to 
evaluate and predict drug exposure using different dosing regimens, a model-derived neonatal 
cefazolin dosing regimen based on current weight and postnatal age as most important PK 
covariates, was proposed. The attainment of unbound concentrations for at least 60% of the 
dosing interval above 8 mg/L [i.e. the CLSI Minimal Inhibitory Concentration (MIC) for 
staphylococcal species 
28
] for the different weight and age groups defined, was the a priori 
target used in the development of the model-based dosing regimen 
27
. We hereby would like 
to stress that the distribution of bacterial species and their MIC values usually differ between 
units, hospitals, regions and countries. This illustrates why not only the choice of an antibiotic 
agent, but also the dosing regimen used, the concentrations achieved in the subcutaneous 
tissues and the susceptibility pattern of the bacterial species all contribute to the success of 
surgical prophylaxis. At least, our dataset can also be used to develop dosing regimens with 
other a priori target concentrations. However, when referring to the research sequence 
presented in this doctoral thesis, every new model-derived dosing regimen needs prospective 
validation (‘can the final PK model adequately describe a dataset prospectively collected 
using the model-derived dosing regimen?’), before integration in clinical care is possible.  
 
Part 3: Prospective dosing validation 
In our unit, amikacin is used for both (suspected) early and late onset sepsis. In chapter 6, we 
performed a prospective validation of a population PK model-based amikacin dosing regimen 
for neonates. This dosing regimen, based on postnatal age (covariate for clearance) and 
 203 
 
General discussion and future perspectives 
current weight (covariate for volume of distribution) was implemented in our neonatal 
department in 2011, but was not yet prospectively validated. In total 1195 routine amikacin 
TDM results collected in 579 neonates were included. During clinical practice we aim for 
early trough levels <3 mg/L and peak >24 mg/L. 90.5% of the observed peak levels reached 
24 mg/L and 60.2 % of the early observed trough levels were <3 mg/L (93.4% ≤5 mg/L). The 
observed concentrations were accurately predicted by the model. Monte Carlo simulations 
showed that peak predicted concentrations >24 mg/L were reached in almost all patients. 
Trough values <3 mg/L were documented in 78-100% and 45-96% of simulated cases, 
respectively when ibuprofen was co-administered or not, with largest percentages of trough 
levels >3 mg/L in subgroups with PNA <14 days and current weight >2000g. For these 
subgroups, a slightly adapted dosing regimen was proposed. Except for these subgroups, the 
model-based dosing regimen overall resulted in optimized trough and peak concentrations.  
 
With this study, we illustrated the relevance of prospective validation. Although routine 
sampling of amikacin TDM peak values was in the meanwhile abandoned in our unit, 
monitoring of trough values remains important, especially in specific clinical conditions 
impairing exposure predictability. Secondly, although TDM helps the clinician to adapt 
dosing regimens, -even for amikacin- different neonatal target values can be found in 
literature. Again, this illustrates the need for validated targets in neonatal PK/PD research. 
Finally, the introduction of the model-based dosing regimen in 2011 
29
 resulted in an almost 
similar total daily dose range compared to the dosing regimen administered previously in our 
unit 
30
, but dosing is now refined on a weight-and age-based approach instead of only 
considering age. Appropriate dosing for neonates with PNA< versus ≥14 days is an add-on 
value in the current approach compared to the regimen of Langhendries et al 
30
, which mainly 
focused on the first days of life.  
 
 
Future perspectives: Closing the gaps between developmental PK, PD and clinical care 
Throughout this doctoral thesis, some concerns, limitations and challenges, of relevance 
beyond the individual studies performed appeared. First, it would be time consuming to 
conduct the same research sequence for every individual drug. Therefore, the methods 
described in the drug-specific studies should be used and extrapolated to further explore 
PK/PD patterns of other compounds or in other patient populations. Secondly, optimal 
pharmacotherapy is more than only providing adequate dosing regimens. Selection of the 
Chapter 7 
 
204 
 
appropriated treatment indication and duration needs to be studied. Third, bioanalytical assay-
related variability as well as the lack of clinical definitions are challenges to perform covariate 
analyses in neonates. Finally, the translation of PK/PD data into clinical guidelines will be a 
future challenge.  
 
Beyond compound specific observations 
We performed studies with selected ‘probe’ drugs to explore compound-specific PK/PD 
questions. However, these observations are of relevance for drugs with ‘similar’ 
characteristics. For example, besides vancomycin, teicoplanin is also a glycopeptide. As an 
aminoglycoside, amikacin is considered as a probe for gentamycin, netilmicin and tobramycin 
31
. To a certain extent, amikacin shares PK characteristics with other water soluble drugs 
mainly excreted by GFR like other aminoglycosides or glycopeptides 
31,32
. Compared to 
aminoglycosides, the renal excretion of cefazolin -at least in adults- is a combined result of 
GFR and tubular secretion. Furthermore, cefazolin is a probe drug illustrating the importance 
of protein binding determination. Future efforts to compare amikacin versus cefazolin PK 
aspects, will presumably improve knowledge on the role of renal tubular functions in neonates 
33
. Propofol represents the lipophilic drugs which immediately after intravenous 
administration distribute to the central nervous system and fat tissue. In contrast to the 
aforementioned probes, propofol undergoes hepatic metabolisation by glucuronidation. 
Similar to the GFR maturational pattern, a glucuronidation covariate model has also been 
extrapolated from morphine glucuronidation to zidovudine glucuronidation 
34
. Such 
initiatives, in which drug-specific data are used to improve knowledge of other compounds, or 
to explore patterns in other populations, should be further encouraged.  
 
‘Less is More?’ 
For some of the probe drugs investigated (propofol, cefazolin), a trend towards lower drug 
doses was found. This can be of add-on value to avoid side-effects [including toxicity or 
disturbance of vital signs (propofol)] or to increase the available albumin binding places 
(cefazolin study) for endogenous (bilirubin) or other exogenous compounds. In general, the 
fact that ‘less may very well be more’ is not only applicable to ‘dosing’. Also about the 
selection of indications and treatment durations in neonatal pharmacotherapy, improvements 
can be made. Based on point prevalence surveys, to which we in part contributed 
35
, it was 
documented that antimicrobial drugs in NICUs are mainly administered to neonates with PNA 
<7 days 
35
 and on empirical basis 
36
. In essence, we only need to treat those patients who need 
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it and we have to reduce the need to treat 
37
. These two tenets are for example of relevance in 
case of suspected early onset sepsis 
37,38
. 
 
Challenges in neonatal covariate analysis  
Difficulties in the correct interpretation of biomarkers, covariates or TDM results, may rely on 
bioanalytical techniques (serum creatinine, free fatty acids, vancomycin), definitions of 
clinical covariates (weight, hypotension, perinatal asphyxia) or overall evolutions in neonatal 
care (trends in practices throughout time in a given unit). It is important to raise awareness 
about these factors, since they can influence study results and hereby limit the transferability 
of PK models to other settings, or at least limit the suggested PK models in time. Each of 
these factors will be discussed to stress their possible impact as well as to put the results of 
this thesis into a broader perspective. 
 
Bioanalytical techniques  
Serum creatinine: Although serum creatinine (Scr) is often integrated in neonatal population 
PK analyses as a potential covariate of drug disposition, it is usually not retained as a major 
factor explaining drug exposure variability. However, Scr reflects -to a certain extent- GFR in 
neonates and supports the clinician to adapt drug doses, fluid administration and electrolyte 
support in neonates. Besides variability related to (patho)physiology, differences and related 
inaccuracy of bio-analytical techniques may also in part explain this variability.  
 
As reported for extreme low birth weight (ELBW, < 1000 g) neonates 
39,40
, postnatal Scr 
observations depend on the quantification assay used, e.g. the Jaffe (based on a colorimetric 
assessment) or the enzymatic technique. In an attempt to further assess the impact of the Scr 
measurement technique we retrospectively extended the dataset with Scr observations of 
neonates with higher birth weight. Figure 1 presents these Jaffe Scr data of 1139 neonates 
compared to enzymatic Scr data of 1110 neonates of our UZ Leuven NICU. All Scr data 
during the first 42 days were collected 
41
. The normal postnatal pattern of initial Scr increase 
(highest and last in the smallest neonates) followed by a decrease (most delayed in the 
smallest neonates) was confirmed. Jaffe hereby always resulted in higher Scr values compared 
to the enzymatic assay, without fixed conversion factor to correct for the difference between 
both techniques. This figure also nicely documents postnatal trends for cohorts <1 kg, 1-2 kg, 
2-3 kg and >3 kg for both techniques. To reduce between assay Scr differences, Jaffe and 
enzymatic Scr methods were calibrated to isotope dilution mass spectrometry (IDMS), in a 
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Scr standardization program. Even after introduction of IDMS traceability and 
standardization, there are still limited differences between neonatal Scr values determined by 
Jaffe versus enzymatic assay 
42
. Irrespective of IDMS traceability we still need a more 
creative approach to turn Scr into a useful covariate of clearance. We suggest to consider age-
or weight-adapted reference values with centiles or Z scores. Using such an approach, PNA-
dependent Scr centiles (<p25, p25-75, >p75) were a relevant covariate of amikacin clearance 
in ELBW neonates. Higher amikacin clearance was observed in cases with lower creatinine 
43
.  
 
  
 
Figure 1: Median postnatal trends of serum creatinine (Scr, mg/dL) for consecutive birth weight 
categories (<1kg, 1-2 kg, 2-3 kg, >3 kg). Scr values were determined by either Jaffe (full lines, year 
2001-2006) or enzymatic (dotted lines, year 2007-2011) method. Creatinine conversion: 1 mg/dL is 
equal to 88.4 µmol/L 
41
. 
 
One can assume that instead of Scr, other biomarkers can be used to assess renal function, e.g. 
cystatin C (CysC). However, CysC observations in neonates are limited, cover a 4-5 fold 
range and age-specific CysC reference values for neonates are lacking. Furthermore, and 
similar to creatinine, the impact of different measurement techniques on CysC values need to 
be considered 
44,45
. In essence, the remarks mentioned for Scr and CysC are applicable for 
many other biomarkers. For infants and older children, a research project defining age- and 
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gender- appropriate reference intervals for a wide range of blood tests [e.g. the Canadian 
Laboratory Initiative on Pediatric Reference Intervals (CALIPER)] is still ongoing and tries to 
close some gaps in paediatric reference intervals 
46,47
. Similar projects, specifically focusing 
on the preterm neonatal population, are a future challenge, but urgently needed.  
 
Free Fatty Acids: One of the covariates suggested in literature to influence the disposition of 
albumin-bound drugs (like cefazolin) in neonates are free fatty acids (FFA). Literature search 
strongly suggests that neonates display higher FFA values compared to adults 
20
, and that 
FFA values depend on age 
48
, disease state, co-medication (e.g. heparin) and nutritional state. 
Reports on neonatal FFA concentrations are rare, differ methodologically and often do not 
mention feeding regimen. As mentioned in the discussion of section 5.1 we documented FFA 
concentrations in remnant CFZ plasma samples. Surprisingly, our median (range) FFA 
concentration was 0.10 (0-0.84) mmol/L, which is lower than intervals reported in literature. 
We hypothesized that this was probably due to heparin interference (samples collected by 
arterial line or use of heparinized tubes) and sample handling (freezing and thawing) 
18
. As a 
proof of concept, we therefore prospectively collected FFA values in neonates (n=48), using 
standardized sampling methods and an enzymatic quantification assay (DiaSys, Diagnostic 
systems, Holzheim Germany). However, it turned out that median (range) FFA (C16-C18) 
concentration was 0.19 (0.06-0.79) mmol/L. Despite this 10-fold difference, neither weight, 
age nor feeding regimen (parenteral, formula feeding, mothers milk) were covariates of this 
variability. 
 
Vancomycin TDM measurement: Measurement-related problems are not only present on the 
covariate level, also methods used for drug TDM differ. An external evaluation of neonatal 
vancomycin PK models documented that differences in predictive performance of the models 
were in part attributed to both vancomycin and creatinine assays used. This illustrates that 
besides patient-related characteristics, also measurement techniques should be considered in 
dosing individualization of vancomycin in neonates 
49,50
. Since between-assay differences in 
vancomycin quantification may influence clinical decisions, a novel LC-MS/MS method to 
measure vancomycin (unbound and total) in human plasma was recently developed at the 
laboratory department of our hospital. Data collection for a paired analysis with the currently 
applied immunoassay and the novel LC-MS/MS of neonatal blood samples is ongoing. 
Furthermore, the extent of vancomcyin protein binding within the neonatal population will be 
explored (EudraCT nummer 2014-001124-29; ClinicalTrials.Gov).  
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Definitions of clinical covariates 
Besides bioanalytical factors, also clinical definitions can be a challenge to perform covariate 
analyses in neonates. A challenging ‘clinical’ covariate is perinatal asphyxia. Although 
guidelines to start hypothermia therapy in severely asphyxiated term neonates are 
straightforward, the clinical definition of perinatal asphyxia remains unclear. Not all cases 
qualify for hypothermia (e.g. preterm neonates, limited clinical signs), which makes the 
retrospective but also prospective handling of this covariate complex in neonatal PK/PD 
research. The combined report of potential indicators of asphyxia e.g. Apgar score, lactate 
levels and Tompson score 
29
 in medical files should be encouraged. The same holds true for 
other straightforward covariates, like weight. Neonatal dosing regimens often contain weight 
as clinical covariate of drug exposure, without further specification of the weight referred to 
(i.e. birth weight, or current weight, and how to manage this when the current weight is below 
the birth weight).  
To illustrate the clinical relevance of both covariates, we refer to Figure 3 in chapter 6. 
Especially patients with clinical conditions influencing clearance (asphyxia) and/or 
distribution volume (sepsis 
51
, hydrops foetalis) can display an impaired predictability of 
amikacin exposure, requiring TDM. 
 
Evolutions in neonatal care 
Not only patients are dynamic biological systems, also PK/PD covariates and endpoints can 
change over time, due to evolutions in clinical practice.  
With the introduction of extended dosing intervals for aminoglycosides in neonates, target 
trough and peak values also shifted over time. Although we earlier mentioned the lack of 
integrated and validated amikacin targets, -at least in our unit- an evolution towards lower 
trough and higher peak target values was seen (from trough <5 to trough <3 mg/L, from peak 
>20 to 24-35 mg/L). The final aim of new PK/PD knowledge is improved exposure 
predictability for the individual patient. In 2006, the consecutive steps to optimize amikacin 
dosing and administration, with the resulting impact on exposure predictability in a specific 
subgroup of neonates (i.e. PMA <31 weeks, PNA <3 days and on respiratory support) in our 
unit was published 
52
. The subsequent introduction of a PMA-based amikacin dosing regimen 
(2002, Langhendries et al 
30
), the introduction of a pediatric amikacin vial (2004, 50 mg/mL 
instead of 250 mg/mL) reduced the inter-individual variability in amikacin clearance. This 
was obvious by the increase in attaining the predefined TDM targets. In an effort to explore 
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the impact of the step taken after 2006 (i.e. the implementation of the age-and weight based 
model-derived dosing regimen 
29
), we extracted the results of neonates with PMA <31 weeks, 
PNA <3 days and on respiratory support from the dataset used for the prospective amikacin 
validation as described in chapter 6 (Table 2).  
During this 14-year period (1999-2012), also the diagnostic and treatment modalities in the 
neonatal landscape have changed dramatically. As derived from Table 2, the use of prenatal 
indomethacin, postnatal non-steroidal anti-inflammatory drugs (e.g. ibuprofen) and dopamine 
decreased in the past decade. This in part reflects an altered neonatal ‘population’ and/or 
outcome variables applied.  
 
 
Table 2: Clinical characteristics and amikacin plasma concentration measurements of 4 cohorts of 
neonates studied, indicating the increase in the number of neonates attaining predefined targets. The 
table is adapted and extended from Allegaert et al 52. ° Mean (± SD), * Target zones used up to 2011.  
 
 
1999-2002 
52
 2002-2004 
52
 2004-4006 
52
 2011-2012 
Number of neonates 129 75 69 79 
PMA (weeks) 28 (24-30) 28 (24-30) 28 (24-30) 29 (25-30) 
Birth weight (g) 1047 ± 346 1130 ± 332 1080 ± 314 1229  ± 308 
Prenatal indomethacin 10% 3% 4% NA 
Prenatal betametasone 79% 76% 82% NA 
Aspirin/ibuprofen 89% 52% 23% 7.6% 
Dopamine 54% 39% 41% 11.39% 
Peak amikacin (mg/L)° 45.7 ± 17.8 38.3 ± 13.1 40.9 ± 9.1 29.1 ± 6 
Trough amikacin (mg/L)° 8.2 ± 4.4 4.8 ± 2.6 4.3 ± 1.8 3.1 ± 1.4 
Peak >20 mg/L* 95% 95% 98% 98% (90% 24-35 mg/L) 
Trough <5 mg/L* 24% 63% 73% 90% (53% <3 mg/L) 
 
 
Challenges in translating neonatal PK/PD data into clinical guidelines  
Throughout this doctoral thesis, it became obvious that dosing regimens available in reference 
textbooks for neonates highly vary, as illustrated for vancomycin (chapter 2, Table 1) and 
cefazolin (chapter 5, Table 1). Efforts to improve neonatal dosing regimens of frequently 
used, but off-label drugs are increasing. It will ultimately be a challenge to further explore the 
transferability of PK/PD results obtained in one NICU center or in a specific clinical setting to 
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other centers and finally to translate PK/PD data into useful bedside tools and guidelines. The 
joined forces of multicenter and/or international initiatives will certainly be helpful to achieve 
these goals.  
 
Conclusion  
 
At the end of this PhD thesis, we conclude that the 3-step research sequence suggested in the 
introduction, may not be simply considered as a straight line trajectory with one final 
endpoint but rather as a continuous process. Every result hereby announces the beginning of a 
new exploration, towards improved predictability (Figure 2).  
 
 
        
 
 
 
Figure 2: Research process towards improved predictability and more individualized 
pharmacotherapy. The studies conducted in this PhD thesis are mentioned in the corresponding part of 
the figure.  
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Clinical pharmacology has the intention to predict drug effects based on pharmacokinetics 
(PK) and pharmacodynamics (PD). The general principles hereby used, also apply to 
neonates. However, fast developmental changes during the neonatal period result in extensive 
inter- and intra-individual PK/PD variability, making both clinical care and research in this 
specific subpopulation more challenging.  
 
In this doctoral thesis we performed an exploration of covariates explaining this extensive 
PK/PD variability, for commonly used -but still insufficiently understood- drugs in neonates. 
We reported up to 70% of vancomycin routine trough levels below the target level (10 mg/L), 
despite the use of published dosing regimens. We hereby illustrated the extent of 
unanticipated problems in neonatal drug exposure. Small and immature neonates, and with 
higher postnatal age (PNA) seemed to be most prone to display subtherapeutic vancomycin 
exposure (chapter 2). Similar, disposition of drugs at an effect site or deep body compartment 
in neonates is under-studied. In ventilated neonates, amikacin concentrations were quantified 
in epithelial lining fluid (chapter 3). The highest concentration measured was reached between 
6-14.5 h after administration, which is delayed compared to adults. In chapter 4 covariates of 
propofol disposition were further explored. Using 24 h- urinary propofol metabolite profiles, 
postnatal age turned out to be the main driver of propofol metabolism. The limited 
contribution of glucuronidation to propofol metabolism was in line with other reports of drug 
glucuronidation in early life. Based on the link between phenotypic glucuronidation and 
propofol clearance, and on the fact that bilirubin also needs glucuronidation, we explored if 
indirect hyperbilirubinaemia could be a predictive biomarker to anticipate further reduced 
propofol clearance in neonates. Since both iso-enzymes involved (UGT1A1 for biliruin and 
UGT1A9 for propofol) display a similar maturational pattern, this hypothesis seemed 
reasonable. However, it turned out that postmenstrual age (PMA) and PNA as covariates were 
most optimal, irrespective of the presence of hyperbilirubinaemia. This can be explained by 
the fact that neonatal jaundice is the final result of either increased production or decreased 
elimination. Elevated bilirubin, respiratory distress syndrome, hemodynamic instability are all 
characteristics most often seen in the first days of life. Since we use propofol for 
(semi)elective endotracheal intubation in these neonates, without appropriate propofol dosing 
regimens, a prospective dose-finding study with simultaneous assessment of propofol PD 
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(sedation and relaxation state, vital signs) was conducted. A trend towards lower doses 
compared to previous reports was documented, while clinical recovery after the propofol 
bolus takes time. Based on continuous vital sign data, safety was assessed with only a 
moderate decrease in blood pressure and a short decrease in peripheral and cerebral oxygen 
saturation. For preterm neonates <10 days PNA, propofol ED50 values were provided. Until 
validated dosing guidelines appear, these ED50 values can be used at induction with 
subsequent up-titration based on clinical need. At least for INSURE indications this targeted 
policy is requested. 
 
Integration of covariates, explaining variability in neonatal PK and/or PD processes, in drug 
dosing regimens, can improve drug exposure prediction. This was illustrated with cefazolin 
in chapter 5. Based on a population PK model, covariates of neonatal cefazolin disposition 
were determined, taking into account saturable protein binding. Since the unbound fraction of 
a drug is responsible for drug (side)effects, we encourage both the determination and 
implementation of protein binding data in PK/PD models. The unbound cefazolin fraction in 
neonates was in part explained by covariates PMA, albuminaemia, total cefazolin 
concentration and unbound cefazolin concentration. Pooling of our cefazolin protein binding 
data with published adult cohorts revealed that besides anticipated covariates (albuminaemia, 
total cefazolin concentration, unbound cefazolin concentrations), also the patient subgroup 
contributes to variability in unbound fraction across different populations.  
Monte Carlo simulations, using the neonatal cefazolin data, indicated that lower cefazolin 
doses could be used while still reaching unbound concentrations above a target of 8 mg/L, 
during >60% of the time. A weight-and age-based model-derived cefazolin dosing regimen 
for neonates was proposed. Although this dosing regimen should theoretically result in 
improved cefazolin exposure in NICU patients, prospective validation by a clinical trial is 
needed. 
 
In chapter 6, amikacin was used to document how such a prospective dosing validation can 
lead Towards Improved Predictability of drug exposure in neonates. An amikacin population 
PK-based dosing regimen was validated using 1195 routine therapeutic drug monitoring 
(TDM) results. Overall, target peak and trough values were attained in most patient groups. 
Specific subgroups who would benefit from a limited additional dosing adaptation were 
identified. Consequently, this prospective validation effort ended with the proposal of a new, 
improved dosing regimen, which in turn needs adequate evaluation and subsequent validation. 
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Summary 
This at least illustrates that optimizing pharmacotherapy needs to be considered as a 
continuous research process, in which every result announces the beginning of a new 
exploration.  
 
Throughout this scientific journey, it became obvious that many gaps in neonatal clinical 
pharmacology still have to be resolved. Nevertheless, the results obtained in this doctoral 
thesis yield a small contribution to bridge some gaps. Besides improvements in compound-
specific pharmacotherapy for neonates, our observations provide a basis to further explore 
PK/PD patterns of other compounds or in other patient populations.  
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Klinische farmacologie tracht de effecten van een geneesmiddel te voorspellen op basis van 
de farmacokinetiek (PK) en farmacodynamiek (PD). De algemene principes die hierbij van 
toepassing zijn, gelden evenzeer voor pasgeborenen. Veranderingen ten gevolge van de snelle 
ontwikkeling tijdens de neonatale fase zorgen echter voor een grote inter- en intra-individuele 
variabiliteit. Dit brengt extra uitdagingen met zich mee, zowel in de klinische zorg als bij het 
uitvoeren van het wetenschappelijk onderzoek in deze specifieke populatie. 
 
In deze PhD thesis hebben we gezocht naar covariabelen, die de grote variabiliteit in PK/PD 
(mede) kunnen verklaren. We hebben hiervoor geneesmiddelen bestudeerd die frequent 
toegediend worden aan pasgeborenen, maar nog onvoldoende begrepen zijn. 
Tot 70% van de vancomycine dalspiegels, bekomen na gebruik van gepubliceerde 
doseerschema’s, zijn lager dan de vooropgestelde grens voor effecitiviteit (10 mg/L). Dit 
illustreert de uitgebreidheid van onverklaarde, en soms onverwachte, problemen in 
geneesmiddelen blootstelling bij pasgeborenen. Immature neonaten met een laag gewicht, en 
met hogere postnatale leeftijd (PNL), blijken het meest vatbaar om subtherapeutisch 
vancomycine dalspiegels te behalen (hoofdstuk 2). De mate waarin een geneesmiddel zijn 
plaats van effect of een diep lichaamscompartiment bereikt, is onvoldoende bestudeerd bij 
pasgeborenen. In kunstmatig beademde neonaten hebben we amikacine concentraties bepaald 
in het bronchiaal epitheliaal vocht (hoofdstuk 3). De hoogst gemeten concentratie werd 
bereikt tussen 6-14.5 uren na de amikacine toediening. Dit is later, in vergelijking met 
volwassenen. In hoofdstuk 4 werd een verdere exploratie verricht naar variabelen van 
propofol dispositie. Op basis van de propofol metabolieten bepaald in 24 uur urine collecties 
bij pasgeborenen, bleek postnatale leeftijd de belangrijkste drijfveer te zijn van propofol 
metabolisme. De beperkte bijdrage van glucuronidatie tot het metabolisme van propofol is 
vergelijkbaar met andere studies betreffende geneesmiddelen glucuronidatie in het jonge 
leven. Omwille van de link tussen fenotypische glucuronidatie en propofol klaring, en 
omwille van het feit dat ook bilirubine glucuronidatie ondergaat, werd nagegaan of indirecte 
hyperbilirubinemie een voorspellende biomarker zou kunnen zijn van lagere propofol klaring 
bij pasgeborenen. Gezien beide betrokken iso-enzymen (UGT1A1 voor bilirubine en 
UGT1A9 voor propofol) een vergelijkbaar maturatie patroon vertonen, was dit een 
aannemelijke hypothese. Echter, postmenstruele leeftijd (PML) en PNL waren de meest 
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optimale covariabelen, ongeacht de aanwezigheid van hyperbilirubinemie. Deze bevinding 
kan verklaard worden door het feit dat icterus bij een pasgeborene het gecombineerd resultaat 
kan zijn van een toegenomen productie en/of een verminderde eliminatie van bilirubine. 
Gestegen bilirubinemie, het respiratoire distress syndroom en hemodynamische instabiliteit 
zijn kenmerken die vaak gezien kunnen worden tijdens de eerste levensdagen. Omdat 
propofol gebruikt wordt als premedicatie voor (semi)electieve endotracheale intubatie op deze 
leeftijd en in afwezigheid van aangepaste propofol doseerschema’s, werd een prospectieve 
dose-finding studie uitgevoerd met gelijktijdige evaluatie van farmacodynamische aspecten 
van propofol (sedatie en relaxatie status, vitale tekens). In vergelijking met vroegere 
bevindingen, kunnen lagere propofol dosissen gebruikt worden, terwijl het klinische herstel 
na toediening van de lagere propofol bolus toch nog tijd vraagt. Op basis van continue 
metingen van vitale tekens werd de veiligheid van de propofol toediening geëvalueerd. Enkel 
een matige bloeddrukdaling en een kortdurende daling in perifere en cerebrale 
zuurstofsaturatie werd gedocumenteerd. Voor preterme neonaten met een PNL <10 dagen 
konden ED50 dosissen voor propofol bepaald worden. In afwachting van gevalideerde 
propofol doseerschema’s, kunnen deze ED50 dosissen gebruikt worden als startdosis, met 
individuele titratie van de bolus dosis indien klinisch nodig. Zeker voor INSURE indicaties is 
deze geleidelijke aanpak vereist. 
 
Integratie van covariabelen, die variabiliteit in neonatale PK/PD verklaren, in doseerschema’s 
kan leiden tot een verbeterde voorspelling van geneesmiddelen expositie. Dit werd 
aangetoond voor cefazoline in hoofdstuk 5. Op basis van een populatie PK model werden 
covariabelen van cefazoline dispositie bij pasgeborenen gedefinieerd. Hierbij werd rekening 
gehouden met concentratie-afhankelijke eiwit binding. Gezien de vrije fractie van een 
geneesmiddel verantwoordelijk is voor de (neven)effecten van het geneesmiddel, is het zinvol 
de eiwitbinding te bepalen en vervolgens te implementeren in PK/PD modellen. De vrije 
cefazoline fractie bij pasgeborenen werd gedeeltelijk verklaard door de covariabelen PML, 
albuminemie, totale cefazoline concentratie en vrije cefazoline concentratie. De neonatale 
data over cefazoline eiwitbinding werden samengevoegd met gepubliceerde observaties bij 
volwassenen. Naast verwachte covariabelen (albuminemie, totale cefazoline concentratie, 
vrije cefazoline concentratie), was ook de patiënt subgroep een verklarende factor voor de 
verschillen in vrije cefazoline fractie tussen de verschillende populaties. 
Monte Carlo simulaties op basis van deze neonatale cefazoline data, toonden dat lagere 
cefazoline dosissen gebruikt kunnen worden terwijl nog steeds vrije concentraties boven 8 
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mg/L bereikt worden gedurende >60% van de tijd. De populatie PK analyse resulteerde dan 
ook in een voorstel tot aangepast cefazoline doseerschema voor pasgeborenen, op basis van 
gewicht en leeftijd. Dit nieuwe doseerschema zou tot betere cefazoline blootstelling moeten 
leiden bij pasgeborenen, maar hiervoor is eerst nog prospectieve validatie noodzakelijk. 
 
In hoofdstuk 6 werd met behulp van amikacine getoond hoe prospectieve validatie van een 
doseerschema tot een betere voorspelbaarheid van geneesmiddel blootstelling kan leiden bij 
pasgeborenen. In totaal werden 1195 routine amikacine therapeutische drug monitoring 
(TDM) resultaten gebruikt om een doseerschema, afkomstig van een populatie PK analyse, te 
valideren. Vooropgestelde piek- en dalwaarden werden bereikt in de meeste patiënten. 
Specifieke subgroepen voor wie een bijkomende aanpassing van het doseerschema zinvol zou 
zijn, werden geïndentifieerd. Hiermee werd duidelijk dat prospectieve validatie tot een nieuw 
doseervoorstel kan leiden, dat op zijn beurt een adequate evaluatie en validatie moet 
ondergaan. 
 
Het verbeteren van farmacotherapie moet beschouwd worden als een continu proces, waarbij 
elk resultaat het begin van een nieuwe exploratie aankondigt.  
 
Doorheen dit onderzoekswerk werd vastgesteld dat vele facetten binnen het domein van de 
neonatale klinische farmacologie nog bestudeerd moeten worden. De resultaten uit deze PhD 
thesis kunnen beschouwd worden als een kleine bijdrage. Naast het verbeteren van 
geneesmiddel-specifieke farmacotherapie voor pasgeborenen, vormen de resultaten een basis 
voor verdere exploratie van PK/PD patronen voor andere geneesmiddelen of binnen andere 
populaties.  
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